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IBD is a complex genetic disease characterised by chronic inflammation of the 
gastro-intestinal tract, with Crohn’s disease (CD) and ulcerative colitis (UC) 
being the two most common forms. Genome wide association studies (GWAS) 
and meta-analysis have identified >200 genomic IBD susceptibility regions, the 
most of any complex disease. Here, whole transcriptome sequencing was 
employed to investigate the role of altered gene expression in intestinal tissue. 
Differential expression and potential underlying biological pathways 
were assessed between UC, CD and controls. Furthermore, the effect of indexed 
IBD risk SNPs on changes in gene expression was investigated. Heterogeneity 
within the RNA sequenced intestinal biopsy samples was addressed through 
cellular phenotyping and computational sample deconvolution. Additionally, 
the presence of a transcriptional signature to predict relapse was investigated.  
1,637 transcripts exhibited differential expression at q ≤ 0.05 between 
the IBD sub phenotypes and controls. Most notably, GLS (Glutaminase), an 
enzyme which hydrolysis glutamine into glutamate and ammonia. Glutamine 
is known to be an important energy source for immune and gut mucosal cells. 
Furthermore, it was observed that these differentially expressed genes 
significantly perturbed 50 biological pathways. The majority of the identified 
pathways were involved in processes known to play an important role in IBD: 
immune regulatory, autophagy and transmembrane signalling. One novel 
finding was the perturbation of Nicotine degradation pathway II and III within 
CD patients versus controls and UC patients. Potentially providing insight into 
the mechanism behind the known opposing effects of smoking on the clinical 
course of UC and CD patients. Expression of 9 genes located within an IBD loci 
showed association with an IBD risk SNPs, making them strong candidate genes 
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1.1 Inflammatory bowel disease 
Ulcerative colitis (UC) and Crohn’s disease (CD) are two forms of inflammatory 
bowel disease (IBD). They are two distinct diseases with different disease 
manifestations but with an overlapping clinical feature, chronic inflammation 
of the gastrointestinal tract (GI). IBD is a complex disease thought to be caused 
by a dysregulation in the mucosal immune response to commensal gut flora in 
a genetically susceptible host, which results in inflammation. Due to the early 
onset and the fluctuating disease course IBD has a substantial impact on a 
patients’ quality of life.  
 
1.1.1 Clinical presentation and treatment 
IBD diagnosis is confirmed by clinical evaluation including relevant patient 
history, physical examination, laboratory testing, radiographic and/or 
endoscopic imaging and histology. Symptoms of IBD include diarrhoea, fever, 
abdominal pain, weight loss and rectal bleeding, with relapse and flare-ups 
often being part of the disease course. IBD is neither medically nor surgically 
curable; therapeutic approaches aim to induce and maintain symptomatic 
control, induce mucosal healing and improve quality of life. Therapeutic 
recommendations depend on the disease location, disease severity and disease-
associated complications. Whilst a wide variety of effective therapeutics is 
available, surgery to remove damaged sections of the intestine is often needed 
(see section 1.1.1.3 for more detail). Although CD and UC are both forms of 
IBD, there are differences in disease manifestation and some treatments, 
although a successful differentiation between them cannot always be made.  
1.1.1.1 Crohn’s disease  
In 1932 CD was first described by Burill Crohn, after whom the disease is 
named 1. The disease is characterised by asymmetric, transmural and 
sometimes granulomatous inflammation which can affect any part of the 
gastrointestinal (GI) tract, creating patchy areas of inflammation 2,3. The 
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terminal ileum is most commonly affected in CD and the earliest mucosal 
lesions tend to appear over the Peyer’s patches 4. CD is a phenotypically diverse 
disease with clinical manifestations, which include transmural inflammation, 
including strictures, lesions, penetrating fistulas, abscesses and, extra-intestinal 
manifestations (Figure 1.1) 3. CD patients with a positive family history are 
more likely to have small bowel disease manifestations and demonstrate earlier 
disease onset 5. Disease onset occurs in approximately 25% of cases during 
childhood; the remainder of cases occurs second and third decades of life. Age 
of onset does not appear to have an impact on increased disease development 
in IBD 6. Therapeutic approaches attempt to induce and maintain clinical 
remission but in Crohn’s disease this a real challenge and a large proportion of 
patients will relapse multiple times during their disease course. Disability 
caused by CD tends to be greater than by UC, with only 75% of patients being 
able to work in the year following diagnosis and 15% still unable to work after 
5-10 years of disease 7. 
  
 
Figure 1.1 | Phenotype of Crohn's disease 
(A) Various forms of CD disease manifestations including patterns of inflammation and 
additional manifestations. (B) Major extraintestinal manifestations and associated 
autoimmune disorders (blue). GI=gastrointestinal (Picture adapted from Baumgart et al.3). 
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1.1.1.2 Ulcerative colitis  
Pinpointing the first observation and description of Ulcerative colitis is more 
difficult, although the British Physician Sir Samuel Wilks first refers to it by 
name in 1859 8. UC is a more homogenous condition with inflammation 
classically involving the rectum and extending proximally in a continuous 
manner, involving part of or the entire colon 9. Disease extent is an essential 
factor in determining treatment in UC. UC can broadly be subdivided into 
proctitis (inflammation confined to the rectum), left-sided colitis 
(inflammation up to the splenic flexure), extensive colitis (inflammation up to 
the hepatic flexure), and pancolitis (involving the whole colon) (Figure 1.2) 
10. Patients with a more extensive form of UC occasionally display segmental 
inflammation, backwash ileitis or a caecal patch, which may lead to confusion 
with CD 11. In contrast to CD, inflammation in UC only affects the surface 
mucosal layer of the bowel and does not extend to its full thickness. Onset for 
UC shows a bimodal pattern with the first and biggest peak of onset being 
between ages 15 and 30 years and a second smaller peak at age 50-70 years 12. 
Therapies focus on inducing clinical remission and management of flare-ups.  
 
 
Figure 1.2 | Anatomy small and large intestine 
Anatomy of the large intestine indication essential locations used when 
determining the extent of ulcerative colitis including the spelinc flexture and 
hepatic flexture as well as sides of segmental manifestations backwash Ileitis 
and cecal patch (picture adapted from http://encyclopedia.lubo-
pitkobg.com/Stomach.html). 
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1.1.1.3 Treatment of IBD 
There are three main aims in the treatment of IBD, achievement of remission, 
mucosal healing and maintenance i.e. prevention of disease flares. Clinical 
treatments to achieve this can be either medical or surgical in nature, with 
medical therapy being a rapidly evolving field in IBD over the last few years. 
Currently, the first-line of treatment in mild to moderate cases of CD exists of 
anti-inflammatory drugs such as corticosteroids or immunosuppressive drugs 
such as azathioprine, whereas the most common forms of treatment for UC are 
anti-inflammatory drugs such as aminosalicylates (ASAs) in mild to moderate 
cases and corticosteriods in moderate cases or for people not responding to 
ASAs. Immunosuppressive drugs such as azathioprine or cyclosporin are often 
used to maintain remission in UC if previous therapies have not been successful. 
Patients with more severe forms of IBD, or ones that have failed first-line 
treatment drugs, might require treatment with biologics. Biologics are a fast 
growing field of therapies with currently up to six agents approved for use in 
IBD 13. The first biologics to the market were anti-tumour necrosis factor (anti-
TNF) drugs of which three are now approved in Europe for induction and 
maintenance of remission: infliximab, adalimumab, and golimumab. In terms 
of maintenance, an infliximab study in CD showed a 12% loss of response per 
patient-year of treatment 14, whereas another study showed 55.7% sustained 
benefit after 5-years 15. Within UC 30.6% of patients have been reported to stop 
infliximab within 3 years due to adverse events, lack of efficacy or other reasons 
16.  
More recently, vedolizumab an anti-integrin agent, was approved for 
treatment of IBD. Vedolizumab, an anti-alpha-4 beta-7 integrin antibody, 
decreases lymphocyte trafficking into the gut by preventing white blood cells 
from binding to the vascular endothelium through the interaction between 
alpha-4 beta-7 and MAdCAM, thereby limiting inflammation. It is a relatively 
slow acting drug, and therefore is often better for maintenance than induction 
17. Vedolizumab has shown higher efficacy in UC than CD with 47.1% vs 14.5% 
of patients showing clinical response at week 6 in clinical trials although real 
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life use suggests that its effectiveness in Crohn’s disease may be better than its 
efficacy 18,19.  
Lastly, an anti-p40 antibody, ustekinumab, which functions through the 
blocking of the p40 subunit of IL-12 and IL23 disrupting signalling though Th1 
and Th17 pathways, has recently been approved for use in Crohn’s disease. 
Ustekinumab has been shown to be affective for both induction (43%) and 
maintenance (50.5% of the 43% of patients showed successful induction) in 
CD patients over a year, and is effective in both biologic naïve patients and 
patients that have failed anti-TNF treatment 20. Although, biologics offer great 
promise they might cause serious side effects including increased risk of 
cancers, congestive heart failure or serious infections 21. Furthermore, biologics 
impose a considerable cost on the NHS 22 and other healthcare systems 23.  
In addition to drug therapies, IBD patients often need surgery to treat 
the disease. Approximately, 70%-80% of CD patients require surgery during 
their lifetime 10, most commonly due to disease complications in the form of 
recurrent intestinal obstruction, strictures and perforations 7. Surgery is not 
curative in CD; it is used to manage and minimise the impact of the disease. 
For UC, surgery rates at 10 years post diagnosis vary between 3% and 17%, 
with colectomy being needed either for severe UC or treatment-refractory UC 
in up to 27% of cases 24. 
  
1.1.2 Epidemiology  
The incidence and prevalence of IBD are highly variable between geographic 
regions and different ethnicities. The highest prevalence rates for both UC and 
CD are found in Europe (UC, 505 per 100,000 persons; CD, 322 per 100,000 
persons) and Canada (UC, 248 per 100,000 persons; CD, 319 per 100,000 
persons) 25. Within Europe the highest prevalence and incidence is found 
within the United Kingdom 26,27 and Scandinavia 28-30 with the occurrence in 
Eastern Europe to remain rare 31, suggesting a North-West/South-East gradient 
in IBD incidence 32. When evaluating the influence of ethnicity on IBD disease 
incidence, IBD is observed to be most common in Caucasians (324 per 100,000) 
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compared with Africans, Asians and Hispanics (239, 162 and 147 per 100,000), 
respectively 33. Incidence rates for IBD have been increasing world-wide with 
75% of CD and 60% of UC studies showing a statistically significant increase in 
incidence over a minimum 10-year period 25. Specifically, developing nations 
with low incidence that have adopted an industrialised lifestyle see a major 
increase in IBD incidence, which suggests an important role of environmental 
factors in triggering the disease onset 25. Nevertheless, twin studies have shown 
a definite genetic component to IBD with concordance rates in monozygotic 
(MZ) twins of 35-58% in CD and 6-13% in UC 34,35. Additionally, having one 
or more affected first degree relatives still confers a greater risk than any known 
environmental factor 36,37, with the lifetime risk to offspring of two IBD affected 
parents exceeding 30% 38. More recently Genome Wide Association Studies 
(GWAS) have been used to investigate genetic aetiology in IBD (see section 
1.2.1). GWAS allows us to compare allele frequencies for each of more than 
500,000 single nucleotide polymorphisms (SNPs) spanning the entire human 
genome in many thousands of disease cases and controls 39. SNPs showing 
differences in allele frequencies between cases and controls will highlight 
regions of the genome that are associated with disease. To date 26% and 19% 
of heritability for CD and UC, respectively, has been explained by identified 
disease associated SNPs 40.  
 
1.1.3 Environment  
A clear genetic factor in the onset and occurrence of IBD has been established. 
Nevertheless, the incidence and prevalence of IBD has been increasing at a rate 
too rapid to be purely explained by a genetic effect, suggesting that other 
factors are involved in the occurrence of IBD. Environmental factors like 
smoking, appendectomy, diet and lifestyle have been implicated in IBD 
development.  
 




Smoking is one of the most studied environmental risk factors in IBD, 
demonstrating a paradoxical relationship between smoking and IBD. Through 
a discordant sib pair study Bridger et al. showed significant influence of 
smoking on the development of IBD; 21 out of 23 sibling pairs discordant for 
smoking at diagnosis showed non-smokers to develop UC and smokers 
developing CD (p<0.0001) 41. A meta-analysis identified a direct association 
of smoking with a twofold increased risk in CD, whereas an association of the 
same magnitude was identified between never smokers or ex-smokers and UC, 
indicating a strong inverse association with UC 42. The metabolite nicotine in 
cigarette smoke is most likely the main driver of the effects on IBD disease 
course, although studies examining the individual effects of nicotine and 
tobacco failed to recreate the same magnitude of association seen by smoking, 
suggesting that other components of tobacco smoke might be important 43,44. 
Suggested ways of interaction include changes to the immune system, on both 
humoral and cellular level 45,46, altered cytokine production 47,48 and the body’s 
increase in oxygen-free radicals production 49. Additionally, changes to the 
intestinal mobility and permeability have been observed 50,51. A gene expression 
study identified three genes significantly upregulated in CD smokers with active 
disease versus CD non-smokers 52, indicating a complex gene – environment 
interaction. The protective effect of smoking in the development of UC versus 
the causative effect in CD development highlights the difference in 
pathogenesis of the two diseases.  
 
1.1.3.2 Appendectomy 
Another factor which demonstrates a contradictory effect on CD and UC is 
appendectomy. Results are conflicting depending on age and reason for 
appendectomy, but it is reported that appendectomy prior to age 50 and for 
inflammatory reasons is associated with a protective effect for UC and a slight 
increase in risk for CD 53,54. 
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1.1.3.3 Diet and food antigens 
Food antigens are the most common type of luminal antigen following bacterial 
antigens, making diet an important environmental factor to investigate. In 
addition, differences in diet might contribute to the geographical variance in 
IBD incidence. Case-control studies focusing on diet have numerous limitations. 
Nevertheless, associations between fibre, saturated fat and vitamin D intake 
have been reported. A 40% reduction in risk of CD was shown in women with 
long-term fibre intake 55, although it is difficult to establish if a reduced fibre 
intake increases risk or is a result of the disease. Human - as well as mouse - 
studies have indicated that high intake of saturated fat increases the 
inflammatory response and thus risk of IBD 56,57. Furthermore, low levels of 
vitamin D are common in newly diagnosed IBD patients and are associated with 
hospitalisation and surgery in CD patient 58,59.  
 
1.1.3.4 Lifestyle risk factors 
Factors such as stress, exercise, sleep and hygiene can all be captured under 
the environmental risk factor lifestyle. Multiple studies have investigated the 
various environmental risk factors, although these studies come with 
limitations and data does not contribute to the treatment course. Of these, 
stress is the most convincing contributor to IBD, with studies suggesting an 
association between major life stressors or anxiety and IBD activity 60,61. Gut 
inflammation can be influenced by stress through various neural components 
of the brain-gut axis, resulting in pro-inflammatory cytokine production, 
activation of macrophages, and changes in intestinal permeability and gut 
microbiota 62. A higher risk of IBD development was noted in people with 
sedentary occupations, whereas, people with heavy labour jobs were at lower 
risk of IBD 63, implicating physical activity to have a beneficial effect. This was 
confirmed by a study reporting a 44% reduction in risk of CD in participants 
with high weekly activity versus inactive participants 64.  
 
Sleep and hygiene are two factors that have proven more difficult to study. An 
association between disturbed sleep quality and active IBD active has been 
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reported, although this association might be bidirectional where higher disease 
activity causes poor sleep quality 65. Studies investigating hygiene have mainly 
been focused on differences in exposure to certain organisms between 
developed countries and developing countries. It is hypothesised that the 
immune development is negatively affect by raising children in an extreme 
hygienic environment 66. The use of chlorinated water and supermarket 
produce in developed countries reduces the exposure to organisms such as 
saprophytic Mycobacteria, Lactobacilli and Helminths. They are often harmless 
organisms, common in developing countries, found in mud, untreated water 
and fermenting vegetable matter. During exposure they interact with the innate 
immune system and induce T regulatory cells (Tregs), which in turn regulate 
anti-inflammatory cytokine IL10 production 67. Absence of exposure to these 
organisms is thought to contribute to the inappropriate inflammation seen in 
IBD patients. 
 
1.1.4 Gut microbiome 
The gut microbiome is a collective name for the wide variety of bacterial 
species, viruses and fungi inhabiting the intestinal tract. The gut microbiota 
and their human host have had a symbiotic relationship and co-evolved for 
millennia, proving many benefits to its host. Nevertheless, microbes are foreign 
to the body and require tight regulation by the host immune system to maintain 
homeostasis. Disruption of this homeostasis can potentially lead to chronic 
inflammation. Microbiome composition varies depending on exposure to 
microbes via dietary intake and environmental factors as well as our genetic 
state, as shown by a large twin study 68. By investigating the gut microbiome 
of 416 twin pairs, they identified microbial taxa who were highly heritable as 
well as microbial taxa which were influenced by diet and environment 68. 
Furthermore, the gut microbiome has been shown to influence a host’s 
metabolism and development of the immune system and its function 69. An 
imbalance, or dysbiosis, of the microbiome can thus have broad effects on the 
general health of an individual. Normal gut flora can contain over 100 trillion 
 1. Introduction 
26 
 
microbes, with the majority being bacteria. Healthy microbiota consists of 
nearly 1000 different bacterial species, with over 90% being from one of four 
phyla. Firmicutes (both Bacillus and Clostidiales) and Bacteroidetes phyla 
dominate with 30-60% and 20-50%, respectively, with Proteobacteria and 
Actinobacteria phyla accounting for a smaller proportion 70 (Figure 1.3).  
 
1.1.4.1 Microbiome in IBD patients 
When investigating the microbiota in IBD patients, an altered composition and 
reduced diversity of microbes is observed 71. The most consistent observation 
in IBD patients is a reduction in Firmicutes and an increase in Proteobacteria 
(Figure 1.3) 72.  
 
 
Figure 1.3 | Bacterial Phyla in the human microbiome 
Relative abundance of predominant bacterial phylotypes in the 
human intestinal tract in relation to the location of the distal gut for 
healthy controls and IBD patients. (nd = not done) (picture adapted 
from Peterson et al. 72). 
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Besides the altered diversity in IBD patients it has also been established that 
the microbiota in IBD patients – both with active disease and in remission - is 
less stable than in healthy people 73,74. Beyond bacterial dysbiosis, non-bacterial 
microbes including viruses and fungi should be considered in IBD pathogenesis. 
Fungal dysbiosis has been reported in IBD patients compared to healthy 
controls, with CD patients gut environments maybe giving favour to fungi over 
bacteria 75. It was suggested their might be disease-specific inter-kingdom 
alterations present in IBD gut microbiota 75. Finally, there is the intestinal 
virome to consider; in depth analysis have shown that the enteric virome is 
abnormal in CD and UC patients 76. Moreover, data suggests that changes in 
the virome may cause bacterial dysbiosis and contribute to intestinal 
inflammation 76. Factors such as medication and inflammation are known to 
affect the microbiota, making it difficult to establish if the observed dysbiosis 
is caused by IBD or contributing to causing IBD.  
 
1.1.5 Immune response in IBD 
The intestinal tract is constantly exposed to a multitude of antigens, including 
food and bacterial antigens, requiring the host immune system to regulate an 
appropriate response. The layer of epithelial cells lining the gut wall is covered 
by a mucus layer secreted from goblet cells, which form the first line of defence 
by preventing direct interactions between luminal antigens and the host 
immune system. Intestinal inflammation in IBD is caused by a defect in 
epithelial barrier, combined with a dysfunctional response of the innate and 
adaptive immune system to commensal gut flora 77.  
Epithelial cells are linked by tight junctions, preventing access of luminal 
antigens to the lamina propria. Damage to the epithelial barrier leads to 
increased permeability and enables the uptake of luminal antigens, triggering 
an immune response 78,79. In addition to acting as a physical barrier, epithelial 
cells secrete various bactericidal agents including defensins. Reduced levels of 
human ß-defensin-1 (HBD-1) have been observed in both CD and UC, whereas, 
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human ß-defensin-2 (HBD-2) and human ß-defensin-3 (HBD-3) have shown 
lack of induction in CD but not UC 80.  
The lamina propria, located beneath the epithelial cell layer, is densely 
populated with both innate and adaptive immune cells. The innate immune 
system includes immune cells such as dendritic cells (DCs) and macrophages, 
but also intestinal epithelial cells and myofibroblasts. Innate immunity provides 
rapid and effective inflammatory responses against microbial invasion. Innate 
immune cells express pattern recognition receptors (PRR), such as Toll-like 
receptors (TLR) and nucleotide binding domain (NOD) like receptors (NLR), 
with DCs containing the widest range of PRRs 81. Within healthy intestinal 
mucosa TLR3 and TLR5 are primarily expressed, whereas, TLR2 and TLR4 
expression is negligible 82. In IBD an increased expression of TLR2 and TLR4 
was reported 81. Additionally, polymorphisms in NOD2, a NLR caspase 
recruitment domain, were highly associated with CD 83. Activation through 
PRRs results in nuclear factor-kB (NF-kB) expression and production of pro-
inflammatory cytokines 81. It has been shown that patients with active UC and 
CD have higher levels of pro-inflammatory cytokines TNF-a, IL-6 and IL-8 due 
to a higher number of DCs present 84. Furthermore, DC PRR activation triggers 
the adaptive immune system by initiating T cell differentiation.  
The adaptive immune system, with T and B lymphocytes as the major 
cell types, is highly specific and creates long lasting immunity. The adaptive 
immune system is thought to be involved in the persistence of inflammation, 
with adaptive immune responses in IBD patients characterised by an imbalance 
of Tregs and effector T cells including CD4pos T helper cells and CD8pos cytotoxic 
T cells 85,86. CD4pos T helper cells have been shown to be important to CD as 
they represent the majority of the activated mononuclear cells that infiltrate 
the intestinal wall 87. Where, CD8pos cytotoxic T cells can be found in the 
mucosa in mouse models of IBD and several studies have suggested that 
autoreactive CD8pos T cells may be involved in the initiation of the 
inflammatory response in IBD 88. Furthermore, CD14pos monocytes have been 
suggested to play an important role in intestinal inflammation. Macrophages 
(present in the lamina propria) expressing the CD14 (LPS) receptor are 
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markedly increased in tissues of patients with IBD 89. They respond to microbial 
products such as LPS and interferon-γ (IFN- γ), and are extremely important in 
mucosal immunity 89.  
Naïve T cells (Th0) in the adaptive immune system differentiate into one 
of three T cell sets: Th1, Th2 or Th17 cells. With Th1 cells being essential for 
elimination of intracellular pathogen, Th2 cells mediating allergic reactions 
and protecting against parasites, and Th17 contributing to the removal of 
extracellular fungi and bacteria 90,91. Notably, studies have reported that CD is 
identified by an upregulation in Th1 cytokines (e.g. TNF-a, IFN- γ, IL-12) as 
well as Th-17 associated cytokines (e.g. IL-17A, IL-21 and IL-23), whereas UC 
is identified by increase of Th2 cytokines (e.g. IL-5 and IL-13) in inflamed 
mucosa 3,9,85,86. Genetic studies investigating single nucleotide polymorphisms 
(SNPs) support the imbalance model by linking loci involved in Treg, Th1, Th2 
and Th17 differentiation to IBD 92. Changes in cytokine production, pro- and 
anti-inflammatory, have major downstream effects in causing and maintaining 
inflammation.  
 
1.2 Genetics of IBD 
1.2.1 Early linkage studies in IBD 
Linkage mapping has proven to be a powerful tool for mapping highly 
penetrant disease loci, with more limited successes observed within complex 
diseases. Early linkage studies in IBD identified potential disease susceptibility 
loci on chromosomes 3,7,12 and 16 93,94. In 2001 the NOD2 gene (nucleotide-
binding oligomerization domain containing 2), also known as CARD15, was 
identified as the first CD susceptibility gene, using linkage analysis and 
positional cloning 83,95,96. NOD2 to date, still accounts for the highest explained 
heritability of CD, with ~50% of CD patients carrying at least 1 mutation in 
NOD2 97. NOD2 is involved in recognising bacterial molecules within the 
intestine and stimulating an immune response, highlighting the importance of 
innate immunity within IBD. NOD2 variant Leu1007insC leads to a truncated 
protein, resulting in altered activation of NF-kB following bacterial triggers 96. 
 1. Introduction 
30 
 
Furthermore, susceptibility at several other loci was detected including 
chromosome 5q31 (IBD5), a region encoding for several immunoregulatory 
cytokines including IL-4, IL-5 and IL-13 which have been implicated in CD 
pathogenesis 98, chromosome 10q23 encoding discs large homologue 5 (DLG5) 
which is involved in the maintenance of epithelial integrity 99, and chromosome 
6p (IBD3) containing the major histocompatibility complex (MHC) 100. 
Although some progress was being made by linkage analysis in identifying 
regions of the genome which might contain IBD susceptibility genes, the 
introduction of genome-wide association studies (GWAS) in 2006 provided a 
leap forward in unravelling the complex genetics of CD and UC.  
 
1.2.2 GWAS success in IBD 
In very early GWAS, four new IBD susceptibility loci at genome-wide 
significance (p<5x10-8) were identified, highlighting the power of the GWAS 
approach. New associations included IL23R, a protective variant involved in a 
signalling cascade which promotes inflammation and coordinates an adaptive 
immune response 101 and ATG16L1 a protein-coding variant involved in the 
autophagosome pathway 102. Additionally, an association was found with two 
locations devoid of any genes, referred to as gene deserts, on chromosome 5p13 
and 10q21 103,104. The largest IBD GWAS in this first phase was done for Crohn’s 
disease by the Wellcome Trust Case Control Consortium (WTCCC) 105, which 
identified 9 genome-wide significant associations, including the autophagy 
related gene IRGM. Further GWA studies increased the power of GWAS and 
this way identified many more IBD susceptibility loci. Currently, 27 GWA 
studies have been performed on CD and 21 on UC 106, with the major ones 
being by Jostins et al., Liu et al., Huang et al. and De Lange et al. 
In 2012 a major IBD meta-analysis of 15 GWAS and follow-up study on 
cases and controls mainly of European origin was performed 92. A total of 
25,000 SNPs with at least nominal association in the meta-analysis were tested 
for association in and independent set of 14,763 CD, 10,920 UC cases and 
15,9777 controls by genotyping on the Immunochip. This identified 163 IBD 
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susceptibility loci (p ≤ 5.0 x10-8) in at least one of the three analyses (Ulcerative 
colitis, Crohn’s disease, IBD). Of these loci, 110 were associated with IBD (i.e. 
both UC and CD) whereas 30 loci were classified as Crohn’s-disease-specific 
and 23 as ulcerative-colitis-specific 92. Furthermore, 38 additional IBD 
susceptibility loci have been identified by expanding the 2012 meta-analysis by 
Jostins et al. with 11,535 individuals of European descent and 9,846 
individuals of non-European descent 107, in the first trans-ancestry GWAS 
(Figure 1. 4). De Lange et al. identified a further 25 IBD susceptibility loci by 
expanding the GWAS analysis by 25,305 individuals, bringing the total to 224 
IBD susceptibility loci 108.  
 
 
Figure 1.4 | Variance explained by the 200 IBD loci 
Comparison of variance for Crohn’s disease (a) and ulcerative colitis (b) between East Asians 
and Europeans. Each bar represents an independent disease associated locus. The width of the 
bar is proportional to the explained variance of that locus in East Asians or Europeans. 
Associations between both ancestries are represented by connecting lines, and the colour of 
each box indicates if any difference in variance is due to difference in allele frequency. 
MAF=Minor Allele Frequency, OR=odds ratio (picture adapted from Lui et al. 107).  
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In an attempt to prioritise genes for causality within the ~220 identified IBD 
susceptibility loci, various analysis were performed including GRAIL (Gene 
Relationships Across Implicated Loci), DAPPLE (Disease Association Protein-
Protein Link Evaluator), and eQTL (expression Quantitative Trait Loci) 
107,109,110. Approximately, 400 genes were prioritised for causality, with 
associated pathways underlying IBD susceptibility. Suggested pathways are 
involved in innate immunity, JAK/STAT signalling, cytokine production, 
lymphocyte activation and epithelial barrier function 92. Prioritised genes 
within the 64 newly identified loci enforce previous finding, with ATG4B 
playing a key role in autophagy, OSMR modulating the epithelial barrier 
function, SLAMF8 disrupting the migration and inflammatory response of 
myeloid cells, RORC regulating Th17 cells, and various other prioritised genes 
showing involvement with both CD4pos and CD8pos T cell responses 107,108.  
Although, above mentioned methods have made some progress in 
prioritising causal genes, efforts are being made to identify causal genes and 
variants within the IBD loci via fine-mapping. Fine mapping or association 
mapping statistically identifies minor differences in strength of association 
between variants with high levels of correlation to infer which is likely to be 
causal 111. Ninety-seven regions previously associated with IBD and containing 
at least one associated variant were chosen for a fine mapping analysis by the 
International IBD Genetics Consortium using dense sets of SNPs across these 
regions on the Immunochip 112. Within 3 out of 97 regions no consistent 
credible association could be identified, whereas 139 independent associations 
were defined across the remaining 94 regions. Bayesian analysis was used to 
estimate the posterior probability of causality for associated SNPs in these 
regions. This way 45 out of 139 single associations were refined to a single 
causal variant with >50% probability, of which 18 associations had a 
probability of >95% to be the causal variant. Of these 45 most credible 
associations, 13 caused protein-coding changes, 3 disrupted a transcription 
factor (FT) binding site, 10 fell within tissue specific epigenetic markers and 2 
showed co-localisation with a significant cis-eQTL. The remaining 21 single 
causal variants mapped to non-coding variants that are not located within 
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known motifs, annotated elements or are involved in known eQTLs 112. While 
physical proximity does not guarantee functional relevance, fine-mapping has 
converted 94 IBD susceptibility loci into statistical convincing causal variants. 
Fine mapping can provide a powerful tool in guiding further experiments to 
investigate disease mechanism. 
Despite these efforts fine mapping studies have shown that the majority 
of IBD associated SNPs are correlated with non-coding variants that may 
perturb regulation of gene expression instead of directly altering gene structure 
and function 92,112. This is strengthened by the fine mapping findings by Farh 
et al., showing that ~90% of IBD causal variants are non-coding 113. Therefore, 
it seems reasonable to begin to shift focus from GWA studies to gene expression 
studies, in order to attempt to understand how the majority of common 
susceptibility loci may influence IBD pathogenesis.  
 
1.2.3 Functional mapping of GWAS loci 
1.2.3.1 Gene expression in IBD 
To date, GWAS findings have facilitated a number of functional/gene 
expression studies in IBD but these were generally focused on a limited number 
of target genes. One such study looked at known CD risk variants on 
chromosome 5q33.1 located upstream of the autophagy gene IRGM (Immunity 
related GTPase related family, M). They investigated correlations between the 
risk haplotypes and gene expression, demonstrating that the CD risk haplotype 
was associated with a significant decrease in IRGM expression (p<10-12) in 
untransformed lymphocytes from CD patients 114,115. Various other studies have 
investigated the biochemical mechanism by which IL23R variants might 
provide protection against IBD, with the most recent being by Sivanesan et al. 
116. IL23R (interleukin 23 receptor), involved in initiating the differentiation of 
helper T cells (Th17), was one of the first CD susceptibility genes to be 
confirmed by multiple GWAS 101. Investigation of multiple potential causal 
variants in IL23R, showed a reduction in IL23 mediated IL23R activation and 
subsequently a reduction in inflammatory response. It was established that the 
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observed reduction in IL23R signalling was due to lower levels of cell surface 
receptor expression 116. Ellinghaus et al. showed that a significant reduction in 
expression of PRDM1 (PR domain-containing 1) was associated with the CD 
risk C allele in both ileal biopsy specimens and peripheral blood mononuclear 
cells (PBMCs) (combined P=1.6x10-8). A reduction in PRDM1, which encodes 
for a master transcriptional regulator in B and T cell, resulted in increased 
CD4pos and CD8pos proliferation, INF-γ secretion and upregulation of activation 
markers upon stimulation 117.  
 
1.2.3.2 Differential expression analysis in IBD 
The majority of differential expression analysis is performed at a small scale i.e. 
within single genes or groups of functionally similar genes suspected in IBD 
pathogenesis as part of validation and functional studies. Although, Granlund 
et al. performed a genome wide microarray-based expression study 
investigated gene expression in both inflamed and un-inflamed mucosa from 
63 patients with UC, CD and 20 controls 118. They identified 3 and 0 
differentially expressed genes in the uninflamed CD and UC vs control analysis, 
respectively. Within the inflamed tissue they identified differential expression 
within 8,539 genes, with many antimicrobial peptides to be upregulated in 
inflamed tissue. Additionally, they reported altered gene expression in multiple 
IBD-associated genes between IBD cases and controls, with limited differences 
in gene expression pattern between UC and CD. Genes identified to exhibit 
differential expression within IBD cases and controls showed involvement in 
immunological and defence-related roles 118. Furthermore, Peloquin et al. 
investigated differential expression of 678 IBD disease-associated genes, often 
not covered by microarray platforms, within 1,100 inflamed and non-inflamed 
mucosal biopsies 119. They identified 431 DE genes in CD and 439 DE genes in 
UC colonic tissue vs controls, with 88% overlap between the CD and UC DE 
genes 119. Two main findings were the observed downregulation of VDR 
(Vitamin D Receptor) and SLC22A5 (Soluble Carrier Family 22 Member 5) in 
both UC and CD cases vs controls 119. VDR has been reported to mediate 
microbe-host interaction through regulation of autophagy 120 and SLC family 
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members have previously been reported to be associated with IBD 121. 
Furthermore, one of the genes reported to be differentially expressed between 
UC and CD is INF4 (IFN regulatory factor 4). IRF4 is a master transcription 
factor for Th17 cells 122, a cell type shown to be important in inflammatory 
responses in CD 92. Both above mentioned studies show that differential 
expression analysis of IBD cases vs controls in either inflamed or non-inflamed 
tissue can contribute to prioritise candidate genes and to inform future 
functional studies.  
 
1.2.3.3 eQTL studies 
GWAS and fine mapping studies have established that the majority of IBD 
associated genetic variants are located in non-coding regions of the genome 
112,113. This indicates that the majority of identified IBD susceptibility SNPs 
perturb regulation of gene expression in some way. Expression quantitative 
trait loci or eQTL studies are used to identify potential causal genes in disease 
by correlating genetic variation with alterations in gene expression 123. eQTL 
can exist either in cis i.e. within 1MB on either side of the genetic variant, or in 
trans i.e. further upstream/downstream or on a different chromosome. So far 
it is suggested that the majority of eQTLs are in cis, although it is hypothesised 
that this might be due to lack of power and low sample size 124. Further 
increased sample size can address the current enrichment of cis vs trans eQTLs 
reflects true biological processes or insufficient power to detect trans eQTLs. 
Early eQTL studies, using lymphoblastoid cell-lines, have been very 
valuable in identifying multiple eQTL loci throughout the human genome 124-
126. The Genotype-Tissue Expression Project (GTEx) characterized eQTLs across 
44 tissues in approximately 449 individuals 127, establishing a major public 
resource database showing cell-type gene expression signatures. Recent studies 
have shown the importance of cell-type specific gene expression signatures 
with a study comparing eQTLs from 43 different autopsy-derived tissues 
including PBMCs, detecting only a 50% overlap in eQTLs within 9 tissues 
sampled in >80 donors 128. Another study compared cis eQTLs from three 
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different cell types from the same individuals; fibroblasts, LCL’s and primary T 
cells, reported a 69-80% cell type specificity in eQTLs 129.  
Several studies investigating the presence of eQTL correlated with IBD 
associated variants have now been performed 130-132. An early eQTL study by 
Kabakchiev et al. investigated eQTL within human small intestine 130. They 
identified more than 15,000 statistical significant cis- and trans-eQTLs, of 
which 30% to 40% have previously been identified as eQTLs in various other 
tissues 130. In addition to identifying eQTLs in ileal tissue, they investigated the 
presence of eQTLs specific to IBD risk loci. 155 IBD-associated SNPs were 
associated with altered gene expression levels of genes within a 50 kb window 
of each SNP, 27 significant cis-acting eQTLs were identified 130. A study by 
Repnik et al. investigated 9,563 eQTL correlations with 402 IBD associated 
SNPs located within 208 candidate loci within intestinal tissue and PBMCs. 
They were able to confirm multiple previously suggested eQTLs at loci which 
included SLC22A5, ECM1 and PUS10. Additionally, they identified a novel 
eQTL correlation with ECM1 on chromosome 1q21 131. Furthermore, Singh et 
al. 132 performed an eQTL study in 39 IBD patients and 33 controls on tissue 
collected from their terminal ileum and four colonic locations. Approximately 
1,871 independent cis eQTLs were found throughout the colon at a false 
discovery rate (FDR) of 5%, with the majority identified in rectal mucosa. 27% 
of eQTLs found in the rectal dataset were novel when compared to 7 datasets 
from various other tissues, the rectal dataset did show enrichment for genes 
known to be expressed in the colon 132. When investigating eQTLs within IBD 
associated loci only 11 eQTLs were found, 6 of which (ERAP2, SFMBT1, FUT2, 
ADCY3, INPP5E, and UBE2L3) have been previously identified in the Ilieum 130, 
four (CPEB4, IRF5, ATG16L1, and TSPAN14) were previously identified in other 
tissues, and one novel eQTL, STX4, was identified 132. STX4 (Syntaxin 4) is 
involved in regulation of secretion from various immune cells 133. More 
recently, a study by De Lange et al. 108 employed eQTL analysis to investigate 
variant-gene associations within 25 newly identified IBD risk loci. Associations 
between nearby genes and the IBD index SNPs (or SNPs with linkage 
disequilibrium (LD) of r2 ≥ 0.8) were investigated within 12 eQTL databases. 
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Overall, 19 significant eQTLs were identified within 10 out of 25 IBD risk loci 
108. Furthermore, they investigated associations within four identified integrin 
genes (ITGA4, ITGAV, ITGB8 and ITGAL) and their binding partner ICAM1 108. 
Three out of the five associations were observed to be driven by the same 
variants as LPS monocyte-specific stimulus response eQTLs. This suggests 
upregulation of pro-inflammatory cell surface markers are a potential 
mechanism of action 108.  
eQTL studies and their efforts to identify causal genes within complex 
diseases are the next big thing in genetic studies. The main things to consider 
going forward in eQTL studies for mapping IBD causal genes are: disease 
specific tissue, heterogeneity of cell types in tissue and statistical power. Pinch 
biopsies used to identify eQTLs within intestinal tissue are not homogenous 
and contain various cell-types including epithelial cells, stromal cells, and 
various immune cells. Gene expression signatures that are identified therefore 
fail to provide a uniform picture. Primary sorted cells of heterogeneous tissues 
might give a clearer picture of eQTLs in colon tissue but experimentally this is 
not as straightforward.  
 
1.2.4 Biomarkers in IBD 
Biomarkers are measurable indicators of a biological state and are commonly 
used within a clinical setting as indicator of disease. The use of biomarkers to 
aid diagnosis of IBD and the differentiation between UC and CD has been 
increasing over time, although no single biomarker has proven strong enough 
to be used by itself. C-reactive protein (CRP) and erythrocyte sedimentation 
rate (ESR), are two common biomarkers indicative of general inflammation 
which are used in IBD as well as other inflammatory diseases 134. CRP is a 
component of the innate immune system and is produced by hepatocytes in 
response to specific pro-inflammatory cytokines 135. CRP base levels vary 
between people but higher levels of CRP most likely indicate the presence of 
an inflammatory response. Increased levels of CRP are more often seen in CD 
than UC at the time of diagnosis, and within known IBD patients an increase of 
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CRP levels often correlates with active disease 136. ESR evaluates the rate at 
which erythrocytes fall through plasma, which depends largely on the 
fibrinogen concentration within plasma.  
pANCA (perinuclear antineutrophil cytoplasmic antibody) and ASCA 
(anti-Saccharomyces cerevisiae antibody) are antibody biomarkers which can 
help to distinguish between UC and CD. A study demonstrated that 64% of UC 
patients were pANCA positive and ASCA negative 137, whereas CD patients were 
identified as pANCA negative and ASCA positive with 93% specificity 138. 
Unfortunately, pANCA/ASCA has a low sensitivity, 55% in CD 138, preventing 
it from routine clinical use.  
In IBD patients, stool based biomarkers, identifying gastrointestinal 
inflammation, have proven very valuable. An intestinal inflammatory 
biomarker routinely used in clinical practice is calprotectin. Faecal calprotectin 
is a zinc and calcium protein derived from neutrophils, monocytes and 
activated macrophages 139. During the inflammatory process calprotectin is 
released by mucosal epithelial cells and through degranulation of neutrophils 
within the intestine 140. Calprotectin levels are a relatively reliable indicator of 
inflammation in IBD; nevertheless, it will always be used in combination with 
endoscopy and histology to make the diagnosis 141.  
 
Due to the relative lack of specificity of currently available biomarkers to 
differentiate between IBD subtypes or to predict prognosis and relapse rates, 
the development of disease specific biomarkers is of great clinical interest. 
Various research studies into new antibody or protein biomarkers for IBD are 
underway and interestingly, the first use of genetic markers as biomarkers has 
been reported (see section 1.2.5). Successful development of novel biomarkers 
to aid better prognosis and prediction of relapse could have a huge impact on 
patient treatment and wellbeing. 
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1.2.5 Transcription signatures as biomarkers in IBD  
In order to facilitate the need for disease specific biomarkers in IBD, the use of 
gene expression profiles to detect novel transcription signatures with 
biomarker potential has been investigated. Several studies have generated 
expression profiles to aid biomarker development, but so far with limited 
success. This is most likely due to the heterogeneous state of the samples used 
within these studies, e.g. peripheral blood mononuclear cells (PBMCs) or 
mucosal biopsies. Transcriptional variation across multiple genes will 
predominantly reflect differences at a cellular level; thus separation of various 
cell subsets will allow these differences to be more easily detected. Another 
factor suggested to affect the success of identification of transcriptional 
signatures as biomarkers is the activation state of the sample used. Inflamed 
tissue samples as well as in vitro stimulated PBMCs show stronger expression 
signals of immunological and/or pro-inflammatory IBD-associated genes, 
suggesting that gene expression studies in inflammatory diseases require 
activation for signals to protrude from background.  
Von Stein et al. in 2008 identified a 7 gene panel differentially expressed 
between CD and UC patients with active disease 142. Their small scale follow-
up study reported 90% success in diagnosing UC, IBD and non-IBD patients 
based on those 7 genes 142. More recently, the gene panel was tested in 
inflamed colonic tissue from 78 difficult to diagnose patients, leading to a 
change in primary diagnosis for a significant number of patients 143. Although, 
the diagnosis by biomarker remained different from the primary diagnosis in 
6% of UC and 5% of CD patients. Furthermore, Lee et al. using gene expression 
microarrays, has identified a transcriptional signature based on the expression 
profile of 14 key genes in separated CD8pos T cells that was significantly 
associated with altered prognosis. The cohort presenting with this signature 
had higher incidence of experiencing treatment-refractory, relapsing, or 
chronically active disease in both CD and UC 144. Furthermore, a milder course 
of CD has been associated with a noncoding polymorphism in the FOXO3A gene 
(combined p = 2.1x10-8) 145. Monocytes containing the polymorphism were 
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observed to produced twice as much FOXO3A upon stimulation. More FOXO3A 
in monocytes reduces production of pro-inflammatory cytokines and increases 
production of anti-inflammatory cytokines, thus, resulting in a milder course of 
CD 145. 
The outcomes of these studies have shown that gene expression profiling 
may have great potential for the development of biomarkers which can aid in 
prognosis, diagnosis and relapse within IBD. 
  




This PhD consists of two separate projects, the aims for which are outlined 
below.  
 
1.3.1 Quantitative and qualitative analysis of the transcriptome 
in colon  
The aim of this project was to increase the knowledge of the pathogenesis of 
Inflammatory Bowel Disease (IBD). Firstly, a qualitative analysis was 
performed to examine expression levels of genes and non-coding RNAs at the 
known IBD susceptibility loci in biologically relevant intestinal tissue from 
affected patients and controls. Secondly, genes exhibiting differential 
expression between IBD cases and controls were investigated within the colon 
and biological pathways affected by the differentially expressed genes were 
examined. Thirdly, a genome wide expression quantitative trait (eQTL) 
analysis were carried out in colonic tissue to look for association of IBD risk 
SNPs with altered gene expression. Finally, expression deconvolution was 
performed to assess the effects of colonic biopsy cell composition on gene 
expression. 
 
1.3.2 Investigation of transcriptional biomarkers in prediction 
of relapse 
The aim of this study was to identify a panel of new and effective biomarkers 
for the prediction of likely relapse in patients suffering from Crohn’s disease. 
Cell type specific transcriptional profiles were generated for unstimulated and 
stimulated CD4pos T helper cells, CD8pos cytotoxic T cells and CD14pos 
monocytes using Illumina HT-12 expression bead arrays. A comparative 
analysis of the generated transcription profiles will be performed for patients 
relapsed vs non-relapsed for each cell type and for both unstimulated and 
stimulated cells.  
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4'-6-diamidino-2-phenylindole (DAPI) AnaSpec 
CD3/CD28 T-activator beads Thermo Fisher 
Chloroform  VWR 
Collagenase Ia Sigma-Aldrich 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich 
DNase I Roch 
Ethanol Fisher Scientific 
Ethylenediaminetetraacetic acid (EDTA) Ambion 
FcR block Miltenyi 
Fetal bovine serum (FBS) Life Technology 
Gentamicin Sigma-Aldrich 
Hank's Balanced Salt Soln (HBSS) Medium 
w/o Mg+/Ca+ 
Fisher Scientific 
Isoamylalcohol  VWR 
Lymphocyte separation media MP chemicals  
Lypopolysaccaride (LPS) MP chemicals 
Magnesium Chloride (MgCl2) BioLine 
Penstrep Life Technology 
Phosphate-buffered Saline (PBS) Sigma-Aldrich 
Proteinase K Fisher Scientific 
QIAzol lysis reagent Qiagen 
RNAlater® Ambion 
RNase free DNaseI Qiagen 
RNeasy mini Kit Qiagen 
RNeasy miRNA micro Kit Qiagen 
Roswell Park Memorial Institute (RPMI) 1640 
Medium w/o Mg+/Ca+ 
Sigma-Aldrich 
Sodium Chloride (NaCl) Sigma-Aldrich 
Sucrose Sigma-Aldrich 
Tris  Ambion 
Triton x-100 Sigma-Aldrich 
Trypan blue dye Thermo Fisher 
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2.1.2 Solutions and media 
10x TRIS buffer  
109.5 g sucrose 
10 ml 1M Tris (pH 7.5) 
5 ml 1M MgCl2  
10 ml Triton x-100  
per 1 litre MilliQ H20 
 
1x SET buffer  
5.48 g NaCl,  
10ml 1 M Tris (pH7.5) 
2ml 0.5 M EDTA (pH 8.0)  
per 1 litre MilliQ H20 
 
Tris-EDTA buffer  
10ml 1 M Tris HCL (pH 7.5) 
2ml 0.5 EDTA (pH 8.0) 
per 1 litre MilliQ H20 
 
Collection media 
HBSS w/o Mg+/Ca+ 
1% Penstrep  
1.2 mg/ml Gentamicin 
1 mM EDTA 
 
Digest media  
RPMI1640 w/o Mg+/Ca+  
10%FBS + 1% Penstrep  
1.2 mg/ml Gentamicin  
1 mg/ml filtered collagenase Ia  
10 U/ml DNase I 
 
Culture media  
RPMI1640 w/o Mg+/Ca+  
10% FBS  
1% Penstrep  
1.2 mg/ml Gentamicin 
 
FACS buffer  
1x PBS  
10% FBS  
2 mM EDTA 







Cell sorting solution  
PBS  




2.1.3 Antibodies and primers 
 
Table 2.1| antibodies used for cell sorting and biopsy immophenotyping 
Antigen Conjugate Isotype Supplier Cat. No. 
CD3 PerCP/Cy5.5 Mouse IgG2a, k BioLegend 317336 
CD4 APC Mouse IgG2b, k BioLegend 317416 
CD8 FITC Mouse IgG2b, k BioLegend 344704 
CD14 PE Mouse IgG1, k BioLegend 325606 
CD45  APC/Cy7 Mouse IgG1, k BioLegend 304014 
CD66b PerCP/Cy5.5 Mouse IgM, k BioLegend 305107 
CD68 PE-Cy7 Mouse IgG2b, k BioLegend 333815 
CD90 APC Mouse IgG1, k BioLegend 328113 
CD326 PE Mouse IgG2b, k BioLegend 324205 
Mouse IgG1, k APC - Biolegend 400121 
Mouse IgG1, k APC/Cy7 - Biolegend 400127 
 
 
Table 2.2 |Primers used for assessing TNF expression 
Gene Conjugate Supplier Cat. No.  
RP18S FAM ThermoFisher scientific Hs99999901_s1 
TNFα FAM ThermoFisher scientific Hs00174128_m1 
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2.2 Methods Project 1: Quantitative and qualitative analysis 
of the transcriptome in the colon 
2.2.1 Power Calculation 
Standardised methods to calculate power and samples size in differential 
expression analysis based on negative binomial distribution using RNA 
sequencing data are currently lacking. Such power calculations are dependent 
on multiple factors including the sequencing depth, the number of biological 
replicates and the level of expression of the genes e.g. lower expressing genes 
will require larger sample sizes to reach 80% power than highly expressed 
genes. Multiple studies have attempted to address this issue and performed 
power and sample calculation for RNA sequencing differential expression 
analysis 146,147. Ching et al. established that a sequencing depth of > 20 million 
reads and ~25 samples per condition were needed to reach 80% power using 
EdgeR (differential expression analysis tool) 146. 24 controls, 28 UC and 76 CD 
samples were sequenced, a differential expression analysis on these cohorts 
should provide us with 80% power to detect >0.8 logFold changes. It should 
be considered that these papers only present estimates and that factors such as 
sample heterogeneity or disease state can affect the power. 
 
Power calculation for the eQTL analysis was performed, using Genetic Power 
Calculator (http://statgen.iop.kcl.ac.uk/gpc/). It was calculated that analysis 
of gene expression in 105 samples will provide 80% power to detect an effect 
if the relevant SNP accounts for just 15% of trait variance (gene expression) 
and 93% power to detect an effect of 20%. 24 controls, 28 UC and 76 CD 
samples were sequenced, giving and overall samples size of 128 patients for 
the eQTL analysis.  
 
The presence of a transcriptional signature predictive of relapse will be assessed 
through differential expression analysis between the remission and relapse 
patient samples, with the non-relapsed samples acting as an internal control 
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for natural transcriptional changes over time. Our overall patient cohort existed 
of 50 patient’s samples, 33% of which relapsed. Taking into consideration the 
three different patient cohorts these patients were collected from; post-surgery 
patients, patients withdrawn from anti-TNF therapies and routine 
gastroenterology patients as well as overall relapse rates, this study is not 
sufficiently powered and should be considered a pilot study.  
 
2.2.2 Sample collection 
All 171 intestinal biopsy and peripheral blood samples were collected during 
routine colonoscopies at Guy’s and St Thomas’ Hospital after informed consent 
was given. Samples of 4-8 pinch biopsies from un-inflamed large intestine were 
collected from random sites throughout the transverse and descending colon 
and stored in 500μl RNAlater® (Ambion) at -20 °C until RNA extraction. 2.5 
ml of blood was collected in Paxgene tubes (QIAGEN GmbH) for RNA 
extraction and 10 ml of blood was collected in EDTA tubes (BD Biosciences) 
for DNA extraction. Both were stored at -20 °C. Samples were collected over a 
two-year period by myself (including taking consent from patients and 
attending their colonoscopy), with help from Ariella Amar and the medical staff 
of the endoscopy units. The sample cohort included samples from diagnosed 
CD (108) and UC (32) patients, as well as a control/non-IBD group (31) having 
a colonoscopies for various medical indications (Table 2. 3). The imbalance in 
patient sample numbers per cohort was partly due to the original study design; 
previously the focus lay on CD patients only. Furthermore, the availability of 
patients played a role; there is a higher percentage of CD patients versus UC 
and non-IBD patients having colonoscopies. An almost equal spread between 
males and females was observed; the CD cohort contained slightly more males 
(54% vs 46%), where the UC and control cohorts included slightly more 
females (46% and 42% versus 54% and 58%) (Table 2. 3). The mean age 
within the cohorts was approximately 40 years of age, with UC patients being 
slightly older at mean 44.1 years (Table 2. 3). Treatment regimens, from 
patients at the time of the biopsy being taken, were not recorded. 
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Table 2. 3 | Patient demographics 






Mean age 38.5 44.1 41.4 
# Female 35 15 14 
percentage 46% 54% 58% 
# Male 41 13 10 
percentage 54% 46% 42% 
 
 
2.2.3 RNA preparation 
RNA was purified from colonic pinch biopsies using an RNeasy Plus Universal 
Mini Kit according to manufacturer’s instructions (QIAGEN Gmbh). Briefly, the 
samples were homogenised using a micro-tube pestle following addition of 900 
μl QIAzol lysis reagent. Multiple wash steps were performed on column using 
RW1 and RPE buffer. Genomic DNA was removed using RNase free DNaseI 
(Qiagen). Lastly, 60 μl RNase-free water was added during two elution steps, 
to elute the RNA.  
 
2.2.4 Quantifying RNA 
The Qubit 2.0 Fluorometer (Invitrogen) was employed to quantify RNA yield. 
Either using the Qubit RNA Broad Range (BR) assay kit or Qubit RNA High 
Sensitivity (HS) assay kit, according to manufactures protocol. 
 
2.2.5 Quality control RNA 
The Agilent 2100 Bioanalyser, RNA 6000 Nano chip, was used to test RNA 
quality (RIN), according to manufactures protocol. 
 
2.2.6 DNA preparation from whole blood 
DNA was extracted from 10 ml of peripheral blood collected in EDTA tubes (BD 
biosciences) by means of sodium chloride (NaCl) precipitation followed by 
phenol: chloroform purification. 45 ml lysis buffer was added to whole blood 
prior to 20 min centrifugation at 2000 rpm and 4˚C. Samples were then 
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incubated overnight at 37˚C following the addition of 4.5 ml 1x SET, 250 µl 
10% SDS and 100 µl proteinase K to achieve nuclear lysis and inhibition of 
nucleases. 2.5 ml saturated NaCl solution and an equal volume of 
isoamylalcohol: chloroform (1:24) solution was added prior to a 30-60 min 
incubation at RT under rolling condition followed by a 10 min centrifugation 
at 2,000 rpm, 21˚C. The supernatant was transferred and 2 volumes of 100% 
ice-cold ethanol were added. The precipitated DNA was washed in 70% ethanol 
and re-suspended in Tris-EDTA buffer, before storage at -20˚C. Qubit® 2.0 
Fluorometer (Invitrogen) was used (under standard operating procedures) to 
determine the DNA concentration and quality.  
 
2.2.7 Genome-wide SNP genotyping 
Paired blood samples were collected in EDTA tubes for DNA extraction from 
122 out of 127 patients and controls. The 122 DNA samples were processed for 
genotyping on either the Infinium Human Core Exome array (Illumina) (n=71) 
or Infinium Human Core (n=15) bead chip (Illumina) by the GSTT/KCL BRC 
Genomics Centre. The remaining 36 samples were genotyped by the Sanger 
Centre using the Human Core Exome bead chip via pre-existing collaboration 
with the UKIBD consortium. The Human Core Exome chip contains 551,839 
SNPs (largely overlap with Human Core Chip SNPs) and the Human Core Chip 
contains 306,670 SNPs. When reviewing the genotype results, one sample was 
observed to have failed to generate any genotype data and was subsequently 
removed from the analysis. Genome studio was employed for genotype calling 
and to export genotype data to PLINK prior to use.  
 
2.2.8 RNA sequencing library preparation 
2.2.8.1 Ribosomal RNA depletion 
Both human and bacterial ribosomal RNA (rRNA) was removed using the Ribo-
Zero Magnetic Gold Epidemiology Kit (Epicentre, Illumina), according to 
manufacturer’s instructions. 1 µg RNA (RIN ≥ 6) starting material was used at 
a 40 ng/µl concentration. Following, rRNA removal the RNA samples were 
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purified using RNeasy MinElute Kit (Qiagen), by the manufacturers protocol. 
The Agilent 2100 Bioanalyser, RNA 6000 Pico chip, was used to confirm the 
efficiency of the rRNA removal and the purity of the remaining RNA.  
 
2.2.8.2 Epicentre ScriptSeq V2 RNA-seq library preparation 
Following rRNA removal whole RNA libraries were prepared using ScriptSeq 
v2 RNA-seq Library Preparation kit (Epicentre, Illumina), according to the 
manufacturer’s instructions. Briefly, the RNA is fragmented and primers were 
annealed using fragmentation solution and cDNA synthesis primers. 
Additionally, a 1:1000 dilution of External RNA Control Consortium (ERCC) 
Synthetic Spiking Standards (LifeTechnologies) was added prior to an 85˚C 
incubation for 5min. The cDNA was synthesised and terminal-tagged by adding 
cDNA Synthesis Premix, DTT and ScarScript Reverse Transcriptase prior to 
thermocycler incubation of 5min at 25˚C followed by 20 mins at 42˚C. The 
reaction was then cooled to 37˚C and Finishing solution added. The 
thermocycler programme was continued with a 10 min incubation at 37˚C and 
95˚C for 3min. The reaction was then cooled to 25˚C and Terminal Tagging 
Premix and DNA polymerase was added. Finally, the reaction was terminated 
by incubating at 25˚C for 25 min, 95˚C for 3min and then cooling to 4˚C. The 
cDNA was purified using MinElute Purification Kit (Qiagen), according to 
manufacturer’s protocol. The di-tagged cDNA was amplified and barcoded by 
addition of FailSafe PCR PreMix, FailSafe PCR Enzyme, Forward primer and 
the appropriate Set 1 Index reverse primer (Epicentre, Illumina), PCR was 
performed under the following conditions: 1 min at 95˚C, 15 cycles of 30 sec 
at 95˚C, 30 sec at 55˚C, 3 min at 68˚C, then a final 7 min at 68˚C. The cDNA 
library was purified using AMPure XP Beads (Beckman Coulter), according to 
manufacturer’s instructions. Finally, the cDNA library was visualised using 
Agilent 2100 Bioanalyser, High Sensitivity DNA chip, and quantified using 
Qubit® 2.0 Fluorometer, under standard operating procedures. 
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2.2.8.3 Illumina TruSeq stranded total RNA library preparation 
Whole RNA libraries were prepared using TruSeq v2 RNA-seq Library 
Preparation kit (Illumina), according to the manufacturer’s instructions. 
Following rRNA removal (Epidemiology kit, Epicentre) RNA was fragmented 
using Elute, Prime, Fragment High Mix and a 1:1000 dilution of ERCC 
Synthetic Spiking Standards (LifeTechnologies) was added prior to an 94˚C 
incubation for 8min. First and second strand cDNA synthesis was performed by 
two consecutive steps; First stand synthesis Act D and Superscipt II Reverse 
Transcriptase were added prior to thermocyler incubation of 10 min at 25˚C, 
15 min at 42˚C and 15 min at 70˚C followed by addition of the second strand 
marking mix and 1-hour incubation at 16˚C. The cDNA was purified using 
AMPure XP beads (Beckman Coulter), according to manufacturer’s 
instructions, prior to 3’ end adenylation using A-tailing mix. The index adaptors 
were ligated to the cDNA strands by incubation at 30˚C for 10 min in the 
presence of ligation mix and RNA adapter indexes. Excess adaptors were 
removed using AMPure XP beads (Beckman Coulter), according to 
manufacturer’s instructions. The libraries were subsequently amplified by PCR 
under following conditions: 30 sec at 98˚C, 15 cycles of 10 sec at 98˚C, 30 sec 
at 60˚C, 30 sec at 72˚C, then a final 5 min at 72˚C. The amplified libraries 
were purified using AMPure XP Beads (Beckman Coulter), according to 
manufacturer’s instructions, prior to assessing quality using Agilent 2100 
Bioanalyser, DNA 1000 chip, and quantified using Qubit® 2.0 Fluorometer, 
under standard operating procedures. 
 
2.2.9 RNA sequencing data analysis 
2.2.9.1 RNA sequencing Alignment 
The RNA sequencing results were analysed and validated in collaboration with 
colleagues from the GSTT&KCL BRC Bioinformatics core. All steps were 
performed using in-house Python scripts and the R packages FastQC and 
Tuxedo suite. Quality of RNA sequencing data was assessed using FastQC prior 
to alignment to known transcripts and the reference genome - including ERCC 
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synthetic controls - using TopHat2. The aligned RNA fragments were then 
assembled into transcripts using Cufflinks and CuffMerge generating count and 
FPKM (Fragments Per Kilobase of Exon Per Million Fragments Mapped) values 
per transcript. Counts were normalised against library size and filtered for a 
minimum read-count of n=smallest sample group e.g. n=24 controls whereas 
FPKM values were normalised against library and transcript size.  
2.2.9.2 Principle components analysis (PCA) 
Phenotype data file and normalised count file were loaded into R. Counts per 
million (CPM) were calculated and principle component analysis (PCA) 
performed. The table with calculated PCA values was saved and plotted using 
various pairs of principle component values (PC1 vs PC2, PC2 vs PC3, PC4 vs 
PC5) and coloured-coded for disease type, batch, sex or age using ggplot (R) 
(see Appendix 1 for the script).  
2.2.9.3 Differential expression analysis 
Differential expression between phenotype groups was assessed using EdgeR 
(Bioconductor). Prior to this the ‘remove unwanted variables’ (RUV) method 
RUVseq (Bioconductor) was employed and principle components analysis 
(PCA) using ggplot2 (R) to assess any unwanted variation and biases in the 
data. EdgeR used TMM (trimmed mean of M) with M=library size, to correct 
the count values for RNA library compositional biases prior to building a matrix 
incorporating normalised count values, RUV values and PCA values for age, 
sex, batch and disease type. EdgeR then assessed any difference in expression 
due to disease status following correction of all other observed biases within 
the data. The rate of type I error was controlled for using the Benjamini-
Hochberg method for false discovery rate (FDR). Output files contained fold 
change, p-value, FDR controlled q-value, and counts per million (CPM) (See 
Appendix 2 for the script).  
To confirm pathway analysis results, the differential expression analysis was 
repeated for CD vs controls now including smoking status as a covariate in 
addition to above mentioned covariates.  
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2.2.9.4 Gene Set Enrichment Analysis 
Gene Set Enrichment analysis (GSEA) (https://www.broadinstitute.org/gsea - 
Broad Institute) 148 was employed to assess enrichment of known biological 
pathways within the differentially expressed genes. GSEA assesses the 
presences of the genes of interest against known gene sets within their 
Molecular Signatures Database (MSigDB) 148. A pre-ranked analysis method 
was employed within GSEA where a ranking score was calculated for each gene 
by multiplying the –LOG10(q-value) by the direction of fold change (e.g. -1 or 
1), listing genes with a highest significant change in expression and a positive 
or negative fold change at the top or bottom of the ranked list, respectively. 
Further parameters allowed up to 1000 permutations and applied a weighted 
enrichment statistic. GSEA examined if members of MSigDB gene sets were 
clustered towards the top or bottom of the ranked DE gene list, determining 
correlation between the gene set and the phenotypic class by weighting each 
step. Statistical methods calculated a Normalised Enrichment Score (NES) for 
each gene set incorporating the significance of the Enrichment Score (ES). In 
addition, type I error was controlled for by calculating a false discovery rate 
(FDR).  
A two-sided probability test was employed using the “prop.test” function in R, 
to assess if the probability of success in several groups was the same by 
calculating the chi-square. 
 
2.2.9.5 Ingenuity Pathway Analysis 
Ingenuity pathway analysis (IPA) core analysis (IPA®, QIAGEN Redwood City, 
www.qiagen.com/ingenuity) was utilised to investigate if genes involved in 
curated canonical biological pathways were affected by the previously 
identified differentially expressed gene lists. IPA employs the ingenuity 
knowledge base, a platform built upon a wide range of biological information 
including textbooks, reviews, published biomedical literature, internally 
curated knowledge and a variety of public databases. A spreadsheet containing 
ensemble IDs, fold change values, q-values and expression (FPKM) values was 
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uploaded into IPA. All genes identified to be expressed with intestinal tissue 
(FPKM >1, n=15,553) were indicated as the reference set and genes that were 
significantly differentially expressed (DE q-value <0.05) were indicated as 
genes of interest. Furthermore, only effects observed within IPA pathways 
curated from data collected from humans and human cell lines were included. 
IPA calculates a p-value using the right-tailed Fisher Exact Test and a ratio score 
for each pathway where, the p-value indicates the likelihood that the 
association between input genes and a pathway is due to random chance and 
ratio being based on the number of input genes per pathway over the total 
number of genes in that pathway.  
 
2.2.9.6 Expression quantitative trait loci (eQTL) analysis 
Matrix eQTL (R) (http://www.bios.unc.edu/research/genomic_software/ 
Matrix_eQTL/runit.html) was employed to perform a genome wide eQTL 
analysis, to explore correlations in variation of gene expression within the 
colonic transcriptome with genetic variation in each individual (SNPs). The 
input data included quantitative gene expression values (FPKM), genome-wide 
SNP genotype data for 241,995 SNPs from Infinium Human Core Exome or 
Human Core array and optional additional covariate data, (see section 
2.2.9.6.1 – 2.2.9.6.3 for details). The analysis parameters within Matrix eQTL 
were set to look for significant associations (or correlations) between each of 
241,995 input SNPs with changes in expression of genes located within 1Mb of 
the SNP (cis-eQTLs). P-values and False Discovery Rate (FDR) values were 
generated by Matrix eQTL using a linear regression and the Benjamini-
Hochberg method respectively (See Appendix 3 for the script). 
 
2.2.9.6.1 Gene expression data input 
Generated colonic whole RNAseq transcriptome data was utilised, including 
non-coding RNAs, to perform a comprehensive eQTL survey. A gene expression 
matrix was created including all transcripts with expression above 1 FPKM 
(Fragments Per Kilobase of exon per Million fragments mapped), for each of 
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the 127 patient or control samples. Transcripts located on chromosomes X and 
Y were excluded, resulting in a total of 17,258 genes. Prior to entry into Matrix 
eQTL FPKM values were standardized to have a mean of zero by dividing the 
FPKM of a gene minus the average FPKM of that gene by the standard 
deviation.  
 
2.2.9.6.2 Genotype data input 
Generated genome-wide SNP data from 121 samples was utilised to perform 
the eQTL survey. Genome studio was used to export raw data from the samples 
prior to processing by PLINK to remove indels, tri-allelic SNPs, SNPs with a 
minor allele frequency below 5% and SNPs not within Hardy-Weinberg 
Equilibrium (p<0.0001). Due to the 2 different SNP arrays used there was 
incomplete data for a subset of SNPs, only SNPs containing genotype data for 
over half of the samples (n ≥ 60) were included in the analysis. The genotype 
file following filtering of all above mentioned criteria contained genotype data 
for 241,995 SNPs.  
 
2.2.9.6.3 Covariates input files 
To enable correction for any possible bias in the expression data, a covariate 
file containing the principle components 1-4 from the original PCA analysis (see 
section 2.2.9.2) was included in the matrix eQTL analysis.  
 
2.2.9.6.4 IBD associated SNP coverage  
Linkage disequilibrium (LD) was assessed between 502 IBD index SPNs (based 
on current literature) and the genome-wide SNP genotype data for 241,995 
SNPs evaluated within the patient and control samples using Infinium Human 
Core Exome or Human Core array (see section 2.2.7), in order to establish 
coverage of IBD associated SNPs within the eQTL analysis. The 1000 Genomes 
phase 3 reference data were utilized to calculated LD scores using PLINK. Files 
containing the genotyped SNPs and IBD index SNPs including their genome 
locations were loaded into PLINK and the reference data set was selected as the 
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1000 Genomes phase 3 reference data, prior to identifying direct matches 
between the IBD index SNPs and genotyped SNPs. Following removal of the 
direct matched SNPs, LD scores were calculated for each IBD index SNP with 
the genotyped SNP. Any genotyped SNP with an r2 ≥ 0.8 was indicated as 
tagging an IBD index SNP. 
 
2.2.10 Intestinal tissue cell phenotyping and analysis 
2.2.10.1 Generation of single cell suspension from intestinal pinch 
biopsies 
Single cell suspensions were generated from 2-4 uninflamed gut pinch biopsies 
per patient collected during routine colonoscopies at Guy’s and St Thomas’ 
Hospital after informed consent was taken. The biopsies were transferred into 
10 ml collection media and incubated for 10 min at 37˚C under shaking 
conditions. The tissue was transferred into a petri-dish and cut into tiny pieces 
using forceps and a scalpel. Next, the pieces were washed off the petri-dish into 
a falcon tube containing 10 ml of freshly prepared digest followed by an 
incubation at 37˚C for 30 min under shaking conditions. The remaining 
connective tissue bonds were disrupted by syringe aspiration through a 30-
gauge needle. The single cell suspension was collected in 50 ml falcon tube and 
debris was removed by passing cells through a 100 µm cell strainer (BD). 
Subsequently, cells were washed and resuspended in culture media prior to 
counting and estimating viability using Trypan blue dye exclusion (SIGMA).  
  
2.2.10.2 Flow cytometry based cell phenotyping 
The generated single cell suspensions (n=25) were distributed at 2x105 
cells/tube in 5 ml polystyrene tubes (n=5 tubes per donors; unstained, 
antibody mix 1, 2, 3 and 4) prior to incubation on ice for 10 min in the presence 
of FcR block (Miltenyi) followed by 30 min in the presence of the relevant mAB 
cocktail (Table 2.3 -Table 2.5). After washing with FACS buffer and 1 µM DAPI 
(AnaSpec) was added prior to analyses by FACS CantoII.  




Table 2.4 | Biopsy antibody cocktail 
Antibody Amount 
(µl) 
Supplier Cell type 
CD326 – PE 2.5  BioLegend Endothelial cells 
CD45 – APC/Cy7 2.5 BioLegend Lymphocytes 
DAPI - AnaSpec Live/Dead stain 
 
 
Table 2.5 | FMO for CD45 with Isotype control 
Antibody Amount 
(µl) 
Supplier Cell type 
CD326 – PE 2.5  BioLegend Endothelial cells 
APC/Cy7-IgG k1 Mouse  2.5 BioLegend - 
DAPI - AnaSpec Live/Dead stain 
 
 
Table 2.6 | Leukocyte antibody cocktail 
Antibody Amount 
(µl) 
Supplier Cell type 
CD45 – APC/Cy7 2.5  BioLegend Lymphocytes  
CD4 – APC 2.5 BioLegend T helper cells 
CD8 – FITC 2.5 BioLegend Cytotoxic T cells  
CD14 – PE 2.5 BiolLegend Monocytes 
CD68 – PE-Cy7 2.5 BioLegend Macrophages 
CD66b – PerCP/Cy5.5 2.5 BioLegend Neutrophils 
DAPI - AnaSpec Live/Dead stain 
 
2.2.10.3 Deconvolution biopsy composition 
A deconvolution model was designed and build to enable prediction of cell type 
fractions within the intestinal biopsies from which gene expression data was 
generated (see section 2.2.2). Cellular phenotype data generated by flow 
cytometry (see section 2.2.10.2) for n = 21 was loaded into SAS (statistical 
analysis software) and combined with normalised count expression data for 
15,517 genes, for these patients. A univariate analysis using a marginal model 
was employed to identify which genes exhibited the most significant influence 
on cell count. The Mixed Model included intra-patient covariance to account 
for the known correlation between the cell types (using SAS). The genes 
identified to be significantly associated (p ≤ 3.2x10-6) with cell count through 
the univariate analysis were progressed into a multivariate analysis to identify 
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which set of significant genes can collectively predict cell count per cell type, 
using lasso (least absolute shrinkage and selection operator). The univariate 
analysis in lasso was performed for each cell type individually, using the same 
set of significant input genes. Cell types predicted by gene expression included 
epithelium cells (CD45neg/CD326pos), leukocytes (CD45pos), T helper cells 
(CD45pos/CD4pos), cytotoxic T cells (CD45pos/CD8pos) and monocytes 
(CD45pos/CD14pos). Lasso generated an estimate score for each of between 16-
20 ‘predictive genes’, in addition to an intercept score for each cell type 
(Appendix 6). The cell count for each cell type was calculated by multiplying 
the gene scores by the gene expression value for each of the ‘predictive genes’ 
and added to the intercept value (see equation below).  
 
Using the estimate model that was constructed, predicted count values were 
compared with observed values (generated by flow cytometry) for the n = 21 
patient used to build the model (using SAS). Finally, the estimate model was 
employed to predict cell counts for 57 CD intestinal biopsies based on their 
gene expression values of the ‘predictive genes’.  
 
2.3 Methods Project 2: Investigation of transcriptional 
biomarkers in prediction of relapse 
2.3.1 Power Calculation 
This study was designed as a pilot study. Under the current design, identifying 
transcriptional signatures between relapsed and non-relapsed CD patients 
within three different patient groups, we are not powered to identify 
differentially expressed genes with small effects or which are high variability. 
It was decided to recruit CD patients from three different cohorts; i) Post-
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resection surgery patients, ii) patients being withdrawn from anti-TNF 
treatment, or iii) routine gastroenterology/IBD clinic patients who have had 
active disease within the last year, for logistical reasons. If the generated data 
form this pilot study supports our hypothesis that changes in the transcriptome 
can indicate/predict relapse in CD patients, a full size study should be initiated.  
 
2.3.2 Sample Collection 
Blood samples were collected, either by myself or Dr Kamal Patel, from CD 
patients at Guy’s and St Thomas’ Hospital after informed consent was given. 
Recruited patients included 49 patients in endoscopic remission (Rutgeerts 
score ≤ 1) or self-reported clinical remission at time of recruitment. Their 
progress was monitored over a 12-month period to determine who did and did 
not relapse. A peripheral blood samples (50 ml) was collected in EDTA tubes 
(BD Biosciences) for isolation of peripheral mononuclear cells (PBMCs) at time 
of recruitment to the study (remission sample) and either at time of relapse or 
after 12 months, whichever came first (follow-up sample). Patients within three 
subsets were recruited: 
 20 post-surgery patients, either resection or stoma reversal surgery.  
 20 routine gastroenterology clinic patients 
 9 patients having been withdrawn from anti-TNF treatment, Humira or 
Infliximab  
 
The post-surgery patients were recruited either two weeks post their resection 
surgery or at the day of their stoma reversal, guaranteeing full remission. The 
routine gastroenterology clinic patients were recruited when reporting clinical 
remission during their appointment and the anti-TNF withdrawal patients were 
recruited eight week following their final Infliximab injection (or two weeks for 
Humira). Relapse was assessed at a 6-month follow-up colonoscopy for the 
post-surgery patient cohort, with a Rutgeerts score ≥ 2 classified as relapse. For 
the anti-TNF withdrawal and gastroenterology clinic patient cohorts, relapse 
was classified as a need to change the patients’ medication. Mean age for the 
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Gastro-clinic patients was slightly higher, at 44.8, than for the post-surgery 
(32.7) and anti-TNF withdrawal patients (33.3) (Table 2. 7). 









Mean age  32.7 33.3 44.8 
# Female  14 5 8 
Percentage  70% 56% 40% 
# Male 6 4 12 
Percentage 30% 44% 60% 
 
 
2.3.3 PBMC isolation 
Whole blood was transferred to 50 ml falcon tubes and under-layered with 10 
ml lymphocyte separation media (MP Biochemicals Europe) prior to 
centrifugation (2000 rpm, 20 min, 21˚C) without brakes. Following 
centrifugation, lymphocytes were isolated from the interphase, transferred to a 
new 50 ml Falcon tube and washed with PBS (2000 rpm, 10 min, 21°C). 
Subsequently, cells were washed twice more with PBS (1000 rpm, 10 min, 
21°C) and resuspended in PBMC media prior to counting and estimation of 
viability using Trypan blue dye exclusion (SIGMA). Isolated PBMCs were 
cryopreserved in FBS + 10% DMSO, using temperature controlled freezing at 
-80˚C.  
 
2.3.4 Thawing and resting of cells 
Cryopreserved PBMCs were thawed in a 37˚C water bath prior to dilution in 
12 ml of cold (4°C) PBMC media. Following centrifugation at 1800 rpm for 5 
min, cells were washed twice with 15 ml PBMC media (5 min at 1800 rpm). 
Supernatant was removed and cells were resuspended at 1x106 cells/ml in 
PBMC media + 10U/ml DNAse I and transferred into a cell culture flask 
(ThermoFisher) prior to 2-hour incubation at 37˚C and 5% CO2. 
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2.3.5 Flow cytometry based cell sorting 
Thawed and rested PBMCs were transferred into 50 ml Falcon tube following 
detachment of cells from cell culture flask using cell scraper and cold PBS 
washes. Cells were pelleted (5min at 1800 rpm, 4˚C), resuspended and 
counted using Trypan Blue Dye exclusion. Cells were washed in FACS buffer 
and incubated for 10 min in the dark on ice in the presence of FcR block 
followed by 30 min in the presence of the cell sorting mAB cocktail (Table 2. 
8). After washing with FACS buffer, the cells were filtered through a 30 µm 
grid (Miltenyi) and resuspended at 10-20 x106 cells/ml in cell sorting solution. 
1 µM DAPI (AnaSpec) was added prior to cell sorting into CD4pos, CD8pos and 
CD14pos cell population using an Aria III cell sorter (BD) which was performed 
by the Guy’s and St Thomas/KCL BRC Flow Cytometry Core Service. The purity 
of the separated cell populations, CD4pos, CD8pos and CD14pos, was then 
assessed by Flow Cytometry.  
 
Table 2. 8 | Cell sorting antibody cocktail 
Antibody Amount 
(µl) 
Supplier Cell type 
CD3 – PerCep/Cy5.5 5.0 Cambridge Biosciences T cells 
CD14 – PE 5.0  Cambridge Biosciences Monocytes 
CD4 – APC 5.0 Cambridge Biosciences T helper cells 
CD8 – FITC 5.0 Cambridge Biosciences Cytotoxic T cells 
DAPI - AnaSpec Live/Dead stain 
 
2.3.6 Cell culture and activation 
Following cell separation (section 2.3.4), purified populations of immune cells 
(CD4pos, CD8pos or CD14pos) were pelleted via centrifugation (5 min at 1800 
rpm, 4˚C), supernatant removed and resuspended in PBMC media at 2x105 
cells per well (at 2 wells per sample) (Figure 2.1). 1 out of 2 wells per sample 
were immune stimulated by either CD3/CD28 T-activator beads 
(ThermoFisher) at 50 µl per million cells, (CD4pos and CD8pos cells) or 0.5 mg 
Lypopolysaccaride (LPS) (Sigma-Aldrich) (CD14pos cells) prior to 4-hour 
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incubation at 37˚C and 5% CO2. For samples with less than 2x105 cells per 
sample no stimulation was executed. Following incubation, cells were 
transferred into Eppendorf tubes and centrifuged at 300 x g for 5 min at 4˚C. 
Supernatant was removed and cell pellets resuspended in 700 µl Qiazol 
(Qiagen) followed by a 1 min vortex to lyse cells. Lysates were stored at -80˚C 
until further processing. 
 
  
2.3.7 RNA preparation 
RNA was extracted using an RNeasy miRNA micro Kit according to 
manufacturer’s instructions (QIAGEN Gmbh). Briefly, the samples were thawed 
at 37˚C, incubated for 5 min at room temperature prior to addition of 180 µl 
chloroform. Following 15 min centrifugation at 4˚C and 12,000 x g, the 
aqueous phase was transferred and ethanol added prior to transfer onto 
MiniElute columns. Multiple wash steps were performed on column using RWT 
and RPE buffer. Genomic DNA was removed using RNase free DNaseI (Qiagen). 
Lastly, 28 μl RNase-free water was added during two elution steps, to elute the 
RNA. RNA was quantified using Qubit fluorimeter.  
 
Figure 2.1 | Cell culture plate layout 
Example cell culture plate, with each circle representing a well, containing 
CD4+, CD8+ and CD14+ separated cells, stimulated and unstimulated.  
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2.3.8 Real-time qRT-PCR 
2.3.8.1 Reverse transcription polymerase chain reaction (RT-PCR). 
30 ηg of RNA was added to 4 μl 5x iScript reaction mix (containing oligo T 
primers), 1 μl iScript reverse transcriptase enzyme (iScript cDNA Synthesis Kit, 
BIORAD) and nuclease-free water. After gently mixing samples were incubated 
at 25°C for 5 min followed by 30 min at 42 °C and finally 5 minutes at 85 °C. 
The resultant cDNAs were stored at -20°C until needed for further steps.  
 
2.3.8.2 Assessing cell stimulation by Real-Time quantitative PCR (RT-
qPCR) of the TNFα gene 
25 ng cDNA was dispensed in a 96-well plate along with qPCR master mix 
(ABgene), as well as Taqman assay primers for either the TNFα target gene or 
18S endogenous control gene (Table 2.2). Final reaction volume was made up 
to 20 μl with RNAse free water. Following centrifugation, the plate was placed 
in the ABI 7900-HT Real-Time PCR system and amplified under the following 
conditions: 15 min at 95°C, 40 cycles of (15 sec at 95°C, 1 min at 60°C). 
Abundance of mRNA was calculated by comparing the threshold PCR cycle (Ct, 
cycle at which logarithmic amplification was observed) of the unstimulated 
samples with the stimulated samples, for both the target and the endogenous 
control gene (RP18S) and represented as ∆Ct (delta cycle threshold). The 
relative quantification (RQ) was then calculated by taking 2^(∆Ct PR18S - ∆Ct 
TNFα).  
 
2.3.9 MicroArray sample preparation 
Amplification and labelling of low input RNA samples for gene expression 
microarray analysis was performed by Dr David Chambers from the Drug 
Discovery Unit, Wolfson CARD, King’s College London. See the methods 
described below. 
2.3.9.1 NuGen Ovation RNA Amplification System V2 
RNA extracted from CD4pos, CD8pos and CD14pos separated cells - stimulated 
and unstimulated - were normalised to 1 ng/µl and quality assessed using 
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Bioanalyser Pico RNA chips (Agilent technologies). 5 ng RNA starting material 
per sample was used for cDNA generation and amplification using Ovation RNA 
amplification system V2 (NuGen), according to manufacturer’s protocol.  
2.3.9.2 NuGen Encore BiotinIL module 
Above mentioned amplified cDNA was labelled for hybridization to HumanHT-
12 V4 expression BeadChip (Illumina) using Encore BiotinIL module (NuGen), 
according to manufacturer’s protocol, generating 2-4 µg of labelled cDNA per 
sample. Samples were quantified using Nanodrop One/OneC (Thermo 
Scientific) and normalised to 150 ng/µl prior to submission to the BRC 
Genomics core for microarray analysis using the HumanHT-12 V4 expression 
Beadchips (Illumina).  
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3. Quality control colonic transcriptomics data 
3.1 RNA and DNA quantity and quality 
An average of 60μg of total RNA was extracted from 20-40mg of large intestinal 
tissue with RNA Integrity Number (RIN) values ranging from 2.2 to 8.6, the 
average RIN being 7. The Agilent software tool calculated RIN scores per 
sample based on the ratio of the ribosomal bands as well as the presence or 
absence of degradation product. RIN values range from 1-10, with scores of >7 
indicative of high quality RNA. For this work, a cut-off of 6 was implemented 
as the RNA sequencing technology does not rely on poly(A) binding. Overall 
159 bowel tissue samples were collected and 134 yielded RNA with a RIN >6. 
The absence of DNA contamination was confirmed using a reverse transcriptase 
(RT) negative control during the amplification of the cDNA sequencing 
libraries. Additionally, 175 blood samples for RNA (Paxgene tubes) and DNA 
extraction (EDTA tubes) were collected in parallel to the biopsies. Paxgene 
whole blood RNA extractions were performed on 151 samples resulting in a 
mean yield of 5.9 µg of whole RNA and a mean RIN of 7.5. DNA extraction 
resulted in a mean yield of 153 µg, and was completed for 174 out of 175 
samples. For this study 128 high quality RNA and matched DNA samples were 
taken forward for whole RNA sequencing and genotyping.  
3.2 Ribosomal depletion and library preparation 
RNA samples to be used for Next Generation Sequencing (NGS) of the whole 
transcriptome, require depletion of ribosomal RNA (rRNA). Ribosomal 
depletion relies on rRNA specific probe binding prior to removal using magnetic 
beads, preserving all coding and non-coding transcripts. Intestinal biopsy 
samples contained a high bacterial content, therefore a combined RiboZero kit 
depleting both human and bacterial rRNA (see Materials and Methods 2.2.8.1) 
was used. Bioanalyzer electropherograms were generated pre- and post- rRNA 
depletion to confirm effective removal of 18S and 28S rRNA peaks (Figure 3.1) 
which was a requirement for taking the samples forward for library 
preparation. 






Figure 3.1 | Quality control RNA ribosomal removal 
Electropherograms showing fluorescence units (FU) on y axis versus size, nucleotides (nt), on 
the x axis. (A) Total RNA; marker (25nt), miRNA and 5s rRNA (<200nt), 18s subunit 
(~2000nt) and 28s subunit (~5000nt). (B) Ribosomal depleted RNA; marker (25nt) and 
mRNA + miRNA (100 – 2000nt). (Plots generated through the bioanalyzer (Agilent 
Technologies)). 
 
The two main subunits of human ribosomal RNA are 18S and 28S with sizes 
1869 nt and 5070 nt, respectively. The 16S and 23S bacterial ribosomal 
subunits could not clearly be identified, suggesting low abundance of bacterial 
rRNA or a lack in sensitivity of the RNA Nano chip. The bacterial and human 
5S subunit (120 nt) would most likely be present in the peak observed at <200 
nt, co-localising with the miRNA fraction (Figure 3.1A). Post-ribosomal 
depletion bioanalyser traces suggested complete elimination of the previously 
observed ribosomal peaks, resulting in whole RNA between 150-2000 
nucleotides (nt) (Figure 3.1B). cDNA libraries for sequencing were 
subsequently prepared; 32 libraries were generated using the Epicentre 
Scriptseq chemistry and 96 using the Illumina Truseq chemistry. The change in 
chemistry was decided upon following persistent issues with the Epicentre 
ScriptSeq kit and poor reproducibility. Following the library preparation and 
clean up the quality of the cDNA libraries was assessed via analysis on a DNA 
high sensitivity or DNA 1000 bioanalyzer chip for the Epicentre ScriptSeq and 
Illumina TruSeq cDNA generated libraries, respectively (Figure 3.2). 




Figure 3.2 | Quality control library preparation 
Electropherograms showing fluorescence units (FU) on y axis versus size, base pairs (bp), on 
the x axis (A) cDNA library (150–1000bp) and markers following library preparation using the 
Eppicentre Scriptseq kit. (B) cDNA library (200–500bp) and markers following library 




The median of cDNA library size was observed, as expected, at approximately 
200-300 bp (100 bp fragments plus ~60-70 bp adapters ligated on either side). 
The Illumina TruSeq libraries showed high symmetry within their distribution 
and high similarity across cDNA library samples (Figure 3.2B) whereas the 
Epicentre ScriptSeq libraries showed wider variation in distribution, between 
200 and 1000, with an extended plateau like shape (Figure 3.2A) and larger 
inter-sample variation. The observed variation within the Epicentre Scriptseq 
cDNA libraries suggested lower efficiency during RNA fragmentation. 
 
3.3 FastQC – RNA sequencing QC 
Quality control of the RNA sequencing data was performed by the BRC 
bioinformatics unit using FastQC. FastQC calculated a quality score (Q) of each 
given base by estimating the probability of the base being called incorrectly. A 
Q of 20 represents an error rate of 1 in 100 and a Q of 30 an error rate of 1 in 
1000 corresponding with a base call accuracy of 99% and 99.9%, respectively. 
The FastQC plots (Figure 3.3A-D) represent the highest and lowest quality 100 
bp cDNA library fragments using either Epicentre or Illumina library 
preparation methods. Libraries created with the Epicentre chemistry showed 
good quality overall, with the majority of base pairs showing Q ≥30. However, 
variability in quality, specifically towards the end of the library fragment, was 
observed within the Epicentre Libraries (Figure 3.3 A.1-A.2). FastQC plots of 
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cDNA library fragments generated using the Illumina chemistry are indicative 
of consistent high quality sequencing, with Q scores approaching 40 (Figure 
3.3 B.1-B.2). Overall, Figure 3.3 suggests the cDNA libraries have been 





3.4 RNAseq read alignment  
Following the quality check by FastQC, the Tuxedo Suite was employed for 
further analysis of the RNA sequencing data. The alignment was performed by 
the BRC bioinformatics unit. Tophat2, part of the Tuxedo suite, enabled 
alignment of the RNA-sequence reads against known transcripts and the 
reference genome, providing the most likely genomic location from where the 
sequence reads originated. Following alignment, TopHat2 estimates the 
Figure 3.3 | FastQC plot 
Quality score (Q), calculated by estimating the probability an incorrectly 
called base shown for each position (bp) in a cDNA fragment read. Within 
Epicentre generated libraries (A) and Illumina generated libraries (B). Where 
A.1 and A.2 represent the best quality libraries and A.2 and B.2 the lowest 
quality libraries.  
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percentage of reads per sample mapped back to the reference transcriptome 
and reference genome, allowing evaluation of the data (Figure 3.4). The 32 
Epicentre ScriptSeq cDNA libraries were sequenced in two batches of 16 
samples, P632 (Figure 3.4A) and P344 (Figure 3.4B), with 4 indexed and 
pooled samples run across 2 lanes of a flow cell, in order to provide a target 
coverage of 100X. The 96 Illumina TruSeq cDNA libraries were sequenced in 
three batches of 32 samples, P478 (Figure 3.4C), P524 (Figure 3.4D) and 
P566 (Figure 3.4E), at 4 samples per lane.  
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Figure 3.4 | RNA sequencing read alignment per sample 
Stacked column chart displaying number of RNA sequencing reads aligned to the reference 
genome (y-axis) per individual sample (x-axis) in each sequencing batch (A-E). Height of bar 
shows total number of reads sequenced (red), total number of aligned reads (green), number of 
uniquely aligned reads (turquoise) and number of uniquely aligned reads minus duplicate reads 
(purple). (Alignment was performed by the Bioinformatics unit) 
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Generated transcription reads showed a high level of alignment to the reference 
(60-70%: P362 and P334; 80-90%: P478, P524 and P566) (Figure 3.4). 
Considering the libraries contained transcripts from both non-coding and 
coding RNAs, making mapping more challenging, the observed mapping rates 
are indicative of good performance of the RNA sequencing experiment. 
Following removal of duplicate reads (30%-50%), a coverage of approximately 
40 million reads for each of the Epicentre libraries and 70 million reads for the 
Illumina libraries was achieved (Figure 3.4). Transcripts were assembled using 
Cufflinks and CuffMerge, generating datasets containing count values or FPKM 
(Fragments Per Kilobase of exon per Million fragments mapped) values for 
further analysis. 
 
3.5 ERCC-Spike in controls 
In addition to the QC steps performed during analysis, an ERCC spike-in control 
was added into the libraries prior to sequencing to provide an internal control. 
Known concentrations of ERCC spike-in control RNAs were plotted against 
output FPKM values to produce a standard curve which showed high 
correlation between input amount and FPKM estimate (R2 = 0.907) (Figure 
3.5). Once high correlation was established, the ERRC spike-in controls were 
utilized to correct for any biases between libraries. Covariate values were 
calculated based on ERCC spike-in control values and incorporated in any 
downstream analysis (Materials and Methods). 





3.5 Principle component analysis 
As a final check, following successful alignment, removal of duplicates, 
transcripts assembly and QC, the presence of potential biases in the data was 
investigated. Principle component analysis (PCA) was performed to assess 
variation between samples based on the generated normalised gene expression 
data. PCA is a statistical procedure which converts a set of potentially 
correlated variables into a set of linearly uncorrelated variables called principle 
components (PC). Multiple principle components can be generated in this way 
with the first principle component (PC1) having the largest possible variance. 
The first six principle components were investigated to establish if the observed 
variance in the dataset was influenced by any of the following potential 
covariates: disease status, sex, age and sequencing batch (Figure 3.6 and 
Figure 3.7).  
Figure 3.5 | Calibration curve of ERCC spike-in control 
Calibration curve showing the ERCC spike concentrations versus 
measured FPKM spike values, with R2 = 0.907.  
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When plotted, PC1 versus PC2 indicated no effect due to sex (Figure 
3.6B) or age (Figure 3.6C). For disease status, a minor effect of phenotype on 
distribution was observed with CD cases clustering slightly further to the lower 
left of the plot than UC or controls (Figure 3.6A). When investigating the PCA 
distribution with respect to sequencing batch a clear clustering together of 
batches P334 (red) and P362 (olive green) versus P478 (green), P524 (blue) 
and P566 (purple) was observed (Figure 3.6D). This demonstrated a clear bias 
related to the sequencing chemistry used; P334 and P362 were generated using 
the Epicentre ScriptSeq kit whereas P478, P524 and P566 were generated using 
the Illumina TruSeq kit. Correction for this effect was therefore implemented 
within downstream analysis.  
 
Figure 3.6 | Principle components analysis PC1 vs PC2 
Principle component analysis (PCA) based on normalised gene expression per sample 
for the first (PC1) and second (PC2) principle component. The effects of disease status 
(A), sex (B), age (C) and batch (D) on PC1 vs PC2 distribution was investigated. The 
ellipse in plot A-D represents the 95% confidence interval for each subgroup. (A) Each 
dot represents a sample with red indicating a CD and blue indicating a UC diagnosis 
and green dots indicate control samples. (B) Samples coloured based on sex, where red 
dots are female and blue dots are male. (C) Samples coloured on age, from youngest 
(dark blue) through to oldest (light blue). (D) Sample coloured according to 
sequencing batch. 
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Random distribution was confirmed for disease status, sex, age and batch for 
all other principle components (PC3-PC6), with the exception of one major 
outlier observed in PC5 vs PC6 (Figure 3.7A-D). This sample, a female CD 
patient sequenced in batch P334, was therefore subsequently removed from 




Figure 3.7 | Principle components analysis for PC5 vs PC6  
Principle component analysis (PCA) based on normalised gene expression per sample for the 
fifth (PC5) and sixth (PC6) principle component. The effects of disease status (A), sex (B), age 
(C) and batch (D) on PC5 vs PC6 distribution was investigated. The ellipses in plots A-D 
represent the 95% confidence interval for each subgroup cluster. (A) Each dot represents a 
sample with red indicating CD, blue indicating UC and green indicating control samples. (B) 
Samples coloured with respect to gender, red dots are female and blue dots are male. (C) 
Samples coloured with respect to age, from youngest (dark blue) through to oldest (light blue). 
(D) Samples coloured according to sequencing batch. 
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3.6 Correlation between RNAseq datasets 
To validate batch-effect corrections for the two library chemistries was 
sufficient (Illumina vs Epicentre), the correlation between them was 
investigated. Fold change values between IBD cases and controls, generated by 
the differential expression analysis, were used to perform a Pearson correlation 
test (Figure 3.8).  
 
 
Statistically significant positive correlation was observed between all pairwise 
comparisons (p<2.2x10-16). These results show that the observed batch effect 
has been successfully corrected, and the combined dataset of 127 samples could 
be confidently used for further analyses including the differential expression 
analysis. 
Figure 3.8 | Correlation test in RNAseq datasets 
Pearson correlation test investigating correlation between fold change (FC) values of all 
transcripts (17,936) in the RNAseq datasets; 31 libraries generated with Epicentre ScriptSeq, 
96 libraries generated with Illumia TruSeq and 127 samples from both chemistries combined. 
Each black dot represents a transcript within the scatterplots with a correlation and p-value 
related to each scatterplot shown top right. The histogram represents the normal distribution 
of each dataset.  
 




Quality and reliability was assessed at every stage from RNA input to the final 
RNA sequencing data, confirming high quality data was generated. Due to 
circumstances two different chemistries to generate the whole RNA libraries 
were used. This resulted in a strong batch effects, by applying stringent QC 
measures and incorporating batch effect as a covariate into downstream 
analysis models, we successfully corrected for this batch effect. The combined 
dataset of 127 samples can be confidently used for further analyses including 
the differential expression analysis.  
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4. Qualitative and quantitative analysis of the 
transcriptome in the colon 
The introduction of GWAS in 2006 initiated a major advance in unravelling the 
complex genetics of CD and UC. To date 27 GWA studies have been performed 
on CD and 21 on UC identifying > 200 IBD susceptibility loci 106, the highest 
for any single disease. Studies by Jostins et al, Mokry et al and Huang et al, all 
contribute to the theory that the majority of IBD associated SNPs are correlated 
with non-coding variants that perturb regulation of gene expression instead of 
directly altering gene function, making identification of causal genes 
challenging 92,112,149. Recent progress in prioritising causal genes has been 
made through fine-mapping and expression quantitative trait (eQTL) analysis, 
with 16 of the known IBD susceptibility loci having been reduced to 1 causal 
variant at >95% probability 108,112. A further 445 genes have been prioritised 
to be involved in IBD pathogenesis based on investigation of gene co-
localisation, protein-protein interactions, functional connectivity of a gene 
within literature and eQTL analysis 107,150. In order to attempt to understand 
how the majority of common susceptibility loci may influence IBD 
pathogenesis, the focus of research will have to shift focus from GWA studies 
to gene expression studies. Here whole RNA sequencing data from uninflamed 
large intestinal tissue was utilized to investigate the intestinal transcriptome 
including known IBD susceptibility loci. Differential gene expression was 
investigated between CD cases and controls, IBD vs controls, UC vs control and 
UC vs CD to further the understanding of CD and IBD pathogenesis. 
 
4.1 Sample collection 
The intestinal biopsies were taken from un-inflamed large intestine throughout 
the transverse and descending colon. Tissue samples from 75 CD patients, 28 
UC patients and 24 controls were selected for whole RNA sequencing. The 
imbalance in cohort sizes was partly due to the original study design; previously 
the focus lay on CD patients only. Furthermore, the availability of patients 
played a role; there is a higher percentage of CD patients versus UC and non-
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IBD patients having colonoscopies. It was decided to collect un-inflamed 
colonic tissue over inflamed tissue. The use of un-inflamed vs inflamed tissue 
within expression and functional studies is topic of discussion. Inflamed tissue 
samples show stronger expression signals of immunological and/or pro-
inflammatory IBD-associated genes, but it is hard to distinguish if these genes 
are upregulated due to the primary cause of disease or just secondary to the 
inflammation that results. Using un-inflamed intestinal tissue will slightly 
reduce strength of the signal but will allow the separation between primary and 
secondary effects. An almost equal spread between males and females was 
observed; the CD cohort contained slightly more males (54% vs 46%), where 
the UC and control cohorts included slightly more females (46% and 42% 
versus 54% and 58%) (Table 4.1). The mean age within the cohorts was 
approximately 40 years of age, with UC patients being slightly older at mean 
44.1 years (Table 4.1). Treatment regimens, from patients at the time of the 
biopsy being taken, were not recorded. 
 
Table 4.1 | Patient demographics 






Mean age 38.5 44.1 41.4 
# Female 35 15 14 
percentage 46% 54% 58% 
# Male 41 13 10 
percentage 54% 46% 42% 
 
 
4.2 Qualitative analysis of the transcriptome in colon 
Colonic transcriptome data, corresponding to expression levels (FPKM, 
Fragment per Kilobase per Million) for 56,260 known transcripts, was 
generated for 127 (24 controls, 28 UC and 75 CD) samples. FPKM quantifies 
expression based on read counts normalised against gene size. A threshold 
value of FPKM = 1 to distinguish true expression from background was used. 
Out of the 56,260 aligned transcripts 17,936 exhibited expression of FPKM ≥1, 
corresponding to 32% of the human transcriptome. 77% of these transcripts 
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corresponded to coding genes and approximately 3% were identified as long 
noncoding RNAs (lncRNAs). Furthermore, 30 highly expressed ribosomal RNAs 
were observed, indicating imperfect ribosomal RNA removal (ribodepletion) 
prior to sequencing. Consequently, all rRNA encoding transcripts were 
removed from further analyses.  
To date, 224 IBD susceptibility loci have been identified (Appendix 5). 
In this study it was established that a total of 2,971 transcripts mapped to 
within 500 kb of one of the known IBD susceptibility loci. All IBD susceptibility 
loci were observed to contained a minimum of one transcript ≥1 FPKM, with 
the exception of IBD locus 6.03 (Chr6:14211961-15234463). Although none 
are expressed above background, locus 6.03 has been shown to contains 9 
transcripts (all non-coding RNAs), none of which have previously been 
implicated in IBD pathogenesis. Within the 224 known IBD susceptibility loci, 
16 have been reduced to a single causal variant and various others have been 
reduced to highly suggestive variants. Table 4.2 contains the genes directly 
affected or most likely affected by these identified causal and suggestive 
variants (Table 4.2). When investigated, the genes affected by the 16 causal 
variants all showed to exhibited expression above background (Table 4.2). 
Genes affected by the highly suggested variants showed expression levels to 
range from 1.9 to 83 FPKM; with IRGM, IL12B and BTNL2 failing to reach 
expression levels above background (Table 4.2). 
  
Table 4.2 Level of expression of top IBD susceptibility genes 
Ensemble ID Gene Name Mean FPKM IBD loci  
ENSG00000162594  IL23R 4.4 1.07 
ENSG00000134242 PTPN22 8 1.12 
ENSG00000158714 SLAMF8 4.6 1.16 
ENSG00000115267 IFIH1 14.6 2.11 
ENSG00000115232 ITGA4 31.3 2.12 
ENSG00000085978 ATG16L1 28.4 2.21 
ENSG00000178623 GPR35 24.4 2.22 
ENSG00000237693 IRGM 0.2 5.13 
ENSG00000113302 IL12B 0.1 5.14 
ENSG00000204290 BTNL2 0.2 6.08 
ENSG00000019485 PRDM1 2.1 6.11 
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ENSG00000185811 IKZF1 10.5 7.08 
ENSG00000096968 JAK2 20 9.01 
ENSG00000187796 CARD9 1.3 9.04 
ENSG00000134460  IL2RA  3.4 10.01 
ENSG00000119919 NKX2-3 2.5 10.11 
ENSG00000188906  LRRK2 3 12.03 
ENSG00000166949 SMAD3 19.7 15.03 
ENSG00000005844 ITGAL 11.5 16.04 
ENSG00000167207 NOD2  1.4 16.05 
ENSG00000121281 ADCY7 9.2 16.05 
ENSG00000197943 PLCG2 15.7 16.07 
ENSG00000175354 PTPN2 27.4 18.01 
ENSG00000090339 ICAM1 6.7 19.02 





Each chromosome and susceptibility locus was investigated in more detail 
following the differential expression analysis (see Chapter 4.4). 
 
4.3 Differential expression analysis in IBD 
Differential expression (DE) analysis of all measurable transcripts (17,936) was 
performed using EdgeR. EdgeR implements a statistical methodology based on 
negative binomial distribution to assess differences in expression between 
subsets. The differential expression analysis was executed using count values 
per transcript normalised against library size. Furthermore, ERRC spike-in 
control data, age, sex, batch and disease type were included as covariates in 
the analysis. Reported p-values were adjusted for multiple testing by applying 
the Benjamini-Hochberg method, resulting in corrected false discovery rates 
(FDR). DE analysis was performed between CD cases and controls, IBD vs 
controls, UC vs controls and UC vs CD.  
 
4.3.1 CD versus controls  
Due to the imbalance in the patient cohorts: 75 CD patients, 28 UC patients 
and 24 controls, the CD versus control analysis carries the most power. 
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Differential expression (DE) analysis of all transcripts (17,936) between CD 
cases (n=75) and controls (n=24) was performed to identify transcripts of 
potential importance in CD pathogenesis (Figure 4.1).  
 
 
Evidence of significant difference in expression was found (q ≤ 0.05) for 1,051 
transcripts. The differentially expressed gene with greatest significance was 
SLC14A2 (Solute Carrier Family 14 Member 2) (q=6.18x10-12), a member of 
the solute carriers (SLCs) family (Figure 4.1). SLC14A2 was observed to be 
significantly downregulated in CD patients which is in accordance with 
previously reported findings 151. Additionally, significant decreased CD 
expression of SLC37A2 (q=4.58x10-10), another solute carrier gene, was 
Figure 4.1 | DE analysis between CD and controls 
Log fold change between CD cases and controls –log10(q-value) for DE analysis. Each 
dot represents a transcript with the colour indicating level of expression (logFPKM). 
Threshold for significance at q=0.05 (green line). 
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observed. SLCs can be subdivided into 47 families with more than 300 
members, a subset of SLCs play a role in epithelial permeability and barrier 
function in the intestine and have previously been implicated in IBD 
development 152,153. SLC14A2 has been suggested to be involved in the 
regulation of Urea flux into the gastrointestinal tract with higher Urea levels 
enhancing bacterial growth in the gut. Other top hits were GLS (Glutaminase) 
(q=3.48x10-7) and SNORA57 (Small Nucleolar RNA, H/ACA Box 57) 
(q=1.86x10-7).  
To facilitate prioritisation of DE transcripts based on their likely role in 
CD pathogenesis the significant findings were mapped to within 500 KB of the 
224 known IBD susceptibility loci. When mapping the 1,051 identified 
significant CD (DE) transcripts to their genomic location, it was observed that 
178 of these were located within 500kb of a known IBD susceptibility locus 
(see appendix 5A). When extending these boundaries to 1Mb on either side, 
this number increases to 289 (28% of DE genes), the 1Mb boundaries correlate 
to the boundaries applied in the expression quantitative trait (eQTL) analysis 
(see Chapter 6). The top hit was GLS (Glutaminase), which encodes an enzyme 
involved in the hydrolysis of glutamine into glutamate and ammonia. This gene 
shows reduced expression in CD cases versus healthy controls. Glutamine is an 
amino acid required for protein biosynthesis and an important energy source 
for a wide variety of cells, including rapid dividing immune cells and gut 
mucosal cells which are two major consumers of Glutamine metabolism 154. It 
has been shown that reduced Glutamine metabolism could lead to reduced gut 
mucosal integrity and increased gut permeability to allergens and pathogens, 
causing intestinal inflammation 154,155. Additionally, transcripts included 
TRAF3IP2 (Nuclear Factor NK-Kappa-B activator), DENND1B (DENN Domain 
Containing 1B) and TNFRSF14 (Tumour Necrosis Factor Receptor Superfamily 
Member 14). TRAF3IP2 and DENND1B were identified to show lower 
expression in CD cases whereas, TNFRSF14 showed increased expression. 
TRAF3IP2 (or ACT1) has been reported to activate transcription factor NF-kB 
through IkB kinase (IKK) activation as well as activate Jun kinase (JNK). NK-kB 
is known to play a vital role in immune and inflammatory responses, cell 
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survival and stress responses 156. DENND1B has been shown to regulate T-cell 
receptor (TCR) internalization in Th2 cells, and when disrupted TCR signalling 
was enhanced leading to increased cytokine production and immune responses 
157. TNFRSF14 (or HVEM) has been reported to exhibit ligand dependant bi-
directional signalling. TNFRSF14 has been suggested to induce NF-kB 
activation, triggering pro-inflammatory and cell survival genes; however it also 
mediates inhibitory signalling 158. It has been proposed that TNFRSF14 
mediated signalling represents an important immune regulator, specifically in 
mucosal surfaces, in autoimmunity and infection 159.  
 
4.3.2 IBD versus controls 
By combining the CD and UC patients, transcripts contributing to general IBD 
pathogenies were investigated. IBD specific colonic transcript expression was 
examined by performing DE analysis for IBD (n=104) vs controls (n=24) 
(Figure 4.2).  





526 transcripts were identified with a significant difference in expression 
(q<0.05). The direction of effect was observed to be approximately equally 
distributed with 250 transcripts showing a decreased fold change in IBD and 
276 transcripts showing and increased fold change. The top hits SLC14A2, 
SLC37A2, GLS and SNORA57 corresponding to the top hits found in the CD vs 
controls analysis. However, the magnitude of the significance has decreased in 
all four top hits, most notably SLC14A2 with q = 6.18x10-12 to q = 1.65x10-7 
and GLS q =3.48x10-7 to q=8.4x10-5, suggesting the effect seen in the IBD cases 
vs controls was driven by the CD cases.  
 When mapping the 526 identified significant IBD (DE) transcripts to 
their genomic location, it was observed that 80 transcripts with FPKM ≥ 1 and 
q ≤ 0.05 were located within 500kb of a known IBD susceptibility locus (see 
Figure 4.2 | DE analysis between IBD cases and controls 
Log fold change between IBD cases and controls vs –log10(q-value) for DE 
analysis. Each dot represents a transcript with the colour indicating level of 
expression (logFPKM). Threshold for significance at q=0.05 (green line). 
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appendix 5B), this number increased to 127 (25%) when extending the 
boundaries to 1Mb. An overlap of 59 DE genes was identified in both DE 
analyses, with 21 transcripts being solely differentially expressed in the IBD vs 
controls analysis. Top hit genes including GLS (Glutaminase), HLA-DRB5 
(major histocompatibility complex, class II, DR Beta 5), VIL1 (Villin 1) and 
ITCH (Itchy E3 Ubiquitin Protein Ligase) were observed to have significantly 
reduced expression in IBD cases. HLA-DRB5, a HLA class II molecule, is known 
to be expressed in antigen presenting cells and involved in regulation of 
immune responses. VIL1 plays a role in intestinal cell morphology and cell 
migration, and over expression of VIL1 has been shown to protect against 
apoptosis of intestinal epithelium cells 160-162. ITCH has been shown to be a 
component of an ubiquitin-editing protein complex involved in the control of 
inflammatory signalling pathways, most notably, ITCH ubiquitinated RIP2 to 
allows differential NOD2:RIP2 signalling 163. Furthermore, 3 non-coding RNAs; 
RNY1, SNORA74B and SNORA42, were identified.  
 
4.3.3 UC versus controls 
DE analysis for UC cases (n=28) vs controls (n=24) was performed to identify 
UC specific transcripts (Figure 4.3).  




A plateau formation was observed around a q-value of approximately 0.2           
(-log10 = 0.7) (Figure 4.3), this was contributed to the reduced power within 
the UC (n = 28) vs controls (n = 24) analysis. Only one gene, TPSAB1 
(Tryptase Alpha/Beta 1), reached significance while TMEM232 
(transmembrane protein 232) came close to significance with q=0.053. A 
reduced expression of TPSAB1 within UC cases was observed whereas, 
TMEM232 expression was increased. TPSAB1 encoding Tryptase, a protein 
secreted by mast cells, has been implicated in weakening the inflammatory 
response of β tryptase 164. Other transcripts located above the plateau, 
approximately –log10(1), show relatively high expression levels (FPKM) and 
included HLA-DPB1 (major histocompatibility complex, class II, DP Beta 1), 
Figure 4.3 | DE analysis between UC and controls 
Log fold change between UC cases and controls vs –log10(q-value) for DE analysis. 
Each dot represents a transcript with the colour indicating level of expression 
(logFPKM). Threshold for significance at q=0.05 (green line). 
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TYROBP (TYRO protein tyrosine kinase binding protein) and HLA-DBR5. 
TUROBP (or DAP12) a transmembrane protein has been suggested to associate 
with killer-cell inhibitory receptors (KIR) in natural killer (NK) cells, regulating 
cell activation. Both HLA-DPB1 and HLA-DBR5 have been identified as HLA 
class II molecules involved in antigen presentation in response to extracellular 
proteins. Interestingly, the direction of effect in DE observed for HLA-DPB1 and 
HLA-DBR5 was opposing; exhibited fold change was negative for HLA-DPB1 
and positive for HLA-DBR5. In addition, when mapping the DE transcripts to 
the known IBD susceptibility genomic locations HLA-DPB1 and HLA-DBR5 were 
observed to have the lowest q-value of transcripts within an IBD locus, although 
not significant. Taking into consideration the small sample size – n = 24 versus 
n = 28 - these results suggested the DE analysis was underpowered and an 
increase in sample size should be considered in the future.  
 
4.3.4 UC versus CD 
When comparing UC (n=24) versus CD (n=75) to identify disease specific 
genes, 696 transcripts were identified as significantly differentially expressed 
(Figure 4.4).  




It was observed that a greater proportion of transcripts was more highly 
expressed in CD cases compared to UC (484, 70%), where the remaining 212 
transcripts (30%) demonstrated increased expression within UC cases. The top 
hits for both negative and positive fold change values were previously identified 
in the CD vs controls analysis indicating that the majority of the observed effect 
was driven by the CD cases, or that UC sample size was underpowered. 
SLC14A2, SLC37A2 and MTCO1P12 (MT-CO1 Pseudogene 12) exhibited higher 
expression in UC compared to CD. SLC14A2 and SLC37A2 are members of the 
solute carrier family, and were previously identified in both the IBD and CD vs 
control analyses. MTCO1P12 is a pseudogene affiliated with the lncRNA class. 
RABAC1 (Rab Acceptor 1), C19orf60 and SYTL1 (Synaptotagmin like 1) 
Figure 4.4 | DE analysis between UC vs CD 
Log fold change between UC and CD vs –log10(q-value) for DE analysis. 
Each dot represents a transcript with the colour indicating level of 
expression (logFPKM). Threshold for significance at q=0.05 (green 
line). 
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exhibited higher expression within CD versus UC, equally they were identified 
as overexpressed within the CD vs control analysis. 
Within the UC vs CD DE analysis, 134 DE transcripts were identified to 
be located within 500 kb and 213 (31%) within 1Mb of the 224 known IBD 
loci (see Appendix 5C). Of these, 49 were also identified in the CD vs control 
analysis and 7 were identified in the IBD vs control analysis. Top hits included, 
TMEM259 (Transmembrane protein 259) (q = 4.01x10-5), GAL3ST2 
(Galactose-3-O-Sulfotransferase 2) (q = 2.39x10--4) and GPC1 (Glypican 1) at 
q = 4.72x10-4. TMEM259 and GAL3ST2 were uniquely identified within the UC 
vs CD comparison, both exhibited lower expression levels within UC vs CD. 
GAL3ST2 is thought to be responsible for sulfotransferase within human 
colonic mucins and upregulated in response to inflammatory stimuli. Appendix 
5C contains all CD vs UC differentially expressed genes.  
 
4.4 Prioritisation of potential causal genes in IBD 
Multiple differential expression analyses were successfully performed on the 
generated RNAseq data set including CD, IBD, UC vs controls and UC vs CD 
(Table 4.2). The loci boundaries were extended by 500kB and 1Mb in an 
attempt to prioritise genes potentially casual in IBD. IBD susceptibility SNPs are 
known to be located in between coding regions and are speculated to affect 
regulatory elements or transcription factors of nearby genes. By extending the 
loci boundaries we aim to include genes located outside the IBD loci but whose 
expression is affected by IBD risk SNPs located within the IBD loci. When 
calculating the number of DE genes expected to fall within an IBD susceptibility 
loci by random chance; based on the combined size of the IBD susceptibility 
loci and size of the genome, it was observed that we identify a higher amount 
of genes to be differentially expressed than expected by chance. Based on 
chance alone we would expect to identify 9% of DE genes to be located within 
500Kb and approximately 16% within 1Mb of an IBD susceptibility locus. In 
our analysis, of the total DE identified genes approximately 15-20% fell within 
the boundaries of known IBD susceptibility loci locations extended by 500 kb 
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on either side (Table 4.3). This percentage increased to 25-31% by extending 
the boundaries to 1Mb (Table 4.3).  
Table 4.3 | Differentially expression analysis 









UC vs CD 
Whole 
transcriptome 1051 526 1 696 
Within 500Kb of 
IBD loci 178 80 0 134 
Within 1Mb of 
IBD loci 289 127 0 213 
 
In addition to their location in a known IBD susceptibility locus, overlap 
between the DE gene lists was assessed (Figure 4.5). CD vs control DE genes 
showed the highest overlap; 73% of genes identified in the IBD vs control 
analysis were also found in the CD vs control analysis and 36% of UC vs CD DE 
genes showed an overlap with CD vs control DE genes (Figure 4.5). This 
suggests that the CD cases are driving much of the observed overall results.  




Overall, this analysis revealed a subset of transcripts potentially important to 
IBD pathogenesis based on their phenotype specific expression and genomic 
location.  
 
4.4.1 Previously prioritised genes at known IBD loci 
The number and size of known IBD susceptibility loci combined with the lack 
of definitive single causal variants in most loci 112, results in an immense 
amount of potential causal genes in IBD. In order to prioritise these genes 
Jostins et al. and Liu et al. performed DAPPLE, GRAIL and eQTL analyses 92,107. 
DAPPLE to evaluate the disease association of genes via protein-protein 
interactions functional connectivity and correlation between disease associated 
SNPs and gene expression. More recently, Huang et al. and De Lange et al., 
have performed a summary-statistic fine-mapping and eQTL analysis on these 
Figure 4.5 | Overlap differentially expression analysis results 
Venn diagram showing the overlap between the differential expression analysis 
results between IBD vs control (n=21 unique), CD vs controls (n=77 unique) 
and UC vs CD (n=85 unique). Gene numbers based on genes located within 
500Kb of an IBD susceptibility loci.  
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loci in an attempt to prioritise genes 108,112. By combining all these findings 
92,107,108,112, 461 genes were prioritised to be the most likely candidates to be 
causal in IBD, covering 168 out of 224 IBD loci. For the remaining 56 IBD loci 
however, gene prioritisation has not been possible due to the lack of available 
functional information on the genes within them or the existence of multiple 
independent correlated association signals.  
 
4.4.2 Validation of previously prioritised genes in IBD loci by 
differential expression analysis of colonic RNAseq data 
The results of the IBD vs control differential expression (DE) analyses were 
compared with the list of 461 genes previously prioritised to be causal. 8 genes 
were identified in both lists (Table 4.4, Figure 4.6).  








q-value Summary of function 
RORC 1.14 151.2-152.3 2.9x10-02 
Key regulator of Th17 cell 
differentiation 
CD244 1.17 160.3-161.4 2.9x10-02 
Mediates non-MHC restricted 
killing 
ITLN1 1.17 160.3-161.4 3.9x10-02 
May be involved in the defence 
against microorganisms 
PFKFB4 3.03 47.9-51.6 4.2x10-02 
Regulates of fructose-2,6-
bisphophate concentrations 
FAM49B 8.06 130.0-131.1 2.4x10-02 
Involved in antigen 
presentation 
RAPGEF3 12.04 47.7-48.7 4.2x10-02 
Modulates cAMP-induced 
control of endothelial barrier 
function 
CDH13 16.08 82.3-83.4 1.9x10-02 
Protects endothelial cell from 
apoptosis due to oxidative 
stress 
CTSZ 20.07 57.3-58.3 4.0x10-02 Lysosomal cysteine proteinase 
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Moreover, 7 of the 8 genes are reported to be involved within immune 
responses or endothelial function both of which are known to be important in 
IBD (Table 4.4). It was observed that 10 out of the 56 IBD loci failing to have 
previously prioritised genes contained differentially expressed genes. 
Furthermore, 46 IBD loci out of 224 did not contain either significant DE genes 
or prior prioritised genes which showed expression above background (≥ 1 
FPKM), with one IBD locus (6.03) completely devoid of genes (Figure 4.6).  
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Figure 4.6 | Gene expression versus IBD susceptibility locus locations 
Gene expression levels (FPKM) for all transcripts mapped to within 500Kb of the 224 known 
IBD susceptibility loci plotted per locus with genomic locations given in appendix 5 (A-M). Each 
dot represents a transcript with detectable expression in the intestinal RNAseq data. The spots 
are colour to indicate how they have been implicated as potentially important in IBD. Green 
spot = previously prioritised by other studies; yellow spot = is differentially expressed in IBD 
vs controls in the RNAseq data, red = both differentially expressed and prioritised; blue = all 
other non-prioritised transcripts.   
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Figure 4.6 shows observed gene expression at all 224 IBD loci with previously 
prioritised genes and DE genes highlighted. It was noted that, whilst some 
previously prioritised genes showed no expression above background levels 
(>1 FPKM) within the colon RNAseq data, others contained multiple highly 
expressed and previously prioritised genes e.g. locus 1.18 (Figure 4.6). 
However, it was also observed that 67 loci contained multiple expressed genes 
but only one of the previously prioritised or differentially expressed genes were 
expressed above background e.g. locus 5.01 (Figure 4.6). Furthermore, locus 
6.03 was observed to contain 9 transcripts but none reached expression above 
background.  
 Knowledge about previously prioritised functional candidate genes for 
IBD was combined with the generated qualitative and differential expression 
data from the large intestine. A list of 554 genes, spanning 179 IBD 
susceptibility loci, which are potentially involved in IBD pathogenesis was 
established. Eight regions were identified where the previously proposed 
functional candidate gene showed altered expression in colonic samples from 
IBD patients and a further 64 regions were identified where only one prioritised 
gene shows detectable expression in these tissues.  
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4.5 Discussion  
Recent progress in prioritising causal genes in IBD has been made through fine-
mapping and expression quantitative trait (eQTL) analysis, with 16 of the 
known IBD susceptibility loci having been reduced to 1 causal variant at >95% 
probability 108,112. A further 445 genes have been prioritised to be involved in 
IBD pathogenesis based on investigation of gene co-localisation, protein-
protein interactions, functional connectivity of a gene within literature and 
eQTL analysis 107,150. Here we aimed to increase the knowledge of the 
pathogenesis of CD and IBD by characterising the entire colonic transcriptome, 
using whole RNA sequencing, and investigate differences in gene expression at 
IBD susceptibility loci in biological relevant intestinal tissue from affected 
patients and controls.  
The patient cohort consisted of 75 CD patients, 24 UC cases and 28 
controls. The imbalance in patient numbers was caused by a shift in focus of 
this study from CD only to include UC and controls, as well as by the logistics 
of sample collection; a larger number of CD patients have colonoscopies 
compared to UC and controls. EdgeR has been designed to take into account 
sample imbalance, nevertheless it should be taken into consideration that we 
have a substantial sample imbalance and it might exhibit an effect on the 
differential expression analysis. It was decided to use un-inflamed large 
intestinal tissue over inflamed tissue. Inflamed tissue samples show stronger 
expression signals of immunological and/or pro-inflammatory IBD-associated 
genes, but it is hard to distinguish if these genes are upregulated due to the 
primary cause of disease or just secondary to the inflammation that results. 
Using un-inflamed intestinal tissue will slightly reduce strength of the signal 
and it will exclude any inflammatory signals but it will allow the separation 
between primary and secondary effects. Ideally, future studies will include both 
un-inflamed and inflamed tissue biopsies from IBD patients to address this 
limitation. Furthermore, the intestinal biopsies used to generate transcriptional 
data (see Material and Methods section 2.2.2) consist of a heterogeneous tissue 
including epithelial, stromal and various immune cell types. Expression signals 
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measured within heterogeneous tissues are confounded by relative proportions 
of the cell types involved, making it challenging to determine whether 
variability in gene expression stemmed from differences in phenotype or tissue 
composition. Various methods to resolve tissue heterogeneity have been 
proposed including in silico approaches to address tissue heterogeneity and 
purification of the cell populations through flow cytometry based cell sorting. 
Both methods have their limitations, which are discussed in more detail in 
Chapter 7. We attempted to address tissue heterogeneity of the intestinal 
biopsy samples by investigating a method for deconvolution of biopsy 
composition by utilising the gene expression data. 
 
4.5.1 Gene expression within the colon 
When initiating this study gene expression data was starting to emerge using 
microarray analysis but no whole RNA sequencing data from large intestinal 
tissue of healthy controls or IBD patients had been published. Since then, two 
studies investigating the influence of diet and lifestyle on the transcriptome of 
colonic tissue in healthy controls and colorectal cancer patients have been 
published 165,166as well as an in-depth microarray study mapping the gene 
expression landscape including lncRNA and mRNA in colonic tissue of healthy 
controls and IBD cases 167. The first aim of this study was to examine expression 
levels of genes and non-coding RNAs within uninflamed large intestinal tissue, 
specifically within the IBD susceptibility loci, of an n > 100 individuals. 
Although, the above mentioned studies investigated the transcriptome in 
colonic tissue they did not publish an overall number of genes found to be 
expressed within the colon or specifically within IBD susceptibility loci 
locations 165-167. Within the transcriptomic data generated in this study, 56,360 
transcripts were observed to align to the reference genome within the colonic 
samples, of which 32% exhibited expression above background (≥1 FPKM). Of 
these, 77% were coding genes and approximately 3% were lncRNAs. The 
remaining 20% included pseudogenes, processed transcripts and small RNAs. 
It was observed that 2,971 transcripts within 500Kb of 224 known IBD loci 
 4. Qualitative and quantitative analysis of the transcriptome in the colon 
102 
 
exhibited expression above background. Approximately, 19% of genes 
previously prioritised to be involved in IBD pathogenesis were not expressed 
above background in the uninflamed intestinal tissue data, including cytokines 
IL3, IL4, IL5, IL12B, IL13, IL19, IL20, IL21, IL22, IL26, IL27 and IL31RA 107,150. 
These cytokines had been prioritised using GRAIL connectivity network 
analysis. Their failure to reach expression levels above background in the 
generated uninflamed colonic tissue dataset could suggest their involvement in 
IBD is due to secondary effects or their effect on IBD will only be measurable 
within inflamed tissue. For this study it was hypothesised that sequencing and 
mapping of all transcripts expressed within known IBD loci, would provide 
further insight into overall gene expression in this disease relevant tissue and 
help provide more explicit functional evidence to determine which of the many 
previously prioritised genes are potentially causal.  
 
4.5.2 Differential gene expression analysis 
Beyond quantitative evaluation of transcription within colonic tissue at the IBD 
susceptibility loci, the aim of this study was to further the understanding of 
which genes contribute to IBD pathogenesis by comparing colonic gene 
expression levels between CD cases and controls, IBD and controls, UC and 
controls and UC cases vs CD cases.  
 
4.5.2.1 CD versus control analysis 
In our study 1,051 transcripts were shown to exhibit differential expression 
between CD cases and controls, 178 of which were located within known IBD 
loci. DENND1B (DENN Domain Containing 1B) exhibited reduced expression 
in CD cases vs controls. DENND1B has been shown to regulate T-cell receptor 
(TCR) internalization in Th2 cells, leading to an >3-fold increase of Th2 
cytokines IL4, IL5 and IL13 following stimulation in DENN1B-/- mice 157. 
Variation near the in DENND1B locus has been associated with various immune 
disorders including CD 168-170. Using GRAIL analysis DENND1B was highlighted 
 4. Qualitative and quantitative analysis of the transcriptome in the colon 
103 
 
as potentially important in CD 168, our observed decrease expression in CD cases 
supports to this hypothesis.  
TNFRSF14 (Tumour Necrosis Factor Receptor Superfamily Member 14) 
expression was observed to be increased within colonic tissues of CD cases vs 
controls. TNFRSF14 (or HVEM) function in intestinal mucosa has been studied 
extensively because of its role in host defence and regulation of microbiota. 
TNFRSF14 is unique in its features; it can bind multiple ligands including non 
TNF super family members BTLA and CD160 and it can act as a receptor or 
ligand 171. TNFRSF14 has been shown to induce activation of mucosal T cells 
when interacting with its ligand TNFSF14 (LIGHT) and regulate the epithelial 
innate immune responses to bacterial infection 172,173. However, when 
interacting with BTLA, inhibition of T-cell activation was observed 171,174,175. 
Upregulation of TNFRSF14 within CD patients could indicate an increased 
signalling through the LIGHT ligand resulting in an increased T cell response.  
 
4.5.2.2 IBD versus control analysis 
Further subgroup analysis of colonic expression in IBD cases vs control 
identified 526 transcripts to be differentially expressed, with 80 genes located 
in known IBD loci. The gene with the highest significant difference both within 
the CD and IBD vs control analysis was GLS (Glutaminase) which showed 
reduced expression within CD and IBD cases vs controls. Glutaminase is an 
enzyme involved in the hydrolysis of glutamine into glutamate and ammonia. 
The role of glutamine in the body and specifically in the intestine has been 
researched extensively. It has been shown that glutamine promotes immune 
cell functions including T cell proliferation, B cell differentiation, phagocytosis, 
antigen presentation and cytokine production 176-180. Furthermore, reduced 
glutamine can lead to reduced gut mucosal integrity and increased gut 
permeability to allergens and pathogens 181. A mouse study, showed increased 
bacterial translocations and intestinal permeability following introduction of 
radioactive labelled E. coli or diethylenetriamine pentaacetate (DTPA) into 
mice with or without glutamine in their diet 181. Interestingly, it has been shown 
that the protective effect of glutamine does not require metabolism of 
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glutamine into glutamate 182. The role of glutaminase is in the intestine is less 
defined, although it has been observed that both intestinal glutamine levels and 
glutaminase activity are reduced in CD patients 183. The observed reduction of 
glutaminase levels in IBD patients collaborates our finding.  
VIL1 (Villin1) was identified to exhibit reduced expression within 
colonic mucosa of IBD cases vs controls. VIL1 plays a role in intestinal cell 
morphology and cell migration 160. In addition, increased expression of VIL1 
has been suggested to protect against apoptosis of intestinal epithelium cells, 
with VIL1 knock-down mice with DSS-induced colitis showing increased 
severity of colitis and increased epithelial cell death 161,162. Apoptosis is a tightly 
regulated process with a fine balance between necessary turn-over of epithelial 
cells and excessive levels of cell death leading to compromised epithelial barrier 
function 184. The, in our study, observed reduced expression of VIL1 could 
contribute to increased epithelial apoptosis and compromised barrier function 
in IBD patients.  
 
4.5.2.3 UC versus control and UC versus CD analyses 
When assessing the UC vs control DE results, q-values of a large subset of genes 
were observed to plateau out at approximately q = 0.2 (see Figure 4.3). 
Considering the DE analysis was performed on the smallest group of individuals 
(n=28 UC and n=24 controls), the plateau formation was contributed to 
reduced power in this subset. TPSAB1 (Tryptase Alpha/Beta 1), showing 
reduced expression within UC cases, was the only gene to reach significance, 
although it is not located within one of the known IBD susceptibility loci. To 
overcome the lack of power and attempt to identify UC specific genes, an UC 
vs CD DE analysis was performed. The identified 134 genes, located within 500 
kb of a known IBD locus, were thought to most likely represent unique 
differences between UC and CD phenotypes. Of these, 56 were previously 
found in the CD vs control analysis, the remaining 78 genes were investigated 
in UC pathogenesis. Top hits included, TMEM259 (Transmembrane protein 
259) and GAL3ST2 (Galactose-3-O-Sulfotransferase 2), both exhibited lower 
expression in UC vs CD. TMEM259 may play a role in clearance of misfolded 
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proteins in the endoplasmic reticulum (ER) and has been suggested to promote 
survival of motor neurons. Further functional knowledge about TMEM259 is 
limited, with no obvious link to IBD or the immune responses. GAL3ST2 is 
known to be present in intestinal mucosa where it catalyses the sulfonication 
of mucins e.g. synthesises sulfomucins 185. Sulfomucins have been implicated 
in protection of the intestinal mucosa and are suspected to enhance the mucus 
viscosity and resistance to bacterial degradation and microbe adhesion 185,186. 
Studies have shown that a significant loss of sulfomucins can be observed in 
the mucosal lining of UC patients 187,188. It is possible this loss of sulfomucins 
could be in some part due to the observed reduced colonic expression of 
GAL3ST2. Further investigation into this pathway is warranted in our cohort. 
The observed reduced expression of GAL3ST2 within our UC patient could 
explain the reduced synthesis of sulfomucins.  
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5. Pathway analysis of genes differentially expressed in 
IBD 
In the previous chapter, high quality colonic gene expression data from heathy 
controls and IBD patients (UC and CD), were subjected to differential 
expression (DE) analysis in order to identify genes that may play a role in the 
pathogenesis of IBD. Various sub-analyses were performed to identify 
transcripts contributing to IBD overall and CD or UC specific DE transcripts: 
IBD vs controls, CD vs controls, UC vs controls and UC vs CD, identifying 526, 
1051, 1 and 696 DE transcripts, respectively. The UC vs control DE analyses 
was underpowered, resulting in the identification of only 1 DE gene. Each of 
the significant (q ≤ 0.05) DE gene lists, with the exception of the UC vs controls 
DE genes, were advanced into pathway analysis to devise their potential 
influence on biological processes. To fully utilize the generated data two 
different pathway analyses were employed: gene set enrichment analysis 
(GSEA) and Ingenuity pathway analysis (IPA).  
 
5.1 Pathway analysis tools 
Pathway analysis combines statistical enrichment methods and prior 
knowledge of gene function to identify biological processes and molecular 
pathways affected by differentially expressed genes. Databases containing 
information on gene, protein, metabolite or compound interactions curated 
from the scientific literature are used to aid pathway identification. Here two 
independent methods were employed to investigate potential underlying 
biological pathways implicated in IBD pathogenesis through the DE analysis: 
Gene Set Enrichment Analysis (GSEA) 148, developed by the Broad Institute, 
and Ingenuity Pathway analysis (IPA), developed by Qiagen.  
5.2 Gene Set Enrichment analysis (GSEA) 
GSEA extracts biological insight from differentially expressed genes by 
comparing them to gene sets within the Molecular Signature Database 
(MSigDB) 148. All gene sets are based on experimental outcomes and often 
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report common biological function, regulation or chromosome location. 
MSigDB contains, to date, 13,311 gene sets divided into 8 major collections. 
Out of the 8 available collection 3 were investigated:  
o C2 containing 4,726 curated gene sets collected from various public 
online databases such as Biocarta (an interactive web-based resource for 
life sciences), KEGG (Kyoto Encyclopaedia of Genes and Genomes), 
REACTOME (a curated pathway database), Signalling Gateway and 
Pathway Interaction Database. 
o C5 containing 1,451 gene ontology (GO) gene sets consisting of co-
regulated genes. 
o C7 containing 4,872 Immunological signature gene sets representing 
cell states and perturbations within the immune system 189.  
GSEA pre-ranked analysis allowed the investigated genes to be ranked based 
on q-value and fold change for each gene (see Materials and Methods section 
2.2.9.4). Genes with a low q-value together with a strong positive or negative 
fold change were ranked at the top or bottom of the ranked list, respectively. 
Enrichment for genes ranked towards either the top or bottom of the pre-
ranked list was then assessed against the presence of these genes within gene 
sets recorded in the MSigDB. An enrichment score (ES) and false discovery rate 
(FDR) was calculated for each MSigDB gene set. Pathway analysis was 
performed on three of the DE gene sets: IBD vs controls, CD vs controls and UC 
vs CD. The UC vs control DE analysis was underpowered and therefore not 
taken forward.  
 
5.2.1 IBD versus control GSEA 
All 15,379 genes investigated for differential expression between IBD and 
controls were pre-ranked and run against 11,052 MSigDB gene sets (4,726 
curated, 1,454 GO and 4,872 immunological gene sets) 148. Overall, 3,429 gene 
sets showing enrichment amongst IBD differentially expressed genes were 
identified at a FDR of ≤ 5%. Of which, 2,329 (68%) were amongst the 
immunological gene sets in MSigDB. A two sided probability test indicated that 
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the enrichment in immunological signatures was significantly greater than 
would be expected by chance (p < 2.2x10-16). From the 3,429 significantly 
enriched gene sets, 78 were positively enriched in IBD (containing genes 
upregulated in IBD) and 3,351 showed negative enrichment in IBD (containing 
genes downregulated in IBD).  
Within the 3,351 negatively correlated gene sets, most notably, 
enrichment was observed within gene sets related to glucocorticoid therapy 
and glutamine deprivation (Figure 5.1).  
 
 
Glucocorticoids (GCs) are a class of steroid hormones which reduce 
inflammation and are often used to treat autoimmune diseases including IBD. 
Approximately 340 genes downregulated in IBD were found in a gene set 
identified following glucocorticoid therapy for leukaemia 190. Enrichment in 
this pathway suggests that gene expression changes in response to GCs may 
Figure 5.1 | Gene set enrichment plots  
Gene set enrichment plots showing negative enrichment in IBD vs controls. The top half of 
the graph shows the enrichment score (green line) based on presence and weight of ranked 
genes (black lines in centre) within the pathway. Red indicating top of ranked list (positive 
correlation with IBD) and blue indicating negative correlation with IBD. The bottom half of 
the graph shows ranked list metric scores indicating weight of ranking versus the location 
of each gene (black lines in centre) within the ranked gene list. (The enrichment plot was 
generated by GSEA software 148, http://www.broad.mit.edu/gsea/). 
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overlap in leukemic precursor B-cells and intestinal tissue. In addition, negative 
enrichment within a set of 321 genes downregulated following glutamine 
deprivation suggested that glutamine metabolism might be perturbed in IBD 
patients. Glutamine has been proposed to have an essential function in the gut, 
specifically under stress. It has been shown to decrease gut permeability, 
prevent bacterial translocation, promote gut integrity and optimise nitrogen 
balance 191,192. Furthermore, Reactome pathways including regulation of 
apoptosis, Wnt signalling, antigen cross presentation and adaptive immune 
system showed negative enrichment.  
 Gene sets positively correlated with IBD included, most notably, 
Interferon-alpha (IFNα) activated PBMCs, NCAM1 (Neural Cell Adhesion 
Molecule 1) interactions and signalling by Notch 4 (Figure 5.2A-C). The IFN-
activated PBMCs gene set showed the biggest overlap with the pre-ranked gene 
list at 86 genes (Figure 5.2A). The IFN-activated PBMCs gene set was one of 
various gene sets comparing naïve vs activated immune cell state, including 
CD4pos T cells, CD8pos T cells, monocytes, macrophages, B cells and NK cells, 
suggesting an increased presence of activated immune cells in the IBD intestinal 
tissue vs controls. The NCAM1 interactions gene set showed enrichment for 27 
genes more highly expressed in IBD (Figure 5.2B). NCAM1 interactions include 
cell adhesions, proliferation, differentiation, migration and cell survival. 
Enrichment in signalling by two Notch proteins was observed; Notch 3 and 
Notch 4 (Figure 5.2C-D), although only Notch 4 reached FDR ≤ 5%. 
Enrichment in signalling by Notch 3 and Notch 4 were driven by the presence 
of 12 DE genes, identical in both Notch 3 and Notch 4. Notch 3 and 4 signalling 
is reported to be activated by delta-like and jagged ligands (DLL/JAG) resulting 
in transcriptional changes by the notch intracellular domain. The Notch protein 
family is known to regulate a broad spectrum of cell fate decisions. A further 
subset of positively correlated gene sets were involved in in cell polarisation 
and channel activity including voltage gated channel activity, cation and 
calcium channel activity. 
 





5.2.2 CD versus control GSEA 
All genes investigated for differential expression between CD and controls were 
pre-ranked and run against 11,052 MSigDB gene sets (4,726 curated, 1,454 
GO and 4,872 immunological gene sets) 148. In total, 1,823 gene sets showed 
enrichment at a FDR of ≤ 5% with a significant overrepresentation (p < 2.2e-
Figure 5.2 | Gene set enrichment plots  
Gene set enrichment plots showing negative enrichment in IBD vs controls. The top half of the 
graph shows the enrichment score (green line) based on presence and weight of ranked genes 
(black lines in centre) within the pathway. Red indicating top of ranked list (positive correlation 
with IBD) and blue indicating negative correlation with IBD. The bottom half of the graph shows 
ranked list metric scores indicating weight of ranking versus the location of each gene (black 
lines in centre) within the ranked gene list. (The enrichment plot was generated by GSEA 
software 148, http://www.broad.mit.edu/gsea/). 
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16) of gene sets belonging to the immunological gene set in MSigDB (74%). Out 
of the 1,823 significantly enriched gene sets, 121 were positively enriched in 
CD and 1,702 showed negative enrichment in CD. Interestingly, the CD vs 
control analysis compared to the IBD vs control analysis, identified double the 
number of differentially expressed genes (1,051 vs 526) and only half the 
number of pathway enrichment signals (1,823 vs 3,429). Of the 1,823 enriched 
gene sets identified 1,718 were observed to also be enriched in IBD vs controls, 
resulting in 105 newly identified enriched gene sets, 46 negatively and 59 
positively.  
The 46 significant negatively enriched gene sets included 8 gene sets 
involved in macrophage activation, 2 metabolism pathways, steroid hormone 
biosynthesis pathways and a pathway involved in xenobiotics metabolism 
(Figure 5.3A). Interestingly, negative enrichment was observed within a gene 
set identifying changes in gene expression within keratinocytes following 
exposure to UV (Figure 5.3B).  
 





Sesto et al. identified 9 gene sets showing changes in expression in response to 
UVB, including upregulated genes involved in UV-specific inflammatory and 
stress responses as well as downregulated genes involved in metabolism and 
adhesion processes 193. Upon further investigation enrichment (q ≤ 0.05) in 5 
out of 9 of these identified gene sets was observed. Four UVB response gene 
sets were identified in both IBD and CD vs control analysis and one was 
identified in only CD vs controls. Thiopurines, most commonly Azathioprine, 
have been associated with increased risk to non-melanoma skin cancer, 
enrichment of these gene sets might be an effect caused by the thiopurine drugs 
taken by a subset of patients. 
Within the 59 identified positively enriched gene sets, enrichment 
within the KEGG Notch signalling pathway was observed (Figure 5.4A). 
Signalling by Notch 3 and Notch 4 was observed to be enriched within the IBD 
vs control analysis (12 DE genes); their enrichment has been replicated in the 
Figure 5.3 | Gene set enrichment plots  
Gene set enrichment plots showing negative enrichment in CD vs controls. The top half of 
the graph shows the enrichment score (green line) based on presence and weight of ranked 
genes (black lines in centre) within the pathway. Red indicating top of ranked list (positive 
correlation with CD) and blue indicating negative correlation with CD. The bottom half of 
the graph shows ranked list metric scores indicating weight of ranking versus the location 
of each gene (black lines in centre) within the ranked gene list. (The enrichment plot was 
generated by GSEA software 148, http://www.broad.mit.edu/gsea/). 
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CD vs control analysis. Furthermore, the overall Notch signalling pathway was 
shown to be enriched, with 43 DE genes associated with this pathway. Notch 
proteins have been reported to regulate a broad spectrum of cell fate decisions 
by functioning as a receptor for transmembrane ligands to Jagged and Delta-
like proteins. Furthermore, enrichment in a gene set altered in PBMCs infected 




5.2.3 UC versus CD GSEA 
The UC vs CD analysis was performed to identify pathways specific to either 
disease and not general to IBD. All genes investigated for differential expression 
between UC and CD were pre-ranked and run against 11,052 MSigDB gene sets 
(4,726 curated, 1,454 GO and 4,872 immunological gene sets) 148. In total, 595 
gene sets showed enrichment at a FDR of ≤ 5%. with a significant 
overrepresentation (p < 2.2x10-16) of gene sets belonging to the immunological 
gene set in MSigDB (82%). Out of the 595 significantly enriched gene sets, 285 
Figure 5.4 | Gene set enrichment plots  
Gene set enrichment plots showing negative enrichment in CD vs controls. The top half of 
the graph shows the enrichment score (green line) based on presence and weight of ranked 
genes (black lines in centre) within the pathway. Red indicating top of ranked list (positive 
correlation with CD) and blue indicating negative correlation with CD. The bottom half of 
the graph shows ranked list metric scores indicating weight of ranking versus the location 
of each gene (black lines in centre) within the ranked gene list. (The enrichment plot was 
generated by GSEA software 148, http://www.broad.mit.edu/gsea/). 
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were enriched in UC (positive enrichment) and 310 showed enrichment in CD 
(negative enrichment). Notably, a more even spread between negative and 
positive enrichment within the UC vs CD analysis compared to either IBD or 
CD vs controls was observed.  
An overlap of 223 enriched gene sets between all 3 analyses i.e. IBD and 
CD vs control and UC vs CD was detected (Figure 5.5). Of these, 217 showed 
opposite directions of enrichment in the UC vs CD analysis compared to the 
IBD and CD vs control analysis. The 6 gene sets showing negative enrichment 
in all three analyses were all observed within immunological cell types; 
regulatory T cells (Tregs), CD4pos T helper cells, CD8pos cytotoxic T cells and B 




Figure 5.5 | Overlap GSEA analyses results 
Venn diagram showing the overlap between the GSEA significant 
enrichment results of the IBD versus control (n=1,630 unique), CD 
vs control (n=59 unique) and UC vs CD (n=245 unique) analyses. 
With 223 enrichment gene sets showing overlap in all three results.  
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The UC vs CD analysis showed 245 gene sets to be uniquely enriched, with the 
most significant UC enriched gene sets observed to be involved in pathway 
activation processes within various cell types, providing insight into gene 
expression changes following immune response. For example, LPS 
(lipopolysaccharide) vs control IgG treated monocytes (Figure 5.6A) or IFNα- 
vs IFNγ-treated endothelial cells (Figure 5.6B) both showed positive 
enrichment. LPS, the outer cell membrane of gram-negative bacteria, is known 
to activate immune and inflammatory responses through TLR4 (Toll-like 
receptor 4) signalling 194.  
 
 
Negatively enriched pathways – showing increased expression within CD – 
exhibited a large overlap with gene sets enriched within the CD vs control 
analyses (65 out of 77). Pathways negatively enriched and unique to the UC vs 
CD analysis were 85% immune response related, including apoptosis and 
interferon activation pathways.  
 
Figure 5.6 | Gene set enrichment plot 
Gene set enrichment plots showing negative enrichment in UC vs CD. The top half of the 
graph shows the enrichment score (green line) based on presence and weight of ranked 
genes (black lines in centre) within the pathway. Red indicating top of ranked list (positive 
correlation with UC) and blue indicating negative correlation with UC. The bottom half of 
the graph shows ranked list metric scores indicating weight of ranking versus the location 
of each gene (black lines in centre) within the ranked gene list. (The enrichment plot was 
generated by GSEA software 148, http://www.broad.mit.edu/gsea/).  
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5.3 Ingenuity Pathway Analysis 
Ingenuity pathway analysis (IPA®, QIAGEN Redwood City) utilises the 
Ingenuity knowledge base to provide insight into molecular and chemical 
interactions as well as cellular phenotypes and disease processes within a 
dataset. The Ingenuity knowledge base is built upon a wide range of published 
information including textbooks, reviews, biomedical literature and a variety 
of public databases. All this information is structured into a framework 
organising and describing biological evidence including contextual 
information; species specific info, cell type/tissue context, direction of change 
and experimental methods. IPAs strength lies in the quality control and 
structuring of information within the database as well as the fact that the 
knowledge base is updated weekly.  
IPA input files contained gene names, fold change values, q-values and 
FPKM (Fragments Per Kilobase of exon per Million fragments mapped) 
expression values for all genes identified as differentially expressed. 
Subsequently, Ingenuity generates a p-value and ratio score for each pathway 
assessing the level of pathway perturbation. The knowledge base tissue specific 
information allowed us to test pathways involved specifically in the large 
intestine.  
 
5.3.1 IBD versus control IPA 
Differential expression analysis identified 526 transcripts that were 
differentially expressed between IBD cases and controls (see Chapter 4.2.1). 
IPA identified 17 pathways to be significantly more perturbed than by chance 
(p  0.05) due to the observed differential expression within these genes 
(Figure 5.7). Pathways included Granzyme A signalling, Notch signalling, 
communication between innate and adaptive immune cells, Altered T and B 
cell signalling and Crosstalk between dendritic cells and natural killer cells 
(Figure 5.7).  
 





Figure 5.7 | IPA pathway analysis on colonic genes differentially expressed between IBD 
cases and controls  
Pathways that are significantly more perturbed than by chance based on differentially 
expressed (DE) genes between IBD cases and controls. Bars represent the –log p value for the 
statistical test of number of genes DE in each pathway being more than expected by chance. 
Threshold indicated significance at p = 0.05. Bar shading indicates the direction of effect of 
DE genes on pathway activity with downregulated (blue) through to upregulated (orange), 
with grey indicating no information on direction of effect. Orange squares connected by the 
orange line indicate the ratio of the fraction of genes within a pathway which are significantly 
differentially expressed (q<0.05). (The pathway analysis was generated through the use of 
QIAGEN’s Ingenuity Pathway Analysis (IPA®, QIAGEN Redwood 
City, www.qiagen.com/ingenuity). 
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The most significant pathway observed was Granzyme A signalling (p = 
7.8x10-5) with 33% of genes (5 out of 15) in the pathway differentially 
expressed in IBD (Figure 5.7). The observed effect is due to five genes: four 
H1 histone family genes and HMGB2 (High Mobility Group Box 2) gene which 
encodes a DNA-binding protein (Figure 5.8). Although the direction of effect 
on Granzyme A signalling is not known (no z-score) (Figure 5.7), all 5 genes 
showed a negative fold change in expression in IBD biopsies compared to 
controls (Figure 5.8). Granzyme A is known to aid cytotoxic T lymphocytes 
and natural killer (NK) cells in response to cell infection, cancer transformation 
and antigen presentation (Figure 5.8).  




Figure 5.8 | Granzyme A signalling pathway 
Granzyme A signalling pathway initiated within a cytotoxic T lymphocyte affecting a target cell, 
with double purple circles indicating protein complexes being affected by DE genes and green 
indicating downregulated DE genes. (The pathway analysis was generated through the use of 
QIAGEN’s Ingenuity Pathway Analysis (IPA®, QIAGEN Redwood 
City, www.qiagen.com/ingenuity). 
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The Notch signalling pathway (p = 2.9x10-3) was identified with 5 out of 31 
genes within the pathway significantly differentially expressed (16%) (Figure 
5.9). The 5 DE genes affecting the Notch signalling pathway were DLL4 (Delta 
like canonical Notch ligand 4), DTX2 (Deltex E3 ubiquitin ligase 2), NOTCH3 
(Notch 3), NOTCH4 (Notch 4) and NUMBL (NUMB like). The positive z-score 
(Figure 5.7) indicated upregulation of pathway activity with all 5 genes 
showing increased expressed within IBD. Notch signalling has been implicated 
in maintenance of gut homeostasis and induction of UC when disturbed 
(Figure 5.9) 195,196. Although the ratio of DE genes observed within the Notch 
signalling pathway was lower than within the Granzyme A signalling (33% vs 
16%), the DE genes within the Notch signalling pathway appeared to affect the 
majority of protein complexes within the pathway (Figure 5.9).  
 




5.3.2 CD versus control IPA 
CD and control DE analysis identified 1,051 transcripts that were differentially 
expressed (see Chapter 4.2.2). Within these genes IPA identified 28 pathways 
to be significantly more perturbed than by chance (p <0.05), with Figure 5.10 
showing the 20 most significant pathways.  
Figure 5.9 | Notch signalling pathway 
Canonical pathway Notch signalling pathway showing both signalling and receiving cells. With 
purple double circles indicating protein complexes containing DE genes with the fill-in colour 
of the circle indicating direction of effect. NUMB indicated to be strongest upregulated (red). 
(The pathway analysis was generated through the use of QIAGEN’s Ingenuity Pathway Analysis 
(IPA®, QIAGEN Redwood City, www.qiagen.com/ingenuity).  
 




Figure 5.10 | IPA pathway analysis on colonic genes differentially expressed 
between CD cases and controls 
Pathways that are significantly more perturbed than by chance based on differentially 
expressed (DE) genes between CD cases and controls. Bars represent the –log p value for 
the statistical test of number of genes DE in each pathway being more than expected by 
chance. Threshold indicated significance at p = 0.05. Bar shading indicates the direction 
of effect of DE genes on pathway activity with downregulated (blue) through to 
upregulated (orange), with grey indication no information on direction of effect. Orange 
squares connected by the orange line indicate the ratio of the fraction of genes within a 
pathway which are significantly differentially expressed (q  0.05). (The pathway analysis 
was generated through the use of QIAGEN’s Ingenuity Pathway Analysis (IPA®, QIAGEN 
Redwood City, www.qiagen.com/ingenuity). 
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The top two pathways suggested to be affected were Nicotine Degradation II 
(p = 5.7x10-4) and Nicotine Degradation III (p = 1.51x10-3). An overlap of 7 
DE genes (Table 5.1) was observed between the two pathways. Of these, 4 
were reported to be part of the Cytochrome P450 superfamily, known to be 
involved in catalysing drug metabolism 197. The remaining 3 genes are part of 
the UDP glucuronosyltransferase family, known to be involved in transforming 
small lipids into excretable metabolites 198. Although no z-score was recorded 
for either Nicotine degradation pathway, the 7 genes involved in both pathways 
all showed reduced expression within CD cases. Nicotine degradation II is 
reported to be involved in breaking down nicotine into various metabolites, one 
of which is cotinine (Figure 5.11). Nicotine degradation III has been observed 
to work downstream from nicotine degradation II and further breakdown 
cotinine into metabolites (Figure 5.11).  
 
Table 5.1 | Gene functions of DE genes within Nicotine Degradation pathway 
Gene 
Symbol 
Family Gene Function 
CYP2B6 







Transformation of small 
lipophilic molecules into water-




These 7 genes were observed to affect nearly every arm of both nicotine 
degradation pathways (Figure 5.11) suggesting they might exhibit a large 
effect on the degradation and metabolism of nicotine within CD cases. It was 
hypothesised that the observed effect might be due to a larger population of 
smokers within the CD cohort. The differential expression analysis was 
therefore repeated now including smoking status (current smoker, ex-smoker 
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or never smoked), as a covariate. The 7 genes driving the perturbation of the 
nicotine degradation pathway maintained their differential expression within 
the smoking-corrected CD vs control analysis (Table 5.2). IPA analysis likewise 
confirmed that both nicotine degradation pathways (II and III) remained 
perturbed, indicating that the observed effect cannot be attributed to smoking 
status, but to CD-specific gene expression patterns. 
 
Table 5.2 | DE genes within Nicotine Degradation pathway 
 Original analysis   Smoking corrected analysis 
Genes P-value Q-value 
Fold-




CYP2B6 1.0E-01 4.4E-01 -0.50   1.1E-01 4.8E-01 -0.48 
CYP2C9 8.4E-04 8.5E-02 -0.99   3.7E-03 1.5E-01 -0.85 
CYP2C18 8.6E-04 8.5E-02 -0.75   1.7E-03 1.2E-01 -0.70 
CYP2C19 4.6E-04 7.6E-02 -0.95   1.5E-03 1.1E-01 -0.85 
INMT 4.4E-04 7.5E-02 0.38   3.8E-04 8.0E-02 0.36 
UGT1A4 2.6E-01 6.1E-01 -0.20   1.7E-01 5.5E-01 -0.24 
UGT1A6 9.1E-02 4.2E-01 -0.29   8.4E-02 4.4E-01 -0.29 
UGT1A8 2.3E-02 2.6E-01 -0.35   4.4E-02 3.5E-01 -0.30 
 
 




Figure 5.11 | Nicotine Degradation II 
and III Canonical pathways 
Showing Nicotine Degradation II and III. 
Purple double circles indicating protein 
complexes containing DE genes with the 
fill-in colour of the circle indicating 
direction of effect: downregulation 
(green) to upregulation (red). (The 
pathway analysis was generated through 
the use of QIAGEN’s Ingenuity Pathway 
Analysis (IPA®, QIAGEN Redwood 
City, www.qiagen.com/ingenuity). 
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The 7 genes from the nicotine degradation pathways (Table 5.1) were 
identified to be involved in an additional 3 significantly perturbed pathways; 
Melatonin Degradation I, Superpathway of Melatonin Degradation and 
Xenobiotic Metabolism. Moreover, the 4 Cytochrome P450 family genes also 
drove the observed significant enrichment within one of the other implicated 
pathways (Bupropion Degradation and Acetone degradation) and the 3 UDP 
glucuronosyltransferase family genes were identified within the Serotonin 
degradation pathway. The highest number of DE genes (23) was observed 
within the Xenobiotic Metabolism pathway, with the majority (16) indicating 
reduced expression levels within CD cases. These findings indicate that large 
portion of the observed pathways perturbed in CD tissues was due to a subset 
of genes involved in drug metabolism.  
Ephrin Receptor signalling (p = 2.9x10-2) exhibited a strong 
downregulated effect (negative z-score) due to 16 DE genes within the pathway 
(Figure 5.10). Ephrin receptor signalling has been shown to be involved with 
cell morphology, integrin-mediated adhesion and cell migration. Furthermore, 
pathways including Notch signalling and Gas signalling were identified in both 
IBD and CD vs control comparisons, with similar direction of effect and p-
values.  
5.3.3 UC versus CD IPA 
To investigate IBD disease sub-type specific effects differential expression 
analysis between UC and CD was performed (see Chapter 4.2.4). The 696 
transcripts that exhibited differential expression were investigated for their 
involvement and effect upon canonical pathways using IPA. In total, 21 
pathways were observed to be significantly more perturbed than by chance (p 
 0.05) (Figure 5.12).  




Figure 5.12 | IPA pathway analysis on colonic genes differentially expressed between UC 
and CD cases 
Pathways that are significantly more perturbed than by chance based on differentially expressed 
(DE) genes between UC and CD cases. Bars represent the –log p value for the statistical test of 
number of genes DE in each pathway being more than expected by chance. Threshold indicated 
significance at p = 0.05. Bar shading indicates the direction of effect of DE genes on pathway 
activity with downregulated (blue) through to upregulated (orange), with grey indication no 
information on direction of effect. Orange squares connected by the orange line indicate the 
ratio of the fraction of genes within a pathway which are significantly differentially expressed 
(q  0.05). (The pathway analysis was generated through the use of QIAGEN’s Ingenuity 
Pathway Analysis (IPA®, QIAGEN Redwood City, www.qiagen.com/ingenuity).  
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Perturbed pathways identified in the CD vs controls and UC vs CD analyses 
showed an overlap of 10 affected pathways that were not implicated using DE 
genes identified in the IBD vs control analysis. Most notably, Nicotine 
Degradation II and III, Melatonin Degradation and GPCR-Medicated Nutrient 
Sensing in Enteroendocrine Cells (Figure 5.13).  
 
 
The data summarised in Figure 5.13 suggest that the observed effects within 
these pathways may be specific to CD pathogenesis, although the consideration 
needs to be made that there was an imbalance in numbers for CD and UC cases 
(75 and 28, respectively). Similarly, it was speculated that the effect observed 
in pathways only affected by the UC vs CD DE gene list could be attributed to 
UC pathogenesis. Three such pathways were Adenosine Nucleotide 
Degradation II, Purine Nucleotide Degradation II and Guanosine Nucleotide 
Degradation III. Observed effects were all driven by decreased expression of 
Figure 5.13 | Comparison subset IPA results  
Bar charts plotting the -log(p-value) indicating levels of perturbation of a pathways based on 
differentially expressed genes versus a subset of pathways identified using Ingenuity Pathway 
analysis for UCvsCD, CDvsControl and IBDvsControl. Threshold (orange line) indicated 
significance at p = 0.05. (The pathway analysis was generated through the use of QIAGEN’s 
Ingenuity Pathway Analysis (IPA®, QIAGEN Redwood City, www.qiagen.com/ingenuity). 
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ACPP (Acid Phosphatase, Prostate), ADAT3 (Adenosine Deaminase, TRNA 
specific 3) and NT5C3B (5’-Nucleotidase, Cytosolic IIIB), and increased 
expression of NT5C2 (5’-Nucleotidase, Cytosolic II) in UC cases. Functions 
associated with these pathways include infectious diseases, cell signalling and 
cell death and survival. Two further pathways solely observed within the UC vs 
CD comparison were urate biosynthesis and NAD salvage pathway; when 
investigated it was observed that these were also driven by changes in 
expression of ACPP, NT5C2 and NT5C3B genes. Gas signalling was the only 
pathway observed to be significantly affected in all three IPA analyses. Gas 
signalling was observed to be downregulated (negative z-score) within the UC 
vs CD comparison (Figure 5.13) where the observed affect in Gas signalling 
was neutral (z-score = 0) within the IBD and CD vs control analyses (Figure 
5.7 and Figure 5.10). It was observed that the DE genes driving the detected 
effects within the Gas pathway varied between the three IPA analyses (Table 
5.3), accounting for the fact the pathway was identified in all three analyses.  
 
Table 5.3 | Genes differentially expressed within the Gas signalling pathway 
Analysis Genes differentially expressed  
IBD vs Control ADCY2, ADCY4, ADORA2B, RAPGEF3, PTGER2, RAP1A 
CD vs Control ADCY2, ADCY4, ADORA2B, RAPGEF3, PTGER2, RAP1A, 
CHRM3, GNG2, GNG12 
UC vs CD GPER1, GNG2, RAPGEF3, CREB3L4, ADCY7, CHRM3, 
GNG12, GNG7 
 
ADCY7, a gene in which a rare mutation has previously been implicated to give 
a 2-fold increase in risk for UC 199, was solely observed to be affected within 
the Gas signalling pathway in UC vs CD analysis (Table 5.3). It was observed 
that the difference in DE genes driving the perturbation within the Gas 
signalling pathway resulted in different protein complexes and thus arms of the 
pathway being affected (Figure 5.14). Gas signalling is reported to be involved 
intracellular and second messenger signalling through G-proteins, with 
functions reported to involve cellular assembly, development, function and 
maintenance 200-202.  




Figure 5.14 | Gas Signalling pathway 
Canonical pathway showing Gas signalling pathway with Purple double circles indicating protein complexes containing DE genes and the fill-in colour of the 
circle indicating direction of effect; downregulation (green) to upregulation (red). With A. showing DE genes for IBD vs controls and B. showing DE genes for 
UC vs CD. (The pathway analysis was generated through the use of QIAGEN’s Ingenuity Pathway Analysis (IPA®, QIAGEN Redwood 
City, www.qiagen.com/ingenuity). 
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5.4 Comparison of GSEA and IPA results  
Although both forms of analysis – GSEA and IPA – are aimed at generating 
hypotheses about functional implications of the identified differentially 
expressed genes, seemingly quite different results were observed. This can be 
attributed to the form of analyses, e.g. gene set enrichment versus tissue 
specific canonical pathway analysis. To investigate coherence and increase 
confidence in the obtained results, the GSEA analysis was repeated for all sub-
phenotypes, this time using a canonical pathway dataset as the MSigDB 
reference dataset. For the IBD vs control analysis IPA identified pathways 
including Notch signalling, Adaptive Immune system, NK cell pathway and 
phagosome formation were replicated. Within the CD vs control analysis, the 
Xenobiotic pathway and metabolism of xenobiotic by cytochrome P450 were 
identified, replicating previous IPA results. Although no direct matches with 
IPA were found for the UC vs CD analysis, the CREB pathway was identified 
which acts downstream of the IPA identified Gas pathway. Furthermore, 
biological oxidation and drug metabolism pathway were identified related to 
the IPA identified phosphatase pathway and p450 pathway, respectively.  
 
5.5 Discussion 
A pathway analysis was performed to elucidate how genes exhibiting 
differential expression within the sub-phenotypes of IBD affect biological 
pathway. Two well-known methods for pathway analysis were employed; Gene 
Set Enrichment Analysis (GSEA) and Ingenuity Pathway Analysis (IPA). 
Although both forms of analyses are aimed at generating hypotheses about 
functional implications of the identified groups of differentially expressed 
genes, seemingly quite different results were observed. This is most likely due 
to the form of analyses, e.g. gene set enrichment versus tissue specific canonical 
pathway analysis. Gene set enrichment compares the presence of differential 
expressed genes within experimentally generated gene lists reported to be 
differentially expressed under specific condition, whereas IPA estimated the 
effect of DE genes on canonical pathways containing genes expressed the gut.  
 5. Pathway analysis of genes differentially expressed in IBD 
132 
 
GSEA analysis identified 3,348 gene sets enriched in IBD patients, 59 
pathways were enriched in genes solely differentially expressed between CD 
and controls. Although, 245 pathways suggested to be specific to UC 
pathogenesis were identified through the UC vs CD DE analysis. The extremely 
high number of significantly enriched pathways within the GSEA analysis 
combined with the highly specific nature of the MSigDB, it was decided that 
the use of IPA was preferable.  
Using IPA the IBD vs control DE gene set was enriched for genes involved 
in 17 canonical molecular pathways. The CD vs control DE analysis was 
enriched for genes in 28 pathways, 25 of which were unique to this analysis. 
Furthermore, 21 pathways were identified to be enriched in the list of UC vs 
CD DE genes, of which 11 were not found in either the IBD or CD analyses 
suggesting they might be involved in UC pathogenesis.  
 
5.5.1 Gas and G-protein signalling pathways 
Gas signalling was the only pathway observed to be perturbed by DE genes 
within all sub-phenotypes. Gas signalling involves intracellular and second 
messengers signalling through G-proteins. In addition to Gas signalling, several 
other pathways involved with G-protein signalling were observed to be 
perturbed including Gai signalling, cAMP-mediated signalling, GPCR-mediated 
nutrient sensing in enteroendocrine cells and GPCR-mediated integration of 
enteroendocrine signalling amplified by an L cell. Different arms of the gas 
signalling pathway were observed to be effected within CD or UC phenotypes, 
cAMP signalling was perturbed within the IBD vs control and UC vs CD analyses 
and perturbations in Gai signalling and both GPCR signalling pathways might 
be CD specific. G-proteins have well established functions within 
transmembrane signalling 200 and have been implicated in the regulation of 
tight junction formation within epithelial cell, with overexpression of Gα 
subunits increasing epithelium permeability 201,203. In addition to G-protein 
involvement in epithelial tight junction formation, RGS1 (regulator of G protein 
signalling 1) has been shown to reduce T cell migration to lymphoid-homing 
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chemokines in the gut 202. Although, the role of G-proteins has previously been 
shown to regulate processes important to IBD (transmembrane signalling, tight 
junction formation, gut permeability and T cell responses in the gut), the data 
presented in this study was able to add value by providing insight into IBD sub-
type specific G-protein pathway perturbations.  
 
5.5.2 Notch signalling pathways 
Notch signalling, hematopoiesis from pluripotent stem cells, 
phosphatidylcholine biosynthesis I, Phosphatidylglycerol biosynthesis II and 
CDP-diacylglycerol biosynthesis I were all pathways observed to be effected 
within the IBD vs control analysis but not in the UC vs CD analysis, suggesting 
they effect IBD pathogenesis. Notch signalling is known to regulate intestinal 
stem and progenitor cell proliferation and differentiation 204,205. Notch 
maintains adult intestinal stem cells to regulate cell fate choice and control 
epithelial cell homeostasis 195,206,207. It has been hypothesised that activation of 
Notch signalling is required for epithelial repair in IBD, with increased Notch 
activity observed within IBD epithelial cells 196,208. This is consistent with the 
observed positive z-score and upregulation of five genes within the Notch 
signalling pathway in IBD patients. The Notch signalling pathway is comprised 
of four different receptors, NOTCH1 (Notch 1), NOTCH2 (Notch 3), NOCTH3 
and NOTCH4. The two Notch receptors observed to be upregulated within the 
Notch signalling pathway are Notch 3 and 4, consistent with the observed 
enrichment by GSEA. Notch 4 has been shown to effect similar target genes to 
Notch 1, although minor difference in function have been observed with the 
Notch 4 intracellular domain (ICD) having shown to reduce transforming 
growth factor beta (TGF-β) induced growth inhibition of mammary epithelial 
cells 209. Notch 1 has been shown to modulate mucosal chemokines and 
cytokine secretion as well as effector T cell responses, regulating protective 
epithelial pro-inflammatory responses 210. Notch 3 has been reported to 
promote neuronal differentiation 211 and inhibit epithelial differentiation in the 
lung 212. Furthermore, activation of Notch 3 has been observed to enhance the 
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generation of regulatory T cells 213. The observation that Notch 3 and Notch 4 
are the affected Notch proteins driving, in part, the observed perturbation of 
the Notch signalling pathway provided insight into which specific signals of 
Notch signalling are important in IBD.  
 
5.5.3 Drug metabolism, xenobiotics and nicotine pathways 
Several pathways exhibited opposite directions of effect within the CD vs 
controls and UC vs CD analyses, including Nicotine degradation II and III, two 
melatonin degradation pathways and Xenobiotic metabolism signalling, 
suggesting they predominantly affect CD pathogenesis. Smoking and 
inflammatory bowel disease has been topic of discussion for many years. 
Smoking has been shown to have opposite effects on the clinical course of UC 
and CD with smoking being beneficial to clinical remission in UC patients 214 
whereas, detrimental effects are reported in CD 215. With nicotine being an 
important component in smoking, it is interesting that our analysis showed two 
nicotine degradation pathways to be perturbed solely within CD patients. 
Interestingly, a recent study has shown that twice as many CD patients are 
reported to be active smokers compared to UC patients 216. By incorporating 
smoking as a covariate into the here performed differential expression model 
it was ruled out that the higher percentage of smokers within the CD patient 
group was responsible for the observed significant perturbation of Nicotine 
degradation pathways II and III. It has been shown that smoking influences 
both innate and adaptive immunity with smokers exhibiting reduced cytokine 
production 217 and altered immunoregulatory T cell ratios 218,219. Factors like 
intestinal mobility 220, gut permeability and blood flow have also been 
investigated 221, but have conflicting or non-conclusive outcomes. Although, a 
multitude of research studies have been performed, an explanation for the 
opposing effects of smoking on UC and CD has not yet been found. The analyses 
performed in this study, which identifies a perturbation of nicotine degradation 
pathways II and III in CD patients warrants further investigation. Another 
pathway identified within CD patients, by both IPA and GSEA, was Xenobiotics 
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metabolism. Xenobiotics are organic compounds to which an organism is 
exposed that are extrinsic to the normal metabolism and include drugs. The 
altered expression of xenobiotic metabolism genes is most likely due to drug 
therapies in the CD patients compared to controls. GSEA identified various 
additional drug related gene sets with significant enrichment including steroid 
hormone biosynthesis, glucocorticoid therapy, drug metabolism cytochrome 
p450 and drug metabolism other enzymes, indicating that drugs and drug 
metabolism have a significant effect on the transcriptome of IBD patients. 
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6. Expression Quantitative trait loci (eQTL) analysis in 
IBD relevant tissue  
Genomics is a constantly evolving field; one newly emerging technology is 
expression quantitative trail loci (eQTL) analysis. eQTL analysis investigates 
associations between SNPs and changes in gene expression. The abundance of 
a gene transcript could directly be modified by polymorphisms in regulatory 
elements, identifying the effect of a SNP on changes in gene expression could 
provide highly valuable information in complex diseases. Disease associated 
SNPs located in the coding region of a gene often effect that specific genes, for 
disease associated SNPs located in non-coding regions their effect is often more 
complex to identify. eQTL analysis attempts to address this by performing a 
genome wide linkage analysis between genetic polymorphisms and variation in 
gene expression. Associations between a SNP and changes gene expression 
levels can be investigated at a local level (cis-eQTL) or at a distant level (trans-
eQTLs). Cis-eQTLs are identified as associations between SNPs and genes 
located within 1Mb on either side of the SNP. Distant eQTLs (trans-eQTLs) are 
identified as associations between SNPs and genes located beyond 1Mb, 
potentially even on another chromosome.  
The majority of IBD susceptibility SNPs are known to be located in non-
coding regions and do not directly alter gene function. It was therefore decided 
to employ eQTL analysis to attempt and elucidate the effect of IBD 
susceptibility SNPs on changes in gene expression of nearby genes (cis-eQTLs); 
the study is not powered to detect trans-eQTLs. Matrix eQTL was employed to 
perform a genome wide expression quantitative trait loci analysis, correlating 
variation in gene expression within the large intestine to underlying genomic 
variation. Whole transcriptome data was generated from large intestinal tissue 
for 127 individuals (103 IBD patients and 24 controls) (see Chapter 3). For 121 
out of 127 individuals, genome wide SNP genotype data was also generated 
(see Materials and Methods section 2.2.7). Matrix eQTL calculates significant 
associations between genotypes/alleles of each of 241,995 input SNPs to 
changes in gene expression. P-values and False Discovery Rate (FDR) values 
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are generated via linear regression and the Benjamini Hochberg method, 
respectively. A significant association was defined as False Discovery Rate 
(FDR) ≤ 5%.  
 
6.1 Quality control 
Cis-eQTLs were identified by testing all SNPs within 1Mb upstream or 
downstream of the transcription start site of a given gene. Associations between 
241,995 indexed SNPs and 17,258 genes were investigated. In total, 2,096 
significant cis-eQTLs at FDR of 5% (q ≤ 0.05) were identified involving 861 
genes. Validity of the observed results was assessed by quantile-quantile (QQ) 
plot and histogram (Figure 6.1A-B). 
 
 
The QQ plot was used to compare genome-wide distribution of the eQTL 
statistic with the expected null distribution (inflation) (Figure 6.1A). Inflation 
can be introduced through unknown variables such as sample duplication, 
unknown familiar relationships or technical bias. The genomic inflation factor 
Figure 6.1 | Quality control cis-eQTL results 
(A) QQ plot showing theoretical p-values (-log10) against observed p-values (-log10) for cis-
eQTL (red), with 45 degrees (x=y) line shown in grey. (B) Histogram visualising the 
distribution of significant cis-eQTL FDR values, with each bar representing 0.001 FDR. The 
height of bars indicates the frequency of a given FDR value.  
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(Lambda) was calculated to be 1, indicating the data follows normal chi-square 
distribution and no inflation was observed. The histogram visualises 
significance distribution, showing that more than 600 cis-eQTLs were highly 
significant with an FDR of ≤ 0.001 (Figure 6.1B).  
 
6.1.1 Multiple correlated eQTL signals per gene  
Overall, 2,096 significant eQTLs showed association with 861 genes. Multiple 
SNPs showing association with a single gene can be caused by high linkage 
disequilibrium (LD) between the SNPs or indicate multiple individual SNPs 
signals. For example, the changes in expression of GSDMB (Gasdermin B) a 
gene located on chromosome 17 (IBD locus 17.03), were observed to be 
significantly associated with 17 SNPs. LD was evaluated using locus-zoom, 
based on 1000 Genomes data, for the index SNP rs10852936 and all SNPs 
located within 1Mb of GSDMB (Figure 6.2). 
 





LD between rs10852936 and the 16 additional significant eQTL SNPs was 
observed to range from r2>0.8 to r2<0.2, with both LD and eQTL significance 
decreasing as the distance from the index SNP increased (Figure 6.2). Similar 
results regarding LD were observed for the other genes containing multiple 
eQTLs. Although LD calculations can give an indication of the level of 
correlation between SNPs, in depth fine-mapping would be required to 
determine with certainty if there is more than one independent SNP driving the 
observed eQTL signals.  
 
6.1.2 Genotype coverage of IBD loci locations 
To assess coverage of the 224 known IBD susceptibility loci by the chosen 
genome-wide SNP genotyping array, Dr Ken Hanscombe a research associate 
Figure 6.2 | GSDMB expression quantitative trait locus (eQTL) effects around SNP 
rs10852936 
Locus-zoom plot of the GSDMB eQTL effect using hg19/1000 Genomes data for SNP location and linkage 
disequilibrium scores. Showing linkage disequilibrium (LD) scores (r2) between the index SNP, 
rs10852936, and all SNPs located within 1MB of GSDMB. With r2 ranging from 1, high LD (red), through 
to 0, low LD (dark blue). Genes name in box indicate all genes present within the genomic region where 
the SNPs are located. (plot generated with Locus-Zoom http://locuszoom.org/). 
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within the statistical genetics unit, determined the level of LD between the 502 
index SNPs from the IBD associated loci 92,107,108,112 and the 241,995 genotyped 
SNPs (see Materials and Methods section 2.2.9.6.4). It was observed that 255 
out of 502 IBD SNPs were captured by our data (83 genotyped directly, 172 in 
high LD at r2 ≥ 0.8) corresponding to 118 out of the 224 known IBD 
susceptibility loci.  
 
6.2 Cis-eQTLs within known IBD susceptibility loci  
To further prioritise the intestinal cis-eQTL findings in IBD, it was considered 
which of the significant cis-eQTL genes were located within 500kb of the 224 
known IBD susceptibility loci. It was observed that 126 genes with intestinal 
cis-eQTLs were located within one of 76 IBD susceptibility loci (Figure 6.3). 
Five of these genes had also been highlighted as significant in our intestinal 
differential expression data. Furthermore, 25 of these genes had been 
previously prioritised by earlier bioinformatic studies investigating gene and 
protein networks across all IBD GWAS loci 107,150 (from now on these will be 
called “previously prioritised genes”) (See Chapter 4.3.1). Chromosome 6 was 
observed to contain the highest number of cis-eQTLs (19) at high significance 
(Figure 6.3). Chromosome 6 contains 19 IBD loci, 2 of which encompass the 
human leukocyte antigen (HLA) class I and II regions encoding the major 
histocompatibility complex (MHC) proteins in humans. Cis-eQTL signals were 
confirmed within 24 previously prioritised genes (green dots) and 4 genes 
shown to exhibit differences in expression between IBD and controls (yellow 
dots), suggesting that these genes may be important in IBD pathogenesis 
(Figure 6.3). The gene FAM49B (Family With Sequence Similarity 49, member 
B) located on chromosome 8 (chr8:130077267-131124661) was the only gene 
identified as a significant cis-eQTL which was also differentially expressed in 
intestinal tissues in IBD and previously prioritised by other studies (indicated 
by a red dot in Figure 6.3). The remaining 97 genes representing significant 
cis-eQTLs in known IBD loci have not previously been implicated in connection 
with IBD pathology or etiology.  






6.3 Intestinal cis-eQTLs at known IBD susceptibility SNPs 
Overall, 126 genes in cis-eQTL were identified to be located within an IBD 
susceptibility loci. To further explore our eQTL results in relation to IBD, the 
eQTL SNPs were compared to a list of 6,931 IBD associated SNPs compiled 
from recent GWAS studies 92,107,108,112 using LDlink 222. It was established that 
24 genes (out of 126) in cis-eQTL were associated with SNPs in high LD (r2 ≥ 
0.7) with IBD susceptibility SNPs. Furthermore, 8 out of 126 cis-eQTLs SNPs 
were a direct match with an IBD susceptibility SNP, of which 3 were GWAS 
index SNPs (Table 6.1).  
 
Figure 6.3 | Significant Cis-eQTLs within IBD loci  
Significant identified cis-eQTLs per chromosome, each dot representing a gene located 
within the genomic boundaries of a known IBD susceptibility locus plotted by levels of 
significance (-log10(p-value)). With previously prioritised genes shown in green, 
differentially expressed genes between IBD cases and controls in yellow, genes both DE and 
prioritised in red and novel identified genes in light blue.  
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SNP P-value FDR Beta 
Score 
CTSW 11.06 65.1–66.2 rs568617* 1.5E-13 8.6E-09 -0.96 
GPX4 19.01 0.6–1.6 rs4807569 1.7E-06 5.5E-03 0.58 
GSDMB 17.03 37.4–38.6 rs10852936  1.7E-13 9.7E-09 -0.79 
UQCR11 19.01 0.6–1.6 rs4807569 2.9E-05 4.4E-02 0.345 
WDR6 3.03 47.9–51.6 rs11715581* 3.1E-06 8.4E-03 0.39 
SFMBT1 3.04 52.5–53.6 rs9847710* 3.9E-12 1.2E-07 -0.85 
RGS14 5.17 176.3–177.3 rs4976646* 4.1E-09 4.1E-05 -0.53 
ERAP2 5.08 95.7–96.9 rs7719705 8.6E-09 1.5E-13 0.91 
* IBD index SNPs 
 
ERAP2 (Endoplasmic Reticulum Aminopeptidase 2), CTSW (Cathepsin W), 
GSDMB and GPX4 (Glutathione Peroxidase 4) were previously prioritised genes 
in IBD (see Chapter 4.3.1), while the remaining four genes were not included 
on the previously prioritised gene list. WDR6 (WD Repeat Domain 6), RGS14 
(Regulator of G-protein Signalling 14) and UQCR11 (Ubiquinol-Cytochrome C 
Reductase, Complex III subunit XI) map to IBD regions already containing 
prioritised genes, while SFMBT1 (Ubiquinol-Cytochrome C Reductase, 
Complex III subunit XI) maps to an IBD region on chromosome 3 
(chr3:52478418-53642980) without any previously prioritised genes (Figure 
6.4). 





SFMBT1 expression was reduced 2-fold, from 13.6 FPKM within CC 
homozygotes to 7.8 FPKM in TT homozygotes (q = 1.2x10-7) (Figure 6.4A). 
SFMBT1 has been reported to function as a histone-binding protein which 
mediates recruitment of corepressor complexes to target genes 223. RGS14 
expression showed a near 2-fold reduction, from 7.5 FPKM to 4 FPKM, in 
homozygotes with major T allele compared to homozygotes with the minor C 
Figure 6.4 | cis-eQTL in novel genes associated with IBD susceptibility SNPs 
Levels of expression in FPKM (Fragments Per Kilobase of exon per Million fragments mapped) 
associated with genotypes for IBD susceptibility SNPs for SFMBT1 (A), RGS14 (B), WDR6 (C) 
and UQCR11 (D). Blue indicates homozygotes for the major allele, green heterozygote and red 
homozygotes for the minor allele. False discovery rate (FDR) following Benjamini Hochberg 
correction for multiple testing are (A) 1.2x10-7, (B) 4.1x10-5, (C) 8.0x10-3 and (D) 4.0x10-2.  
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allele (q = 4.1x10-5) (Figure 6.4B), and is reported to regulate G protein-
coupled receptor signalling cascades influencing cell division and stress 
resistance 224. WDR6 and UQCR11 showed increased expression within 
heterozygotes and homozygotes for the minor C allele, q = 8.0x10-3 and 4.0x10-
2, respectively (Figure 6.4C-D). WDR6 expression increased slightly, with 
approximately 25 FPKM in homozygotes for the major T allele and around 32 
FPKM observed in samples with minor CC allele (Figure 6.4C). WDR6 has been 
suggested to interact with STK11 (serine/threonine kinase 11) and induce cell 
growth arrest 225. UQCR11 shows the smallest change in expression out of the 
4 genes visualised in figure 6.4, although still significant at q = 4.0e-2, with 
mean expression increasing from 55.7 FPKM in homozygotes for the major A 
allele to 79.2 FPKM in homozygotes for the minor allele C (Figure 6.4D). 
UQCR11 has been reported to be part of a protein complex involved in the 
mitochondrial respiratory chain 226.  
 
6.4 Cis-eQTLs associated with previously prioritised genes 
in IBD  
Out of 126 genes in significant cis-eQTL and located within an IBD locus, 29 
were previously reported to be potentially involved in IBD pathogenesis. Of 
these, 25 were previously prioritised genes, and four genes: ANO7, UBA7, HLA-
DRB5 and MAST were shown to exhibit differential expression between IBD 
cases and controls (see Chapter 4.2.1). FAM49B was the only gene to be 
previously prioritised, exhibit differential expression and be in a cis-eQTL. Our 
identification of these 29 genes in the eQTL analysis strengthens that 
hypothesis (Table 6.2).  
  
 6. Expression Quantitative trait loci (eQTL) analysis in IBD relevant tissue 
145 
 










P-value FDR Beta 
score 
FCGR2A 1.18 160.9 – 161.9 rs12116744 1.1E-05 2.2E-02 0.49 
C2orf74 2.05 60.7 – 61.7 rs720201 1.2E-07 6.3E-04 0.73 
SLC16A14 2.20 230.6 – 321.7 rs1124534 4.7E-10 6.7E-06 1.07 
ANO7 2.23 242 - 243 rs13411510 3.3E-05 4.8E-02 -0.57 
UBA7 3.03 48 – 51.6 rs6446298 8.2E-07 3.0E-03 0.52 
ERAP1 5.08 95.7 – 96.9 rs27045 2.5E-15 2.6E-10 0.88 
ERAP2 5.08 95.7 – 96.9 rs7719705 1.5E-13 8.6E-09 0.91 
SLC22A5 5.09 129.2 – 132.3 rs272885 3.2E-08 2.1E-04 0.56 
HLA-C 6.07 30.74 – 31.8 rs2524074 3.6E-16 4.4E-11 0.97 
PSORS1C1 6.07 30.7 – 31.8 rs3094217 1.8E-14 1.4E-09 -0.88 
MICB 6.07 30.7 – 31.8 rs2516408 2.2E-05 3.7E-02 0.57 
HLA-DRB5 6.08 32.1 – 33.1 rs9270986 1.0E-28 1.0E-22 1.78 
HLA-DRB1 6.08 32.1 – 33.1 rs9270986 2.9E-23 2.2E-17 1.62 
HLA-DQB1 6.08 32.1 – 33.1 rs3135006 1.6E-21 9.5E-16 1.35 
HLA-DQA1 6.08 32.1 – 33.1 rs3135006 1.1E-06 3.6E-03 0.75 
IRF5 7.13 128.1 – 129.1 rs3757385 2.1E-05 3.4E-02 -0.42 
FAM49B 8.06 130.1 – 131.1 rs13340584 2.3E-06 6.7E-03 0.53 
MASTL 10.02 26.6 – 27.7 rs1981296 6.9E-09 6.2E-05 -0.63 
METTL10 10.13 125.8 – 127.1 rs1055256 1.6E-08 1.2E-04 0.49 
FADS2 11.04 61 – 62.1 rs174593 5.3E-08 3.1E-04 0.74 
TRPT1 11.05 63.6 – 64.7 rs11603384 3.4E-07 1.5E-03 0.69 
CTSW 11.06 65.1 – 66.2 rs568617 1.5E-13 8.7E-09 -0.96 
SH2B3 12.06 102.9 – 114.3 rs11065934 3.3E-05 4.8E-02 0.69 
GALC 14.03 87.9 – 89.1 rs10483987 2.7E-05 4.2E-02 -0.91 
GSDMB 17.03 37.4 – 38.6 rs10852936 1.7E-13 9.7E-09 -0.80 
GPX4 19.01 0.6 – 1.6 rs4807569 1.7E-06 5.3E-03 0.58 
FUT2 19.05 48.7 – 49.8 rs281380 5.3E-07 2.1E-03 0.48 
COMMD7 20.02 30.2 – 31.9 rs12480157 9.5E-07 3.4E-03 0.57 
PROCR 20.03 33.3 – 34.4 rs2295888 1.1E-05 2.1E-02 -0.88 
 
Changes in FAM49B expression were significantly associated with SNP 
rs13340584, FDR 0.006 (Figure 6.5). Homozygotes for the minor T allele 
showed a 2-fold increase of FAM49B expression (Figure 6.5). Limited 
functional knowledge is available for FAM49B; it is reported to be highly 
expressed in patients with multiple sclerosis and non-small cell lung cancer 
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tissues 227,228. Furthermore, it is suggested to be the source of the antigenic 




6.5 Novel cis-eQTLs located within IBD susceptibly loci 
In addition to confirming 29 previously prioritised genes, 97 of the significant 
cis-eQTL findings located within known IBD loci were associated with 
expression of genes not previously prioritised in IBD. In the earlier chapter (see 
Chapter 4.3.2) 45 IBD loci were identified for which the previous GWAS studies 
and bioinformatics analyses had failed to identify any plausible candidate 
genes. The data generated here has successfully identified 15 intestinal cis-
eQTLs (Table 6.3), genes in these 45 IBD loci. The 15 genes identified were 
Figure 6.5 | Changes in FAM49B expression associated with rs13340584 
Levels of FAM49B expression in FPKM (Fragments Per Kilobase of exon per Million 
fragments mapped) associated with genotypes for rs13340584, with C being the 
major and T being the minor allele. Blue are homozygotes for major C allele, green 
are heterozygote and red are homozygotes for minor T allele. n=85 and false 
discovery rate (FDR) following Benjamini Hochberg correction = 0.006.  
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observed to fall within 12 out of 45 such IBD susceptibility loci, with locus 7.10 
(chr7:99901433-100933794) containing two eQTLs: TRIP6 (Thyroid Hormone 
Receptor Interactor 6) associated with rs7784933 and FIS1 (Fission, 
Mitochondrial 1) associated with rs6979122 (Table 6.3). Additionally, locus 
21.03 (chr21:35220000-36240000) contained three genes in eQTL: WRB 
(Tryptophan Rich Basic Protein) associated with rs2836995, PSMG1 
(Proteasome Assembly Chaperone 1) associated with rs2297256 and LCA5L 
(Leber Congenital Ameurosis 5-Like) associated with rs2836999, FDR = 
1.3x10-3, 7.39x10-3 and 4.63x10-4, respectively (Table 6.3). The remaining 10 
loci contained one cis-eQTL each (Table 6.3). 
 
Table 6.3 | Novel cis-eQTLs located within IBD loci previously lacking putative candidate 












BTBD8 1.10 92.1-93.1 rs12129878 2.9E-06 8.1E-03 0.90 
HAAO 2.04 43.0-44.4 rs3821349 6.6E-06 1.5E-02 -0.52 
SFMBT1 3.04 52.5-53.6 rs9847710 3.9E-12 1.2E-07 -0.85 
NQO2 6.02 2.9-3.9 rs2070998 3.2E-07 1.4E-03 -0.63 
ECHDC1 6.13 126.9-128.0 rs9398840 1.3E-08 1.1E-04 0.57 
NUP43 6.17 149.1-150-1 rs12529698 3.0E-06 8.3E-03 -0.56 
FIS1 7.10 99.9-100.9 rs6979122 2.2E-06 6.3E-03 -0.70 
TRIP6 7.10 99.9-100.9 rs7784933 5.9E-09 5.5E-05 0.66 
MET 7.12 116.4-117.4 rs6977929 1.4E-05 2.3E-02 0.73 
SPATA6L 9.01 4.5-5.5 rs6476893 3.8E-07 1.6E-03 0.72 
HNRNPA1P70 12.05 68.0-69.0 rs1468487 1.5E-06 4.7E-03 -0.59 
LMAN1 18.03 56.4-57.4 rs1899894 2.4E-08 1.7E-04 0.55 
LCA5L 21.03 40.0-41.0 rs2836999 8.4E-08 4.6E-04 0.65 
PSMG1 21.03 40.0-41.0 rs2297256 2.6E-06 7.4E-03 0.59 
WRB 21.03 40.0-41.0 rs2836995 7.5E-10 1.4E-03 0.72 
 
Six out of 15 genes were observed to exhibit a negative beta score, indicating 
that the minor allele of the SNP in that locus was associated with increased 
gene expression (Table 6.3). The 9 genes identified with a positive beta score 
showed that the minor allele of the SNP was associated with a decreased gene 
expression (Table 6.3). FIS1, TRIP6, MET and PSMG1 were reported to 
contribute to processes previously implicated in IBD development such as 
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apoptosis 230, inflammatory responses 231 and cell proliferation, migration and 
survival 232-235 (Table 6.4). Furthermore, SFMBT1 was reported to regulate 
repression of genes required for development and differentiation by histone-
binding 236 (Table 6.4). Limited functional knowledge has been reported on 
the remaining novel identified genes, which increases the difficulty to elucidate 
their potential involvement in IBD pathogenesis, and might also suggest why 
they have not previously been thought to be important in this disease (Table 
6.4).  
 
Table 6.4 | Functional information on novel cis-eQTLs 
Gene Function information 
BTBD8 Contains double BTB/POZ domain, speculated to be important in 
development 
ECHDC1 Suggested to be involved in metabolism of decarboxylases 
ethylmalonyl-CoA decarboxylase, a toxic metabolite 
FIS1 Can induce cytochrome c release from mitochondrion, leading to 
apoptosis 
HAAO Catalyses the synthesis of quinolinic acid (QUIN), increased QUIN 
might be involved in inflammatory responses.  
HNRNPA1P70 Reported as a pseudogene, no functional knowledge known 
LCA5L Localizes in the nucleus, no functional knowledge known 
LMAN1 Cargo receptor for glycoprotein transport  
MET Receptor for hepatocyte growth factor, regulates processes including 
proliferation, scattering, morphogenesis and survival 
NQO2 Serves as a quinone reductase, mutations have been related to 
neurodegenerative disease and cancers.  
NUP43 Enables bi-directions transport macromolecules between cytoplasm 
and nucleus 
PSMG1 Promotes assembly of proteasome subunits, suggested to regulate 
cell proliferation 
SFMBT1 Histone-binding protein, mediates recruitment of corepressor 
complexes to target genes 
SPATA6L Protein coding gene, no function knowledge known 
TRIP6 Involved in lysophosphatidic acid-induced cell adhesion and 
migration. Additionally, acts as a transcriptional coactivator for NF-
kappa-B and JUN 
WRB Localizes in the nucleus, no functional knowledge known 
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The remaining 82 novel intestinal cis-eQTLs which were located within 179 IBD 
susceptibility loci which contained previously prioritised genes. Most notably, 
PSORS1C3 (Psoriasis Susceptibility 1 Candidate 3) with rs9295957 (q = 
6.63x10-13), YY1AP1 (YY1 Associated Protein 1) with rs12746592 (q = 
3.35x10-5), WDR6 (WD Repeat Domain 6) with rs4974079 (q = 1.4x10-7) and 
LRRC23 (Leucine Rich Repeat Containing 23) with rs1007924 at q =6.65x10-8 
(Figure 6.6).  
 
 











Genotyped SNP coverage of the 2 Mb genomic region surrounding the index 
SNP was observed to be scarce for YY1AP1 (Figure 6.6B) and WDR6 (Figure 
6.6C), while neighbouring SNPs were more abundant for PSORS1C3 (Figure 
6.6A) and LRRC23 (Figure 6.6D). For all four genes, the strongest LD (r2) was 
observed to affect SNPs with significant cis-eQTL scores indicating the observed 
multiple cis-eQTL signals were due to LD and not individual cis-eQTLs. 
PSORS1C3, a long non-coding RNA (lncRNA), it has been associated with 
psoriasis and rheumatoid arthritis (RA) but very little functional information is 
known 237,238. Similarly, there is very little functional information about 
YY1AP1 and LRRC23. YY1AP1 is reported to be a co-activator of transcription 
factor YY1, and suggested to be involved in cell cycle regulation 239. LRRC23 is 
Figure 6.6 | Expression quantitative trait locus (eQTL) effects around top SNPs 
Locus-zoom plots of the PSORS1C3 (A), YY1AP1 (B), WDR6 (C) and LRRC23 (D) eQTL effect 
using hg19/1000 Genomes data for SNP location and linkage disequilibrium scores. Showing 
linkage disequilibrium (LD) scores (r2) between the index SNPs rs9295957 (A), rs12746592 (B), 
rs4974079 (C) and rs1007924 (D) and neighbouring SNPs also in eQTL with the gene of interest. 
With r2 ranging from 1, high LD (red), through to 0, low LD (dark blue). Genes name in the box 
below the plot indicate all genes present within the genomic region where the SNPs are located. 
(plots generated with Locus-Zoom http://locuszoom.org/). 
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known to interact with CD28 protein in a pathway regulating the development 
of regulatory T cells (Tregs) 240. WDR6 has been suggested to regulate cell 
growth arrest and amino acid starvation-induced autophagy 241,242. 
Furthermore, chromosome 6, containing the HLA region, showed several novel 
significant cis-eQTL genes including MICA (MHC Class Polypeptide-Related 
Sequence A), CDSN (Corneodesmosin) and four HLA genes: HLA-DQA2, HLA-
DPB1, HLA-DPA1 and HLA-DQB2.  
 
6.6 GTEX comparison 
Out of 126 cis-eQTLs 32 were identified to be associated - or in high LD (r2 ≥ 
0.7) - with an IBD susceptibility SNP, prioritising these 32 genes as candidates 
for involvement in IBD pathogenesis. The Genotype-Tissue Expression Project 
(GTEx), containing eQTLs data across 44 tissues, reported 23 out of the 32 cis-
eQTLs associated with IBD risk SNPs to have been previously observed within 
colonic tissue. Out of 32, 9 cis-eQTLs are novel within colonic tissue, of which 
5 eQTLs associated with genes C2orf74, NIPSNAP1, CEP192, PROCR and GALC, 
have been previously reported to be present in other tissues 92,127. The 
remaining four cis-eQTLs associated with changes in gene expression of 
BORCS7 (Bloc-1 Related Complex Subunit 7), MAP4K2 (Mitogen-Activated 
Protein Kinase Kinase Kinase Kinase 2), UQCR11 (Ubiquinol-Cytochrome C 
Reductase, Complex III Subunit XI) and IGLVI-70 (Immunoglobulin Lambda 
Variable (I)-70) are novel discoveries. The functional processes involving 
MAP4K2 and IGLVI-70 are both highly relevant to a healthy immune response 
with MAP4K2 acting as an upstream activator of stress-activated protein 
kinase/c-Jun N terminal kinase (JNK) signalling pathway 243 and IGLVI-70 
being a variable of the lambda chain of immunoglobulin molecules, which are 
involved in antigen recognition 244. Although the functional influence of 
BORCS7 and UQCR11 on IBD might not immediately be obvious, the presence 
of significant IBD risk SNP associated cis-eQTLs within colonic tissue warrants 
further investigation of these genes. 
 




To elucidate the effect of IBD risk SNPs upon gene expression levels within the 
large intestine expression quantitative trait (eQTL) analysis was performed. 
Although, eQTL analysis is a powerful tool and it can be used to generate 
invaluable insights into the effect of disease associated SNPs on the abundance 
of transcripts, the input files (e.g. the genotype and gene expression data) 
determine the quality and reliability of the eQTL results. The gene expression 
data was generated through whole RNA sequencing and has been shown to be 
of high quality (see Chapter 3). The genome-wide SNP genotype data was 
generated through the use of two different Infinium arrays: the Human Core 
or the Human Core Exome Array (see Material and Methods 2.2.7). The two 
arrays have a large overlap in SNPs, but it should be considered that the use of 
two different arrays leads to lower power in SNPs only represented on one of 
the arrays. This was, in part, addressed by applying a filter to only include SNPs 
genotyped in > 50% of the samples. Furthermore, coverage by the genotype 
arrays of disease associated SNPs and disease associated loci, plays a major role 
in the ability to assess eQTLs associated with the disease of interest. The 
genotype arrays used here covered 118 out of 224 known IBD disease 
associated loci; meaning we could not assess the presence of eQTLs for 
approximately 47% of disease associated loci. This should be addressed in 
future works, either by inputting the data to increase SNP coverage or by re-
genotyping the samples on Infinium arrays offering better coverage of the 
known IBD susceptibility loci.  
 Overall, 861 significant (FDR<0.05) cis-eQTLS were identified of which 
126 correlated with genes located within the genomic boundaries of IBD 
susceptibility loci. Moreover, 32 out of 126 cis-eQTLs were identified to be 
associated - or in high LD (r2 ≥ 0.7) - with an IBD risk SNP, providing 
compelling evidence for these 32 genes to be involved in IBD pathogenesis. The 
Genotype-Tissue Expression Project (GTEx) 127, containing eQTLs data across 
44 tissues, was employed to confirm the 32 colonic cis-eQTLs associated with 
IBD risk SNPS identified within this study. 




6.7.1 cis-eQTLs implicated in IBD  
From the 861 cis-eQTLs identified within large intestinal tissue from IBD 
patients and controls, 32 cis-eQTLs were shown to be associations between IBD 
risk SNPs and genes located within known IBD susceptibility loci. Employing 
GTEx, it was confirmed that 23 out of 32 cis-eQTLs have been previously 
reported within colonic tissue. The replication of these previously descripted 
results confirms the robustness and validity of the results produces in the here 
performed analysis. Out of 23 replicated cis-eQTLs, 10 associated genes were 
previously prioritised in IBD, including ERAP1, ERAP2, GSDMB and FADS2. 
ERAP1, ERAP2 (Endoplasmic reticulum aminopeptidase 1 and 2) are involved 
in the processing of peptides prior to antigen presentation through the major 
histocompatibility complex (MHC) I 245,246. SNPs affecting ERAP1 and ERAP2 
function have been previously associated with various immune disorders 
including psoriasis 247, Behcet’s disease 248. Franke et al. 249 reported a cis-eQTL 
of IBD risk SNP rs2549782 with ERAP2, which is in high LD (r2 = 0.76) with 
eQTLs SNP rs10044354 reported in our results 249. Furthermore, Jostin’s et al. 
prioritised ERAP1 and ERAP2 as genes potentially involved in IBD pathogenesis 
92. GSDMB (Gasdermin B) is a part of the gasdermin-family, which have been 
implicated to regulate the gastric epithelial cell apoptosis cascade through TGF-
β signalling 250. Cells transduced to express GSDM showed to induce apoptosis 
compared to un-transduced cells in a colony formation experiment 250. 
Although the exact function of GSDMB is unknown, a recent study reported 
that a polymorphism in GSDMB is linked to an increased risk of asthma and 
IBD 251. FADS2 (Fatty acid desaturase 2) encodes an enzyme involved in the 
conversion of linoleic acid to pro-inflammatory arachidonic acid 252. Franke et 
al. 249 and Peters et al. 253 both reported a cis-eQTL for FADS2 with rs102275, 
which is in high LD (r2 = 0.93) with rs174535 identified in our study. The 
eQTLs show an increase expression of FADS2 within individuals with the minor 
allele 249,253, which is contradictory to observation that FADS2 knockdown mice 
develop duodenal and ileocecal ulcerations 254.  
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Furthermore, 5 cis-eQTL, are novel discoveries within colonic tissue 
samples although they have been previously reported to be present in other 
tissues 92,127. The 5 cis-eQTL were associated with genes C2orf74 (Chromosome 
2 Open Reading Frame 74), NIPSNAP1 (Nipsnap Homolog 1), CEP192 
(Centrosomal Protein 192), PROCR (Protein C Receptor) and GALC 
(Galactosylceramidase) were identified within tissues including lymphocytes, 
fibroblasts, spleen, thyroid, adipose tissue, oesophagus epithelial cells, and 
artery.  
 
6.7.2 Novel cis-eQTLs 
By utilising GTEx, it was established that 28 (23+5) here identified cis-eQTLs 
were previously reported within colonic or other human tissues. The remaining 
four out of 32 cis-eQTLs include associations with changes in gene expression 
of BORCS7 (Bloc-1 Related Complex Subunit 7), MAP4K2 (Mitogen-Activated 
Protein Kinase Kinase Kinase Kinase 2), UQCR11 (Ubiquinol-Cytochrome C 
Reductase, Complex III Subunit XI) and IGLVI-70 (Immunoglobulin Lambda 
Variable (I)-70). These have not previously been reported in any tissue and 
therefore add to the novel discoveries of this study. Most notably, MAP4K2 and 
IGLVI-70 can functionally be linked to processes known to be important in IBD 
manifestations. MAP4K2 is a serine/threonine-protein kinase and an essential 
component of the MAP kinase signal transduction pathway. MAP4K2, activated 
by TNF-α and pro-inflammatory stimuli, is an upstream activator of stress-
activated protein kinase/c-Jun N terminal kinase (JNK) signalling pathway. 
JNK activation has been shown to be important in intestinal inflammation in 
IBD 243. IGLVI-70 is a variable of the lambda chain of immunoglobulin 
molecule. Immunoglobulins, antibodies, are produced by B-cells and involved 
in foreign antigen recognition and innate immune responses such as 
phagocytosis and the complement system, processes highly relevant to IBD and 
a healthy immune response 244. Whereas, BORCS7 is a subunit of protein 
complex BORC which regulates intracellular lysosomes trafficking and 
positioning, interference with BORC results in collapse of lysosomes and 
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reduction in cell spreading and mobility 255 and UQCR11 is part of a protein 
complex involved in the mitochondrial respiratory chain. UQCR11 may 
function as an iron-sulfur protein binding factor. Although, their functional 
influence on IBD might not immediately be obvious but the presence of 
significant IBD risk SNP associated cis-eQTLs within colonic tissue warrants 
further investigation of the genes.  
 
Furthermore, here 15 significant colonic cis-eQTL genes were identified within 
12 IBD loci where previously published eQTL and functional data repositories 
had failed to help identify potential candidate genes 92,107,108,112. Most notably, 
SFMBT1 a gene associated with a lead IBD variant rs9847710 at chr3: 
52978418-53142980. SFMBT1 is a histone binding protein which mediates the 
recruitment of corepressor complexes to target genes involved in myogenesis 
and antigen recognition. Although, IBD locus 3.04 did not contain any 
previously prioritised genes as per the most recent studies by the IBD 
consortium, Sing et al. 132 also reported the eQTL within SFMBT1 in ileal tissue 
in 2015. Overall, they identified 11 cis-eQTLs associated with IBD SNPs, of 
which 5 in rectal and 6 in ileal tissue of 39 cases and 33 controls 132. In our 
generated colonic data, 4 of Sing et al. reported eQTLs were replicated. The 
inability to identify 7 out 11 cis-eQTLs considering this study has a larger 
sample size, could be contributed to limited coverage of SNPs across the IBD 
loci within our genotype data or the observed eQTLs might be rectal or ileal 
specific. 
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7. Deconvolution of intestinal biopsy composition 
7.1 Tissue heterogeneity in sequencing 
While whole RNA sequencing is known to be a hypothesis-free and in-depth 
method to quantify gene expression, sample heterogeneity is often a concern. 
Expression signals measured within heterogeneous tissues are confounded by 
relative proportions of the cell types involved, making it challenging to 
determine whether variability in gene expression stemmed from differences in 
phenotype or tissue composition. The intestinal biopsies used to generate 
transcriptional data (see Material and Methods section 2.2.2) consist of a 
heterogeneous tissue including epithelial, stromal and various immune cell 
types. In order to distinguish cell-type-specific transcriptional signals and the 
effect of variation in cell composition on gene expression, a method for 
deconvolution of biopsy composition utilising gene expression data was 
employed.  
7.2 Cellular phenotyping of biopsies 
In Chapter 3.5 it was shown that high quality whole RNA sequencing data was 
generated from intestinal biopsies. In addition to generating transcriptomics 
data, 3-4 biopsies per patient sample were used to assess cellular composition. 
In order to assess the level of heterogeneity within the intestinal biopsies, cell 
populations were phenotyped by flow cytometry (see Material and Methods 
section 2.2.8). Epithelial cell numbers as well as various subsets of leukocytes 
were assessed, with epithelial cells hypothesised to make up the largest fraction 
of the intestinal biopsies, and leukocytes known to play an important role in 
inflammatory responses in the gut and IBD.  
7.2.1 Gating strategy 
The presence of auto-fluorescence and unspecific staining was observed in the 
samples. Considering the biopsy samples went through manual and enzymatic 
separation prior to antibody staining, this was not unexpected. The gating 
strategy was adapted to exclude these unspecific signals (Figure 7.1).  




Through the use of isotype controls, an APC-Cy7dim population was identified 
which showed consistent auto-fluorescence and unspecific staining (Figure 
7.1A.2). Backgating indicated this population contained small, low density 
cells with varying levels of DAPI uptake (Figure 7.1B). The observed APC-
Cy7dim population showed relative clean borders and thus the gating strategy 
was adjusted to exclude this subpopulation of cells from further analysis. 
A gating strategy was optimised to allow for the accurate identification 
of proportionate numbers of epithelial cells (CD326pos), leukocytes (CD45pos), 
T helper cells (CD4pos), cytotoxic T cells (CD8pos), monocytes (CD14pos), 
macrophages (CD68pos) and neutrophils (CD66bpos) within in the large 
intestinal biopsies (Figure 7.2). 
Figure 7.1 | Backgating to identify auto-florescence 
CD45-APC-Cy7 (A.1) and Isotype control-APC-Cy7 (A.2) satin, with gating on a dim positive 
population. Backgating indicated where dim labelled population are located within previous 
gates (red cells) within total population of cells (grey) for CD45-APC-Cy7 (B.1) and Isotype 
control-APC-Cy7 stain (B.2). 





Figure 7.2 | Gating strategy cellular phenotyping biopsies 
Gating strategy to identify cellular subpopulations within the large intestinal biopsies. Live cells were 
identified on basis of DAPI exclusion and cell doublets were gated out using SSC-A vs SSC-H and 
FSC-H vs FSC-A. Epithelial cells were CD45neg/CD326pos and Leukocytes were CD45pos/CD326neg with 
the positive stain based on isotype control staining. Identified leukocytes were further subdivided 
identifying CD4pos T helper cells and CD8neg cytotoxic T cells. CD45pos/CD4neg/CD8neg subpopulation 
identified Monocytes by CD14pos, Macrophages CD68pos and neutrophils CD66bpos 
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An isotype control for APC-Cy7 was included in an FMO (Fluorescence minus 
one) antibody cocktail, to enable accurate gating on the CD45 positive 
leukocyte cell population. Leukocyte subpopulations CD4pos, CD8pos and 
CD4neg/CD8neg showed clear borders when gating and thus no further isotype 
controls were required (Figure 7.2). CD14pos monocytes were observed to 
make up only a minor proportion of leukocytes present in uninflamed intestinal 
biopsies (Figure 7.2). It is possible that influx of CD14pos monocytes occurs 
only during an active inflammatory response in the gut. In response to the 
observed low numbers of CD14pos monocytes within the biopsy samples, a 
CD68 macrophage stain was introduced to assess the presence of macrophages 
that had lost their CD14pos expression within the gut. Low abundance of CD68 
macrophages was observed (Figure 7.2). Furthermore, CD66b, a neutrophil 
marker, was introduced to assess the level of inflammation within a subset of 
the intestinal biopsies (n=4). An uninflamed state of the biopsy tissue was 
observed through the absence of a positive stain for CD66b (Figure 7.2).  
 
7.2.2 Biopsy composition 
The cellular composition was assessed for n=24 CD patient biopsy samples for 
which transcriptomics data was also generated. The most abundant cell 
subtypes were epithelial cells (CD45neg/CD326pos) with median abundance of 
60% of live single cells and leukocytes (CD45pos) contributing 14% of total live 
cells (Figure 7.3A). CD4pos T helper cells were observed to be the most 
abundant cell-type (median 21%) within the leukocyte subset, with CD8pos cell 
(median 16.2%) being a close second. A very low abundance of CD14pos 
monocytes, at approximately 0.5%, was observed (Figure 7.3B).  





Figure 7.3 | Cellular phenotype of intestinal tissue biopsies by FACS 
Box and whiskers plot visualising collective flow cytometry data plotted as % positive live 
cells for epithelial and leukocyte cell subsets (A) and leukocyte immune cell subtype (B). 
The box representing the 25th and 75th percentile from the median and the whiskers 
repressing the lowest and highest value. n=24. 
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Substantial variation within cellular composition of the biopsy samples was 
observed, with epithelial cell proportions varying from 10% to 82% and the 
leukocyte population accounting for 5% to 42% of live cells (Figure 7.3A). 
This, highlights the importance of investigating composition of heterogeneous 
samples used for transcriptional analyses. Variation could be due to inter-
patient variation or the location or depth at which the biopsy was taken. Less 
variation was observed within the leukocyte subpopulations, although CD4pos 
and CD8pos percentages varied from 1% to 7% and 9%, respectively (Figure 
7.3B).  
 
7.3 Deconvolution of biopsy composition 
In 3 out of 24 biopsy samples which were phenotyped for cellular composition 
using FACS, no gene expression data was generated owing to low quality RNA 
(average RIN = 2.3). A total of 15,517 transcripts were detected above 
background within the colonic intestinal biopsies (see Chapter 4.1) of the 21 
CD patients for whom cellular composition was assessed. A univariate analysis 
was employed to identify the genes which had a significant influence on biopsy 
composition. The genes identified as significant were advanced into a penalised 
regression, identifying a set of genes which collectively predict the cell count 
for each cell type. This ‘predictive gene set’ was employed to predict the 
percentage of each of the known phenotyped cell types within the n=21 biopsy 
subset, enabling us to correlate the predicted values with the known values. 
Finally, the ‘predictive gene set’ was used to deconvolute the cellular 
composition of the remaining biopsies. The below analyses was designed and 
executed by Seth Seegobin, a PhD student within the statistical genetics unit. 
7.3.1 Univariate analysis using a marginal model 
To account for the fact that relative proportions of cell types are correlated; 
when one goes up another has to come down, covariates between the cell types 
were calculated into an unstructured covariate matrix using a marginal model. 
The unstructured covariate matrix together with the cell type, cell frequencies 
and normalised gene expression count values were fitted into a univariate 
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analysis using SAS (statistical analysis software). This generated a p-value per 
gene, indicating the gene’s influence on cell type composition of the biopsy per 
patient. Out of the 15,517 genes expressed, 1,725 genes (1.11%) were 
identified to significantly (p<3.2x10-6) contribute to biopsy composition 
(Figure 7.4).  
 
 
7.3.2 Machine learning penalised regression  
The 1.11% of genes significantly associated with intestinal biopsy composition 
were identified, and progressed into a multivariate analysis to identify which 
set of significant genes could collectively predict cell count per cell type, using 
lasso (least absolute shrinkage and selection operator). The cell types predicted 
by gene expression included epithelial cells (CD45neg/CD326pos), leukocytes 
(CD45pos), T helper cells (CD45pos/CD4pos), cytotoxic T cells (CD45pos/CD8pos) 
and monocytes (CD45pos/CD14pos). Lasso identified 20 genes (Table 7.1) 
which could collectively predict the percentage of each above mentioned cell 
type contributing to biopsy composition.  
Figure 7.4 | Contribution of gene expression on cell type 
Gene ID (x-axis) versus influence of expression levels on intestinal biopsy cell composition 
(y-axis). With each dot representing a transcript (n=15,517) and a significance cut-off line 
at p= 3.2x10-6 (red line).  
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ENSG00000011009 LYPLA2 lysophospholipase II, regulates multifunctional 
lysophospholipids within biological membranes 
ENSG00000011083 SLC6A7 Solute carrier family 6 (neurotransmitter 
transporter), member 7, functions as a L-proline 
transporter protein in the brain 
ENSG00000011275 RNF216 ring finger protein 216, inhibits TNF- and IL-1 
induced NFkB activation. 
ENSG00000012779 ALOX5 arachidonate 5-lipoxygenase, plays a role in 
leukotrienes synthesis, which mediate a number of 
inflammatory and allergic conditions. 
ENSG00000012822 CALCOCO1 a coactivator for aryl hydrocarbon and nuclear 
receptors, involved in cellular metabolism, protein 
synthesis and degradation. 
ENSG00000013275 PSMC4 Involved in 26S proteasome assembly, which 
enables ATP-dependant degradation of 
ubiquitinated proteins  
ENSG00000013364 MVP major vault protein, involved in signal transduction 
and nucleo-cytoplasmic transport 
ENSG00000013441 CLK1 CDC-like kinase 1, involved in pre-mRNA 
processing 
ENSG00000013503 POLR3B DNA directed RNA polymerase III 
ENSG00000013563 DNASE1L1 Protein part of the deoxyribonuclease family 
ENSG00000014216 CAPN1 Calcium-regulated non-lysosmal protease which 
catalyses substrates involved in signal transduction 
ENSG00000014257 ACPP Tyrosine phosphatase that dephosphorylates 
various substrate under acidic conditions 
ENSG00000015133 CCDC88C coiled-coil domain containing protein, negatively 
regulator of Wnt signalling pathway 
ENSG00000019505 SYT13 Synaptotagmin, may be a transport vesicle involved 
in calcium ion binding and calcium-dependent 
phospholipid binding  
ENSG00000021355 SERPINB1 Intercellular inhibitor of granzyme H, protecting 
tissue for damage at inflammatory sites.  
ENSG00000023191 RNH1 ribonuclease/angiogenin inhibitor 
ENSG00000023445 BIRC3 Protein regulated caspases and apoptosis, 
modulates inflammatory signals and immunity 
ENSG00000023516 AKAP11 A-kinase anchor protein, binds to regulatory 
subunits of protein kinase A and confines these to 
locations within the cell  
ENSG00000023608 SNAPC1 Part of the SNAPc complex, required for 
transcription of RNA polymerase II and III 
ENSG00000025708 TYMP Promotes angiogenesis and stimulated growth of 
endothelial cells  
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For each of the cell types, a set of 16 – 20 genes and the intercept were 
identified and an estimate score was generated (See appendix 6). The 
predicted fractions of each cell type within an intestinal biopsy sample can be 
calculated by taking the sum of the estimate score multiplied by the gene count 
value for all genes associated with the cell type plus the intercept estimate value 
(see Material and Methods section 2.2.10.3). Cell type fractions were estimated 
for all 21 samples used to build the prediction model allowing comparison 



















GKT1908 49.3% 0.493 21.8% 0.218 4.2% 0.042 
GKT2255 30.5% 0.305 15.0% 0.15   
GKT1914 42.9% 0.429 10.3% 0.103 2.1% 0.021 
GKT2878 71.8% 0.718 12.4% 0.124 1.9% 0.019 
GKT2879 70.3% 0.703 4.8% 0.048 0.9% 0.009 
GKT2697 37.7% 0.377 5.3% 0.053   
GKT2168 82.6% 0.826 8.4% 0.084   
GKT2922 76.9% 0.769 11.4% 0.114 0.5% 0.0045 
GKT2059 25.8% 0.258 35.0% 0.35   
GKT1525 21.4% 0.214 28.2% 0.282 5.4% 0.054 
GKT2329 49.2% 0.492 21.5% 0.215 3.6% 0.036 
GKT3089 68.0% 0.68 12.0% 0.12 2.5% 0.025 
GKT2689 79.6% 0.796 6.9% 0.069 1.3% 0.0125 
GKT3084 52.3% 0.523 27.3% 0.273 6.5% 0.0645 
GKT0327 60.8% 0.608 16.7% 0.167 3.1% 0.031 
GKT0711 60.5% 0.605 11.2% 0.112 3.6% 0.0356 
GKT2790 33.1% 0.331 30.5% 0.305 5.1% 0.0513 
GKT2190 83.7% 0.837 9.4% 0.094 3.8% 0.0378 
GKT3080 66.1% 0.661 11.2% 0.112 2.3% 0.02299 
GKT2126 62.9% 0.629 18.0% 0.18 6.2% 0.0621 

















GKT1908 1.0% 0.01019 0.5% 0.0042 
GKT2255     
GKT1914 1.5% 0.0148 2.2% 0.022 
GKT2878 6.5% 0.0648 0.2% 0.00132 
GKT2879 2.8% 0.0284 0.1% 0.00188 
GKT2697     
GKT2168     
GKT2922 5.0% 0.05 0.1% 0.00049 
GKT2059     
GKT1525 1.4% 0.0141 0.2% 0.0021 
GKT2329 2.3% 0.0234 0.1% 0.0012 
GKT3089 1.4% 0.0141 0.3% 0.0037 
GKT2689 2.1% 0.0212 0.2% 0.0015 
GKT3084 8.5% 0.0850 0.3% 0.0035 
GKT0327 1.4% 0.0135 0.3% 0.0029 
GKT0711 1.4% 0.0142 0.3% 0.0027 
GKT2790 3.7% 0.0370 0.5% 0.0054 
GKT2190 2.3% 0.0233 0.4% 0.0044 
GKT3080 3.8% 0.0379 1.0% 0.0096 
GKT2126 3.1% 0.0312 0.2% 0.0018 
GKT3081 3.4% 0.0339 0.7% 0.0062 
* empty cells indicate missing data 
 
The predictive model achieved a 100% prediction between the observed and 
predicted cell type fractions for all cell types with exception of CD14pos 
monocytes (Table 7.2). The CD14pos monocyte population exhibited 78% 
prediction between the observed and predicted percentage, with GKT2922 
predicted 0.049% and observed 0.1% being the largest deviation (Table 7.2). 
It was hypothesised that this was due to the low abundance of CD14pos 
monocytes (less than 1% to the overall biopsy composition). Cellular 
phenotype data for the leukocyte subsets CD4pos, CD8pos and CD14pos was not 
collected within the early processed samples.  
The 100% predictive power of the model demonstrates that gene 
expression data can be employed for the deconvolution of heterogeneous 
tissues.  
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7.4 Deconvolution of biopsy composition 
In the above section the proportions of epithelial cells (CD326pos), leukocytes 
(CD45pos), T helper cells (CD4pos), cytotoxic T cells (CD8pos) and monocytes 
(CD14pos) within intestinal tissue biopsies were predicted with a 100% 
accuracy, based on gene expression levels of 20 key genes. By applying this 
method to the 57 CD intestinal biopsy samples, for which gene expression data 
was generated, the aim was to deconvolute the composition of these RNA 









The upper and lower quartiles of the predicted fractions of CD45pos leukocytes 
and CD326pos epithelial cells were observed to fall within a biologically realistic 
range (0% -100%), with the whiskers - indicating outliers - showing < 0% or 
>100% values (Figure 7.5A). The median CD45pos leukocyte estimated 
fraction was predicted to be 39.7% (Figure 7.5A) which was higher than the 
14% observed median CD45pos leukocyte cell population within the 24 samples 
that underwent cell phenotyping (Figure 7.3A). The median predicted value 
for the CD326pos epithelial cell fraction was estimated to be 65% (Figure 7.5A), 
which is very similar to the median of 61% observed within the phenotyped set 
(Figure 7.3A). Predictions for the leukocyte immune subtypes appear more 
challenging, which could be due to their small overall contribution to biopsy 
composition. CD14pos monocytes, with median 9.7%, were predicted to be the 
Figure 7. 5 | Cell type predictions based on gene expression 
Box and whiskers plot visualising the predicted percentage of CD45pos leukocytes and CD326pos 
epithelial cells (A) and leukocyte cell subtypes CD4pos, CD8pos and CD14pos (B) within 57 CD 
biopsies based on their gene expression. The box representing the 25th and 75th percentile from 
the median and the whiskers repressing the lowest and highest value.  
 
B 
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most frequent immune-cell subtype (Figure 7.5B), whereas within the 
phenotyped samples their observed frequency was much lower, with a median 
of 0.3% (Figure 7.3B). CD4pos cells were predicted to be more abundant than 
CD8pos cells (Figure 7.5B), which is consistent with the phenotype data (Figure 
7.3B). However, CD8pos cells were predicted to exhibit a median of -1.5% which 
is biologically impossible (Figure 7.5B). Although, the model returns feasible 
predictions for the more abundant cell populations: CD45pos leukocytes and 
CD326pos epithelial cells, biologically-impossible (<0% or >100%) predictions 
are generated within the low abundant immune cell types. This indicates that 
the prediction model is not as accurate as suggested by the predictions of the 
21 cellular phenotyped samples (section 7.3.2). 
To investigate a potential cause for the apparent reduced accuracy of 
the predictive model within the tested 57 CD biopsy samples, mean expression 
values of the 20 predictive genes were compared with the 21 phenotyped 















Figure 7.6 | Expression of 20 genes utilized to predict cell composition 
Box and whiskers plots visualising the gene expression normalised count values of the 20 
predictive genes (5 genes per plot, A-E) for both the 21 cellular phenotyped (left box per gene) 
and the 57 CD samples used in the prediction (right box per gene). The box representing the 
25th and 75th percentile from the median and the whiskers repressing the lowest and highest 
value. Significant difference median gene expression within each gene was calculated using a 
two-tailed Mann-Witney test (p<0.05*, p<0.005**, p<0.0005***). 
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With the exception of BIRC3 and ACPP all of the predictive genes exhibited 
significant difference in mean expression between the 21 samples used to build 
the predictive model and the 57 CD samples (Figure 7.6A-E). The fact that 18 
out of 20 predictive genes show significant differences in expression between 
the two sample groups, could be contributing to the flaws in the accuracy of 
the cell type predictions for the 57 CD biopsies. It suggests that the 21 samples 
used to build the prediction model were not representative of the overall biopsy 
samples. The small sample size of n= 21, sequencing batch effect or the site 




Whole RNA sequencing offers a high throughput, high quality way to quantify 
gene expression, although sample heterogeneity is often a concern. Measured 
expression signals within heterogeneous tissues are confounded by relative 
proportions of the cell types involved. This can lead to cell type specific signals 
being cancelled out or differences in expression being caused by sample cell 
composition. In order to assess sample composition associated expression 
differences and potentially identify cell type specific signals it is essential to 
address sample heterogeneity in RNA sequencing experiments. The intestinal 
biopsies used to generate transcriptional data (see Material and Methods 
section 2.2.2) consist of a heterogeneous tissue including epithelial, stromal 
and various immune cell types. In order to distinguish cell-type-specific 
transcriptional signals and the effect of variation in cell composition on gene 
expression, a method for deconvolution of biopsy composition utilising gene 
expression data was employed.  
 
Experimental methods to resolve tissue heterogeneity have been proposed, 
such as laser-capture microdissection (LCM), allowing dissection of 
morphologically distinguishable cell types. The RNA yield and quality is often 
considerably lower following LCM, furthermore it can only be applied to 
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morphologically distinguishable tissue which in our research is not applicable. 
Another experimental method to address tissue heterogeneity is cell 
purification through bead based or flow cytometry methods. Cell sorting 
through flow cytometry results in high quality, high purity samples, although 
it might prove a challenge to generate the required yield of RNA for sequencing 
of low abundance cell-types. Although with new and improved amplification 
methods becoming available, this is less of an issue. However, cell purification 
methods are laborious, expensive and could trigger uncontrolled processes in 
the cell altering transcription. Taking all this into consideration, the use of an 
in silico approach to address tissue heterogeneity has great appeal. Various 
methods utilising either gene expression profiles or DNA methylation status of 
purified cell types have been used to deconvolute heterogeneous tissue 256-259. 
 
One of the first studies to attempt this using gene expression profiling was D. 
Venet et al. 260. They employed a linear model to predict cell-type proportions 
within colonic cancer biopsies based on ‘marker genes’ which are uniquely 
expressed in each cell type including muscle cells, fibroblasts and macrophages. 
The model was built upon the assumption that the expression of each gene in 
a heterogeneous sample is the weighted average of the expression levels 
existing in pure populations of those cells 260. Computational models have 
evolved over the years but the majority still rely on pre-determined cell-type-
specific expression profiles from a range of pure/single-cell-type found within 
the whole tissue 256,261,262. Deconvolution models, focusing on peripheral blood 
cells, where neither proportions of cells nor signature gene expression data was 
available have been proposed 263. By using known positive and negative marker 
genes specific to each cell type within peripheral blood their ‘pure’ expression 
could be estimated from the mixed RNA sequencing data 257,263. This method 
could potentially be employed to estimate the proportion of leukocytes subsets 
within our intestinal data but ‘marker genes’ were not available for the other 
major cell types in intestinal mucosa, i.e. epithelial or stromal cells meaning it 
had limited use.  
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Due to the large number of different cell types known to be present in intestinal 
biopsies in varying quantities, we set out to find a more suitable approach to 
quantifying them in a large number of samples. This was done using RNAseq 
based gene expression data on a subset of whole biopsies from which the 
proportions of cells by flow cytometry were previously quantified. Although, 
flow cytometry is a validated technology for quantifying cell proportions based 
on antibody based fluorescent labelling; it should be taken into consideration 
that the biopsy samples underwent an enzymatic digestion prior to being 
incubated for 2 hours to stimulated recovery of cell surface receptors. During 
this process a level of cell death was observed and although all biopsies were 
process according to the same protocol some cell subsets might be more 
susceptible to cell death than other cellular subtyped in the biopsy, therefore 
potentially skewing the data. There are currently no other methods without 
limitations to perform cellular phenotyping on tissue biopsies.  
A new deconvolution method was derived based on the ability of a 
subset of genes that had demonstrated high correlation with sub-cellular 
proportions in a training set. It was hypothesised that these ‘predictive genes’ 
could predict cell count per cell type using a machine learning penalised 
regression model. The model was able to predict the cell counts of five main 
cell types within the intestinal biopsy samples used to build the model (n=21) 
with a 100% accuracy. When employing the model to predict cell count of the 
five cell types within intestinal biopsies not used to build the model, biologically 
impossible values were returned i.e. cell counts below 0% or above a 100%. In 
order to address the cause for these biologically impossible results returned by 
our deconvolution model, mean gene expression was assessed for the 
‘predictive genes’ within the sample set used to build the model and the samples 
for which their composition was predicted using the model. It was established 
that the mean expression of the ‘predictive genes’ within the samples used to 
build the model did not represent the overall expression within the intestinal 
biopsy samples accurately. The difference in mean expression can most likely 
be contributed to the small sample size of the sample set used to build the 
model. Repsilber et al. did show that deconvolution models lacking cell-type-
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specific RNA sequencing data, require a large sample size (n=120) to generate 
accurate predictions 263. Furthermore, the intestinal location where the biopsy 
was taken and sequencing batch effects should be considered as potential 
causes for the inaccurate in the deconvolution model.  
 The developed model showed promise in addressing the much debated 
issue of tissue heterogneity in the field of RNA sequencing. Further optimisation 




 8. Biomarkers predictive of relapse in Crohn’s disease 
176 
 
8. Biomarkers predictive of relapse in Crohn’s disease 
Crohn’s disease (CD) is a chronic condition characterised by episodes of relapse 
requiring either medical or surgical intervention to induce remission. In many 
patients the disease is progressive, and the ability to predict who will relapse is 
extremely poor despite extensive work using clinical characteristics and 
biomarkers. Relapse is often subclinical initially, but even at such a stage can 
be associated with irreversible bowel damage. The ability to predict which 
patients are more likely to relapse will enable targeting of expensive drugs, 
restricted in their availability, to the appropriate patients as well as avoiding 
exposing patients to unnecessary medical therapy with potentially serious side 
effects. It will also allow for closer monitoring of patients at higher risk of 
relapse, thereby minimising the burden on patients and clinical services in cases 
where less frequent monitoring is possible. It was therefore decided to use 
genome-wide microarray to derive transcriptional profiles from unstimulated 
and stimulated CD4pos T helper cells, CD8pos cytotoxic T cells and CD14pos 
monocytes isolated from whole blood of patients, and compare profiles in those 
who do and do not relapse within 1 year. With the aim of identifying 
transcriptional differences that could potentially elude to effective biomarkers 
for the prediction of relapse in patients.  
  
8.1 Patient samples 
Blood samples for isolation of peripheral blood mononuclear cells (PBMCs) 
were collected from 49 patients in endoscopic or clinical remission at time of 
recruitment. Their progress was monitored over a 12-month period to 
determine who did and did not relapse, and a second blood sample was 
collected at time of relapse or at 12-months post recruitment. Patients within 
three subsets were recruited: 
 20 post-surgery patients, either resection or stoma reversal surgery.  
 20 routine gastroenterology clinic patients 
 9 patients having been withdrawn from anti-TNF treatment, Humira or 
Infliximab  




The post-surgery patients were recruited either two weeks post their resection 
surgery or at the day of their stoma reversal. The routine gastroenterology clinic 
patients were recruited when reporting clinical remission during their 
appointment and the anti-TNF withdrawal patients were recruited eight week 
following their final Infliximab injection (or two weeks for Humira). Relapse 
was assessed at a 6-month follow-up colonoscopy for the post-surgery patient 
cohort, with a Rutgeerts score ≥ 2 classified as relapse. For the anti-TNF 
withdrawal and gastroenterology clinic patient cohorts, relapse was classified 
as a need to change the patients’ medication. An overall relapse rate of 37% 
was observed, with the highest incidence of relapse seen in the post-surgery 
cohort at 45% (9 out of 20). The anti-TNF withdrawal cohort exhibited 33% 
relapse rates (3 out of 9) and 30% of gastroenterology clinic patients (6 out of 
20) relapsed (Table 8.1).  
 









Mean age  32.7 33.3 44.8 
# Female  14 5 8 
# Male 6 4 12 
# Relapsed 9  3 6 
within  5 - 9 months 2-8 months 1-12 months 
# Remission 11 6 14 
beyond > 6 months >12 months >12 months 
 
8.2 Cell sorting 
An average of 6.45x107 PBMCs were extracted from 50 ml of blood stored for 
between 2 and 12 months. An average of 4.7x106 live PBMCs were retrieved, 
with samples having been stored for longer periods of time showing lower 
viability. Thawed and rested PBMCs were stained with fluorescent labelled 
antibodies (see Materials and Methods section 2.3.4) and flow cytometry based 
cell sorting was employed to isolated CD4pos T helper cells, CD8pos cytotoxic T 
 8. Biomarkers predictive of relapse in Crohn’s disease 
178 
 
cells and CD14pos monocytes. The purity of the separated cells was then 
assessed by flow cytometry (Figure 8.1). Prior to cell sorting a mixed PBMC 
composition within the samples was observed with approximately 10% 
monocytes (CD14pos), 42% cytotoxic cells (CD8pos) and 19% T helper cells 
(CD4pos) of live leukocytes (Figure 8.1A). Post cell sorting cell population 
purities of 99.6% for CD4pos, 99.4% for CD8pos and 96.5% for CD14pos cells was 
observed (Figure 8.1B-D). 




Figure 8.1 | Flow cytometry based purity check  
Gating strategy to identify cellular subpopulations within the peripheral blood mononuclear 
cells (PBMCs) pre and post flow cytometry based cell sorting. Leukocytes were identified 
using SSC-A vs FSC-A gating. Monocytes were identified as CD14pos (B) and T helper and 
cytotoxic T cells were CD3pos and CD4pos (C) or CD8pos (D), respectively.  
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Average purities achieved for the CD4pos and CD8pos cell populations within the 
55 processed samples reached 99.5% (Figure 8.2). CD14pos monocytes showed 
the highest variation in purity, although still reaching an average of 97.7% 





Post cell sorting, between 4.7x105 and 3.3x106 purified cells were obtained 
with an average of 8.2x105 purified cells per cell type. One patient sample was 
lost during cell sorting and thus was excluded from further analysis.  
 
8.3 Immune cell stimulation and RNA quality control 
Previous studies suggest that regulatory changes in gene expression in subsets 
of immune cells, and activation of immune-enhancers are more apparent upon 
immune stimulation, it was therefore decided to stimulate a portion of the 
Figure 8.2 | Cell purities achieved post cell sorting 
Box and whiskers plot visualising collective flow cytometry data plotted as percentage 
(%) live cells of CD4pos T helper cells, CD8pos cytotoxic T cells and CD14pos monocytes 
cell population post cell sorting, indicating cell purity. The box representing the 25th 
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separated immune cell subsets. All separated immune cell subsets for which 
more than 2x105 cells were obtained, were divided in two equal parts prior to 
a 4-hour incubation at 37°C and 5% CO2. Half of the cells were left 
unstimulated and the other half were incubated with stimulatory agent. CD4pos 
and CD8pos cells were activated using CD3pos/CD28pos T-activator beads and 
CD14pos cells were activated using LPS (lipopolysaccharides). Stimulation was 
assessed by relative quantification (RQ) of the TNFα gene by qPCR (see 
Materials and Methods 2.3.7). A 10-15-fold increase was observed in the CD8pos 
and CD14pos cells, where CD4pos cells showed a 98-fold increase of TNFα 




Between 13 ng and 14.3 µg, with an average of 159 ng, of total RNA was 
extracted from separated unstimulated and activated CD4pos, CD8pos and 
CD14pos cells, with RNA integrity and quality observed to vary but overall to be 
adequate to high (Figure 8.5).  
Figure 8. 3 | TNFα expression post stimulation 
Fold-change/increase in expression of TNFα following stimulation; CD3+/CD28+ (blue and 








No RIN scores were generated but based on electropherograms it was observed 
that the majority (82%) showed no or minor degradation, indicated by the 
absence of fluorescence between the small RNA and 18s peak at 24-30 sec 
(Figure 8.5). Approximately, 13% of RNA samples showed moderate 
degradation and 4% showed major degradation. Two samples were observed 
to be fully degraded and thus were omitted for the study. For this study 162 
unstimulated - 54 samples x 3 immune cell types – and 109 stimulated RNA 
samples were taken forward for amplification and labelling for microarray.  
 
8.4 Amplification and labelling 
Amplification and labelling of the RNA samples was performed by Dr David 
Chambers, a lecturer in function genomics the CARD (Centre for Age Related 
Diseases). Amplification was performed using 5 ng of total RNA for each of the 
271 RNA samples, producing 2-4 µg of cDNA per sample. Following successful 
amplification, the samples were biotinylated producing single stranded labelled 
cDNA ready for hybridisation to the Illumina HT-12 expression bead array. 
Quality of quantification and labelling was confirmed using the Agilent 
bioanalyzer (Figure 8.6).  
Figure 8.4 | Quality control RNA 
Electropherograms displaying fluorescence units (FU) on y axis versus time (S), on the x axis. 
Showing marker (28sec), small RNAs <200nt (23sec), 18s subunit (~35sec) and 28s subunit 
(~42sec). (A) High quality sample with no degradation, (B) RNA showing an minor level of 
degradation. (Plots generated through the bioanalyzer (Agilent Technologies)). 
 
 




A symmetric peak sized between 100 and 2000 nucleotides was observed for 2 
out of 58 the samples (Figure 8.6A), whereas the remainder of the samples 
showed a more irregular shapes as indicated by Figure 8.6B. Levels of 
fluorescence also varied widely from 2 FU up to 15 FU at the highest point of 
the peak.  
 
8.5 Microarray results  
The samples were normalised to 150 ng/µl of labelled single stranded cDNA 
and provided to the BRC Genomics Unit for processing using the Illumina HT-
12 expression bead chip. The first 96 samples were processed, and the results 
assessed using Genomestudio. Extremely low background signal levels were 
observed within 96 microarray samples. The background signal is generated by 
a subset of probes of random sequence without any target in the genome. The 
expected values for background signal are around 100 to 150 strength of signal, 
however a much reduced background signal range of 0 – 50 was observed 
within the 96 microarray samples. For probes corresponding to genes, a signal 
range between 40-160 was detected; also lower than the average expected 
value of approximately 200. A clear batch affect was present with the first 48 
samples, demonstrating detectable expression levels at p = 0.05 for an average 
5,500 genes, compared to the average of detected genes at p = 0.05 for the 
second 48 samples, which was 2,000 (Figure 8.7). Due to the low background 
Figure 8.5 | Quality control  
Electropherograms showing fluorescence units (FU) on y axis versus size, nucleotides (nt), on 
the x axis (A) Single stranded cDNA (100-2000 nt) and markers following labelling using 
Encore BiotinIL kit (B) Single stranded cDNA (100-2000 nt) and markers following labelling 
using Encore BiotinIL kit. (Plots generated through the bioanalyzer (Agilent Technologies)). 
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signal observed, the low number of genes detected and the apparent batch 
effect, it was advised to discontinue the microarray experiments at this stage, 





The unexpectedly low background and gene expression signals recorded in the 
microarray experiment could have potentially been a result of inaccurate 
starting quantification of samples, or poor quality input RNA. Re-quantification 
of the samples using Qubit fluorometric quantitation technology confirmed 
Figure 8.6 | Detected signal above background 96 samples 
Number of genes for which expression was detected above background p=0.05 (orange line) 
and p=0.01 (blue line) per sample. (Plot generated by GenomeStudio, Illumina). 
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original values to be correct, suggesting this was not the cause of the low 
expression signal observed. Furthermore, the quality of the RNA samples was 
reviewed by bioanalyzer traces generated using the labelled single stranded 
cDNA (sscDNA) (Figure 8.6). Although peaks were observed for all samples 
and suggested that labelled product of the appropriate size was achieved, the 
majority of sample traces did not conform to the recommended symmetrical 
size distribution required for high quality expression data (see Figure 8.6A for 
example). Only 2 samples out of 96 tested were consistent with the 
recommended high quality bioanalyzer profile, whereas the remaining sample 
profiles were highly variable as shown by Figure 8.6B. It was therefore 
suspected that the amplification and/or labelling of the RNA samples had been 
sub-optimal. The most likely cause is partial degradation of the RNA samples. 
Considering that the amplification kit relies on 3’ poly-A tail binding, any level 
of degradation within the RNA will affect the amplification process. Having said 
this, RNA quality was checked using the bioanalyzer (Figure 8.5) and the 
majority of RNA samples showed adequate to high quality RNA, with 82% 
showing no to minor degradation. Another potential cause could be errors with 
the labelling kit or procedure.  
In order to utilise these samples and generate data from them, a pilot 
set of 8 samples including CD14pos monocytes stimulated and non-stimulated, 
from two patients maintaining remission and two exhibiting relapse, were 
submitted of for mRNA sequencing. 
 
8.6 Discussion 
The aim of this study was to identify a panel of new and effective biomarkers 
for the prediction of likely relapse in patients suffering from CD. Relapse is 
often subclinical initially, but even at such a stage can be associated with 
irreversible bowel damage. The ability to predict which patients are more likely 
to relapse will allow the targeting of expensive drugs, restricted in their 
availability, to the appropriate patients as well as avoiding exposing patients to 
unnecessary medical therapy with potentially serious side effects. An important 
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factor to consider when investigating transcriptional biomarkers for clinical use 
is the selection of appropriate cells or tissue. Although, PBMCs are an easy 
tissue to obtain they are a heterogeneous cell population which has been shown 
to reduce the ability to pick up transcriptional signals 264. Within IBD research, 
Lee et all has shown that the separation into purified cell subtypes can 
strengthen a transcriptional signal. They identified a transcriptional signature 
associated with a more severe disease progression using isolated CD8pos cells, 
but failed to observe the same signal in whole PBMCs 144. It was therefore 
decided to look in purified subpopulations of peripheral blood, CD4pos T helper 
cells, CD8pos cytotoxic T cells and CD14pos monocytes, to investigate biomarkers 
for relapse in CD. These specific immune cell subtypes were chosen as they play 
important roles in cell-mediated immunity and have been shown to have a key 
role in the inflammatory response in IBD; CD4pos T cells are crucial in the 
pathogenesis of CD as they represent the majority of the activated mononuclear 
cells that infiltrate the intestinal wall 265. CD8pos cells can be found in the 
mucosa in mouse models of IBD and several studies have suggested that 
autoreactive CD8pos T cells may be involved in the initiation of the 
inflammatory response in IBD 266. CD14pos monocytes respond to microbial 
products such as LPS and Th1-derived IFN-gamma and are important in 
mucosal immunity 267. 
 
CD4pos T helper cells, CD8pos cytotoxic T cells and CD14pos monocytes, from 49 
patients in remission at time of entry into the study, were successfully purified, 
stimulated and RNA was extracted that was of relatively low yield. The 
amplification, labelling and hybridisation of the samples to the gene expression 
microarrays (HumanHT-12, Illumina) was outsourced to a local genomics 
facility, however, they were unable to generate data of sufficient quality from 
the first 96 samples. Troubleshooting indicated that the most likely reason for 
this was that the quality of the extracted RNA was more compromised than 
realised or an error was made in the amplification and labelling process of the 
samples. The employed amplification and labelling chemistries are highly 
sensitive to degradation of the RNA poly-A tail. Considering the limited amount 
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of remaining RNA, it was decided to not repeat the microarray analysis but to 
investigate an alternative method for gene expression profiling using low-input 
RNA sequencing. The initial quality control (QC) of the eight samples 
submitted for RNA sequencing indicated high quality data, with data analysis 
currently being performed. The hope is that this project, ones completed, would 
addresses an important unmet clinical need. 
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9. Conclusions and Future directions 
9.1 Conclusions 
This study aimed to increase the knowledge of the pathogenesis of IBD by 
characterising the entire colonic transcriptome, using whole RNA sequencing, 
and investigate gene expression at IBD susceptibility loci in biological relevant 
intestinal tissue from affected patients and controls. Following successful RNA 
sequencing of large intestinal tissue, differential expression between cases and 
controls was assessed, affected canonical pathways were identified and 
correlations between changes in gene expression and GWAS index SNPs in IBD 
were established. Heterogeneity of the intestinal biopsies used to generate the 
RNA sequencing data was assessed through cellular phenotyping. Finally, a 
pilot study was performed to investigate the transcriptional signature within 
multiple peripheral immune cells to predict relapse in CD patient.  
 
Our study was the first to quantify the whole human transcriptome within 
uninflamed large intestinal tissue in IBD patient and controls, enabling 
hypothesis free quantification of coding and non-coding transcripts. It was 
shown that only 32% of the transcriptome exhibited expression above 
background within uninflamed IBD disease relevant tissue. Furthermore, it was 
established that 2,971 transcripts mapped to known IBD susceptibility loci, 
allowing us to prioritise genes potentially involved in the pathogenesis of CD, 
IBD or UC.  
Differential expression analysis on the various IBD sub-phenotypes 
overall identified 1,637 genes exhibiting significant differences in expression 
within large intestinal tissue. Of these, 284 genes were prioritised to potentially 
be involved in the pathogenesis of IBD, UC or CD based on their genomic 
location within a known IBD susceptibility loci. The gene with the highest 
significance, showing reduced expression within CD and IBD cases versus 
controls, was GLS (Glutaminase). Glutaminase is involved in the breakdown of 
glutamine into glutamate and ammonia. Glutamine provides and important 
energy source for cells and has been shown to be essential to immune function 
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in the gut. Furthermore, reduced glutamine can lead to reduced gut mucosal 
integrity and increased gut permeability to allergens and pathogens. The role 
of glutaminase in the gut is less defined, although it has previously been 
observed that both intestinal glutamine levels and glutaminase activity are 
reduced in CD patients. The identified significant reduction in GLS expression 
in CD and IBD patients, confirmed previously reported results and suggests that 
both glutamine levels as well as breakdown of glutamine by glutaminase might 
contribute to IBD pathogenesis. Another gene highlighted as a strong candidate 
gene to be involved in IBD pathogenesis was GAL3ST2. GAL3ST2 (Galactose-3-
O-Sulfotransferase 2), exhibited a lower expression in UC vs CD patients. 
GAL3ST2 is known to be present in intestinal mucosa where it is involved in 
the synthesis of sulfomucins; sulfomucins have been implicated in the 
protection of the intestinal mucosa through increased mucus viscosity. Previous 
studies have shown that a significant loss of sulfomucins can be observed in the 
mucosal lining of UC patients. It is possible this loss of sulfomucins could be in 
some part due to the observed reduced colonic expression of GAL3ST2. Further 
investigation into this pathway is warranted in our cohort.  
 
In addition to investigating individual genes exhibiting differential expression, 
we utilised pathway analysis tools to investigate underlying biological pathway 
affected by the differential expressed genes and drive hypothesis about 
biological pathways underlying disease pathology or etiology. Overall, 49 
biological pathways were implicated in CD, IBD or UC. The majority of the 
identified pathways were involved in processes known to play an important 
role in IBD: immunoregulatory, autophagy and transmembrane signalling. The 
most significant perturbed pathways fell within three major groups: Gas and 
G-protein signalling pathways, the Notch signalling pathway and drug 
metabolism. One novel finding was the perturbation of Nicotine degradation 
pathway II and III within CD patients versus controls and UC patients. Smoking 
has been shown to have strongly opposing effects on the clinical course of IBD 
subtypes; smoking has proven to be beneficial to clinical remission in UC 
patients whereas, CD patients report detrimental effects. Considering nicotine 
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is an important component in smoking, our finding of two nicotine degradation 
pathways being perturbed solely within CD patients is interesting. Although, a 
multitude of research studies have been performed, an explanation for the 
opposing effects of smoking on UC and CD has not yet been found. The 
perturbation of nicotine degradation pathways II and III in CD patients and not 
UC patients, might be the first indication into the underlying mechanism of 
these differences in clinical outcomes in response to smoking.  
 
Expression quantitative trait (eQTL) analysis is a powerful tool able to generate 
insights into associations between SNPs and changes in gene expression. 
Within complex diseases, eQTL analysis has proven highly valuable considering 
it can be employed to combine GWAS disease specific associations, often 
located in non-coding regions, with functional knowledge. This way eQTL 
results can generate valuable insights into disease mechanism and 
pathogenesis. Our eQTL analysis identified 126 cis-eQTLs located with known 
IBD loci, of these 23 were previously reported within colonic tissue. 
Furthermore, expression of 9 genes located within an IBD loci showed 
association with an IBD risk SNPs, making them strong candidate genes in IBD 
pathogenesis and further investigation should be performed. One of these 9 
was FAM49B (Family With Sequence Similarity 49, member B), a gene which 
exhibited a 2-fold increased expression in the presence of the minor allele of 
IBD risk SNP rs13340584. In addition, FAM49B was previously prioritised to be 
involved in IBD pathogenesis and was observed to exhibit significant 
differences in expression between IBD cases and controls. Limited functional 
knowledge is available for FAM49B, although one study suggested a potential 
role in antigenic peptide presentation on a subset of T cells in the absence of 
ERAAP, with ERAAP1 and ERAAP2 also having been identified as cis-eQTLs 
with IBD risk SNPs. Overall, the eQTL analysis has contributed to our 
knowledge of IBD pathogenesis and the role of aberrant gene regulation within 
IBD, although additional investigation will be required.  
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Furthermore, our research attempted to address an important issue in RNA 
sequencing: tissue heterogeneity. A deconvolution model was build based on 
gene expression and cellular phenotypes of the intestinal biopsies. The 
developed deconvolution model showed for the first time the ability to predict 
cell fractions with a 100% accuracy (in the training set) without known ‘marker 
genes’ or epigenetic markers of specific cell types in the heterogeneous tissue. 
Unfortunately, when applied to a greater subset of biopsies the method proved 
inaccurate in its predictions. Contributing factors to this include the small 
sample size of the training set, cell viability, potential RNAseq batch effects or 
variation in the sites from where the colonic biopsies were taken e.g. transverse 
or descending colon. Although further optimisation is needed, progress towards 
the deconvolution of heterogeneous tissues was made. 
 
Finally, as a separate project, we aimed to investigate biomarkers predictive of 
relapse in CD. Transcriptional profiles were attempted to be generated from 
immune cell subtypes within peripheral blood; CD4pos T helper cells, CD8pos 
cytotoxic T cells and CD14pos monocytes, within patients at time of remission 
and clinical relapse. These specific immune cell subtypes were chosen as they 
play important roles in cell-mediated immunity and have been shown to have 
a key role in the inflammatory response in IBD. Unfortunately, quantification 
of expression through microarray analysis was unsuccessful and no 
downstream analysis has yet been performed. Preliminary data from RNA 
sequencing looked promising and results will be expected in the future. This 
project, although not yet complete, aims to address an important unmet clinical 
need.  
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9.2 Future directions 
When investigating genes exhibiting differences in colonic gene expression 
between IBD sub-phenotypes and controls, the UC vs control analysis generated 
p-values which plateaued out, most likely due to limited power with 24 UC 
patients and 28 controls. Although, it was possible to identify various genes 
suggested to affect UC pathogenesis using the larger CD group as a comparator 
through the UC vs CD analysis (24 vs 76), the number of UC patient samples 
will need to be increased to enable a more powerful UC vs control differential 
expression analysis. The identification of genes differentially expressed 
between UC vs control intestinal tissue, combined with the already performed 
UC vs CD analysis could provide valuable insights into genes contributing 
specifically to UC pathogenesis. Although, there is a clear overlap in disease 
features and biological pathways underlying UC and CD, investigation into 
their sub-phenotype specific etiology should also be performed.  
 
The expression quantitative trait (eQTL) analysis performed in our study has 
provided additional insight into associations between SNPs covering 118 
known IBD susceptibility loci and changes in gene expression of nearby genes. 
Unfortunately, 106 out of 224 IBD susceptibility loci were not covered by our 
genotype data. Through imputation of SNP alleles at these un-genotyped IBD 
risk loci using 1000 genomes data, further insights into genes affected within 
these 106 IBD susceptibility loci could be generated. Through the investigation 
of GWAS association signals with functional studies, such as eQTL studies, 
insights into the mechanistic etiology of complex diseases can potentially be 
generated.  
Although good progress has been made in identifying the effect of IBD 
susceptibility SNPs on proximal or nearby genes, it is hypothesised that a subset 
of the IBD causal SNPs will result in changes in expression of more distal genes, 
outside the 1Mb that was tested in this study, or even on different 
chromosomes. Trans-eQTL studies are limited in their power due to the 
numbed of association tests required. To perform a well powered trans-eQTL 
 9. Conclusions and Future directions 
193 
 
analysis, a samples size of > 600 samples would ideally be achieved. With RNA 
sequencing datasets more frequently being made publically available, a 
potential future meta-analysis might provide the power needed for a trans-
eQTL analysis in uninflamed intestinal tissue of IBD patients.  
 
The identification of cell type specific expression signals within heterogeneous 
tissues will need to be addressed in future research. This can either be done 
through optimisation of our deconvolution method or by purifying cell 
populations using flow cytometry. Purifying cell populations using flow 
cytometry has become more appealing with low input or single cell RNA 
sequencing technologies now being accessible, although it remains to be a 
labour intensive and expensive method which might affect the transcriptome. 
Even though, the by us developed method for deconvolution of the intestinal 
biopsy samples was not accurate in predicting the cell type fractions within our 
intestinal biopsies, it showed major promise by achieving a 100% accuracy in 
the biopsy data set used to build the model. Optimisation of the deconvolution 
model should include expansion of biopsy cellular phenotype data (well 
matched to the colonic site of where they were taken) and incorporation of 
RNAseq batch effects into the model. If the deconvolution model can be 
optimised, the generated data for all 127 patients and controls can be further 
utilised to investigate if observed differences in expression are caused by 
phenotype or variation in biopsy composition. Furthermore, accurate biopsy 
composition predictions could potentially enable identification of tissue specific 
eQTLs.  
 
Although, whole RNA sequencing was performed on the intestinal biopsies this 
did not include micro RNAs (miRNAs). miRNAs are known to be of great 
importance in transcriptional regulation through RNA silencing and post-
transcriptional regulation of gene expression. Furthermore, miRNAs have been 
reported to play a key role in the regulation of immune development cells and 
aberrant expression of certain miRNAs could contribute to autoimmunity 268. 
Considering IBD susceptibility SNPs are known to be located in between genes 
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and hypothesised to affect genes through an indirect fashion, miRNAs and their 
role in IBD will need to be investigated. Our aim is to sequence all colonic 
miRNAs within the 127 intestinal biopsies collected for the whole RNA 
sequencing study and perform a similar analysis package i.e. investigate 
differential expression between sub phenotypes, identify underlying biological 
pathways and incorporate the miRNAs into the eQTL analysis.  
Top hits from both the miRNA and whole RNA sequencing result should 
be validated using real-time qPCR.  
 
Finally, preliminary quality control (QC) has shown that the eight samples 
submitted for RNA sequencing, in the biomarkers for relapse study, generated 
high quality data. This confirms that the RNA quality of the collected samples 
can be sufficiently high to generate good quality transcriptional profiles. The 
remaining 263 unstimulated and stimulated CD4pos and CD8pos T cells and 
CD14pos monocytes should therefore also be submitted for RNA sequencing. 
Comparison of the transcriptional profiles from patients identified as relapsed 
to non-relapsed patients as well as stimulated vs unstimulated samples will aim 
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# Add a 'class' column with 'healthy' or 'ibd' 
metadata = metadata[order(metadata$type),] 
metadata$class = "healthy" 
wIBD = which(metadata$type!="control") 
metadata[wIBD,"class"]="ibd"  
 
#Convert date of birth (DOB) to age 
Dob = as.Date(metadata$dob, format ="%m/%d/%Y") 
age = (as.Date("05/04/2016", format ="%m/%d/%Y") - Dob)/365 
metadata$age = round(age) 
 
#Save phenotype data after changes 
write.csv(x=metadata,row.names = TRUE, 
file=paste("/home/demandtl/RNAseqLD/DE/PCA plots 128 
libraries/correctedMetadata.csv", sep="")) 
 









#Save the counts table 
write.csv(x=countsOriginal,row.names = TRUE, 
file=paste("/home/demandtl/RNAseqLD/DE/PCA plots 128 
libraries/countsOriginal.csv", sep="")) 
 
#Convert counts to counts per-million 
cpmsOriginal = cpm(countsOriginal ); 
 
#Remove all 'unwanted' rows and set cut-off for gene expression levels 
noint = rownames(countsOriginal) %in% 
c("no_feature","ambiguous","too_low_aQual","not_aligned","alignment_not_unique") 
 
keep = rowSums(cpmsOriginal > 1) >= 24 & !noint 
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counts = countsOriginal[keep,] 
cpms = cpmsOriginal[keep,] 
 





#Save the new expression counts table 
write.csv(x=counts,row.names = TRUE, 
file=paste("/home/demandtl/RNAseqLD/DE/PCA plots 128 
libraries/edgeRFilteredCountsTable.csv", sep="")) 
 
#Calculate PCs with normalized counts 
d = DGEList(counts=counts , group=metadata$class ) 
d = calcNormFactors(d) 
nc = cpm(d, normalized.lib.sizes=TRUE) 




#Check that the order of the PC data is the same of the metadata table 
rownames(pca$x)==metadata$sampleName 
 
#Create dataframe with PCs and relevant phenotype data 
dfPCA = data.frame(sampleName=rownames(pca$x), PC1=pca$x[,1], 
PC2=pca$x[,2], PC3=pca$x[,3], PC4=pca$x[,4], PC5=pca$x[,5], PC6=pca$x[,6]) 
 
dfPcaAndMetadata = merge(x=dfPCA, y=metadata, by.x=0 , by.y="sampleName") 
 
#PC1 vs PC2 for batch, sex and disease type 
a = ggplot(data=dfPcaAndMetadata, aes(x=PC1, y=PC2, color=batch)) + 
geom_point(shape=19, size=3) + stat_ellipse(type="norm", level=0.68) 
 
b = ggplot(data=dfPcaAndMetadata, aes(x=PC1, y=PC2, color=sex)) + 
geom_point(shape=19, size=3) + stat_ellipse(type="norm", level=0.68) 
 
c = ggplot(data=dfPcaAndMetadata, aes(x=PC1, y=PC2, color=type)) + 
geom_point(shape=19, size=3) + stat_ellipse(type="norm", level=0.68) 
 
#PC3 vs PC4 for batch, sex and disease type 
d = ggplot(data=dfPcaAndMetadata, aes(x=PC3, y=PC4, color=batch)) + 
geom_point(shape=19, size=3) + stat_ellipse(type="norm", level=0.68) 
 
e = ggplot(data=dfPcaAndMetadata, aes(x=PC3, y=PC4, color=sex)) + 
geom_point(shape=19, size=3) + stat_ellipse(type="norm", level=0.68) 
 
f = ggplot(data=dfPcaAndMetadata, aes(x=PC3, y=PC4, color=type)) + 
geom_point(shape=19, size=3) + stat_ellipse(type="norm", level=0.68) 
 
#PC5 vs PC6 for batch, sex and disease type 
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g = ggplot(data=dfPcaAndMetadata, aes(x=PC5, y=PC6, color=batch)) + 
geom_point(shape=19, size=3) + stat_ellipse(type="norm", level=0.68) 
 
h = ggplot(data=dfPcaAndMetadata, aes(x=PC5, y=PC6, color=sex)) + 
geom_point(shape=19, size=3) + stat_ellipse(type="norm", level=0.68) 
 
i = ggplot(data=dfPcaAndMetadata, aes(x=PC5, y=PC6, color=type)) + 
geom_point(shape=19, size=3) + stat_ellipse(type="norm", level=0.68) 
 
#Visualise and save the plots (perform for plots a-i) 
print(a) 
 
ggsave(plot=a, filename = paste("/home/demandtl/RNAseqLD/DE/PCA plots 128 
libraries/PCAplot_1_2_batch.png", sep=""), height=10, width=10*1.2, dpi=222) 
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#Remove the sample identified as an outlier in the PC analysis 
w1740 = which(metadata$sampleName == "GKT1740") 
metadata=metadata[-w1740, ]  
 
#Save phenotype data after removal outlier 
runDate = paste(unlist(strsplit(as.character(Sys.Date()), split = "-")), collapse="") 













#Save the counts table 
write.csv(x=countsOriginal,row.names = TRUE, 
file=paste("/home/demandtl/RNAseqLD/DE/PCA plots 128 
libraries/countsOriginal.csv", sep="")) 
 
#Convert counts to counts per-million 
cpmsOriginal = cpm(countsOriginal ); 
 
#Remove all 'unwanted' rows and set cut-off for gene expression levels 
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noint = rownames(countsOriginal) %in% 
c("no_feature","ambiguous","too_low_aQual","not_aligned","alignment_not_unique") 
 
keep = rowSums(cpmsOriginal > 1) >= 24 & !noint 
counts = countsOriginal[keep,] 
cpms = cpmsOriginal[keep,] 
 





#Save the new expression counts table 
write.csv(x=counts,row.names = TRUE, 
file=paste("/home/demandtl/RNAseqLD/DE/PCA plots 128 
libraries/edgeRFilteredCountsTable.csv", sep="")) 
 
#Calculate RUV values 
geneEnsgIds = rownames(counts)[grep("^ENSG", rownames(counts))] 
spikeIds =rownames(counts)[grep("^ERCC", rownames(counts))] 
ruv = RUVg(x=counts, cIdx=spikeIds, k=6) 
counts2 = ruv$normalizedCounts 
 
metadata$w1 = ruv$W[,1] 
metadata$w2 = ruv$W[,2] 
metadata$w3 = ruv$W[,3] 
metadata$w4 = ruv$W[,4] 
metadata$w5 = ruv$W[,5] 
metadata$w6 = ruv$W[,6] 
 
#Correct count data using RUVseq and PCA values 
d = DGEList(counts=counts, group=metadata$class) 
d = calcNormFactors(d, method="TMM" ) 
design = model.matrix(~ w1 + w2 + w3 + w4 + w5 + w6 + batch + sex + age + 
class, data=metadata) 
d = estimateGLMRobustDisp(d, design) 
summary(d$tagwise.dispersion) 
f = glmFit(d, design) 
IBD_ruvBatch = glmLRT(f, coef="classibd ") 
 
#Correct for multiple testing 
resultsTable = IBD_ruvBatch$table 
q = p.adjust(resultsTable$PValue, method="BH") 
resultsTable$QValue = q 
 
#Import gene names from Ensemble into results table 
listMarts(host = "www.ensembl.org") 
ensembl = 
useMart("ENSEMBL_MART_ENSEMBL",dataset="hsapiens_gene_ensembl", host = 
"www.ensembl.org") 
ensgIds = rownames(resultsTable) 
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geneSymbol = getBM(attributes=c("hgnc_symbol", "ensembl_gene_id"), 
filters="ensembl_gene_id", values=ensgIds, mart=ensembl) 
 
resultsTable$geneSymbol = "NA" 
 
for(i in 1:nrow(geneSymbol)){gS = geneSymbol[i,"hgnc_symbol"] 
gE = geneSymbol[i,"ensembl_gene_id"]  
w= which(rownames(resultsTable) == gE)  




w = which(colnames(resultsTable)=="LR") 
resultsTable = resultsTable[,-w] 
 
#Generate and save the volcano plot 
ggp = ggplot(data=resultsTable) + geom_hline(mapping = aes(yintercept=-
log10(0.05)), col="darkgreen", linetype = 2) + geom_point(aes(x=logFC, y=I(-
log10(QValue)), col=logCPM ), alpha=0.8, size=2, pch=19) + ylab("-log10(q-
value)") + xlab("log(Fold Change)") + annotate("text", label = "q-value = 0.05", x 






height=8, width=8, dpi=222, plot=ggp) 
 
#Order the results table by significance (q-value) 
o = order(resultsTable$QValue) 
resultsTable = resultsTable[o, ] 
 
#Check ordering worked and save/export results table 
head(resultsTable) 
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#Load appropriate libraries 
library("MatrixEQTL") 
setwd("/gpfs/home/demandtl/RNAseqLD/eQTL/") 
base.dir = "/gpfs/home/demandtl/RNAseqLD/eQTL/" 
 
useModel = modelLINEAR 
 
#Set path to genotype files and SNP location file 
SNP_file_name = paste(base.dir, "genotypes_eqtl_filtered60_output.txt", sep="") 
snps_location_file_name = paste(base.dir, "SNP locations_filtered.txt", sep="") 
 
#Set path to gene expression file and gene location file 
expression_file_name = paste(base.dir, "FPKM_aboveBackground.txt", sep="") 
gene_location_file_name = paste(base.dir, "Gene locations_filtered.txt", sep="") 
 
#Set path to covariate file (PC data) 
covariates_file_name = paste(base.dir, "PCA_variables_table.txt", sep="") 
errorCovariance = numeric() 
 
#Set the dicstance for local gene-SNP pair (cis) 
cisDist = 1000000  
 






#Set the significane threshold 
pvOutputThreshold_cis = 0.02; 
pvOutputThreshold_tra = 0.00; 
 
#Load genotype data 
snps = SlicedData$new() 
snps$fileDelimiter = "\t" 
snps$fileOmitCharacters = "NA" 
snps$fileSkipRows = 1 
snps$fileSkipColumns = 1 
snps$fileSliceSize = 2000 
snps$LoadFile(SNP_file_name) 
 
#Load gene expression data 
gene = SlicedData$new() 
gene$fileDelimiter = "\t" 
gene$fileOmitCharacters = "NA" 
gene$fileSkipRows = 1 
gene$fileSkipColumns = 1 
gene$fileSliceSize = 2000 
gene$LoadFile(expression_file_name) 





cvrt = SlicedData$new() 
cvrt$fileDelimiter = "\t" 
cvrt$fileOmitCharacters = "NA" 
cvrt$fileSkipRows = 1 
cvrt$fileSkipColumns = 1 
if(length(covariates_file_name)>0) {cvrt$LoadFile(covariates_file_name)} 
 
#Run the analysis 
snpspos = read.table(snps_location_file_name, header = TRUE, stringsAsFactors = 
FALSE); 




me = Matrix_eQTL_main( 
  snps = snps,  
  gene = gene,  
  cvrt = cvrt, 
  output_file_name = output_file_name_tra, 
  pvOutputThreshold = pvOutputThreshold_tra, 
  useModel = useModel,  
  errorCovariance = errorCovariance,  
  verbose = TRUE,  
  output_file_name.cis = output_file_name_cis, 
  pvOutputThreshold.cis = pvOutputThreshold_cis, 
  snpspos = snpspos,  
  genepos = genepos, 
  cisDist = cisDist, 
  pvalue.hist = "qqplot", 
  min.pv.by.genesnp = FALSE, 
  noFDRsaveMemory = FALSE) 
 
#View the results 
cat('Analysis done in: ', me$time.in.sec, ' seconds', '\n'); 
cat('Detected local eQTLs:', '\n'); 
show(me$cis$eqtls) 
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1.01 chr1 1194804 1346703 694804 1846703 
1.02 chr1 2470681 2514575 1970681 3014575 
1.03 chr1 7969507 8186232 7469507 8686232 
1.04 chr1 20133810 20227723 19633810 20727723 
1.05 chr1 22681214 22711473 22181214 23211473 
1.06 chr1 62900811 63204364 62400811 63704364 
1.07 chr1 67598347 67743552 67098347 68243552 
1.08 chr1 70991829 71040166 70491829 71540166 
1.09 chr1 78450517 78623626 77950517 79123626 
1.10 chr1 92554283 92554283 92054283 93054283 
1.11 chr1 101293753 101575205 100793753 102075205 
1.12 chr1 114303808 114377568 113803808 114877568 
1.13 chr1 120437718 120638604 119937718 121138604 
1.14 chr1 151792984 151802356 151292984 152302356 
1.15 chr1 155612197 156011444 155112197 156511444 
1.16 chr1 159800000 159890000 159300000 160390000 
1.17 chr1 160837622 160919496 160337622 161419496 
1.18 chr1 161463601 161479745 160963601 161979745 
1.19 chr1 169090748 169519049 168590748 170019049 
1.20 chr1 172803959 172870991 172303959 173370991 
1.21 chr1 186862512 186967702 186362512 187467702 
1.22 chr1 197342380 197813558 196842380 198313558 
1.23 chr1 198598663 198670555 198098663 199170555 
1.24 chr1 200065713 200105746 199565713 200605746 
1.25 chr1 200874229 201024059 200374229 201524059 
1.26 chr1 206939904 206968955 206439904 207468955 
1.27 chr1 209970000 210020000 209470000 210520000 
2.01 chr2 25075281 25161265 24575281 25661265 
2.02 chr2 27598097 27752871 27098097 28252871 
2.03 chr2 28602911 28647084 28102911 29147084 
2.04 chr2 43517088 43850357 43017088 44350357 
2.05 chr2 61186829 61231014 60686829 61731014 
2.06 chr2 62551472 62575443 62051472 63075443 
2.07 chr2 65604914 65692016 65104914 66192016 
2.08 chr2 102610642 103094213 102110642 103594213 
2.09 chr2 145417530 145627269 144917530 146127269 
2.10 chr2 160691494 160878364 160191494 161378364 
2.11 chr2 163110536 163124051 162610536 163624051 
2.12 chr2 182310000 182330000 181810000 182830000 
2.13 chr2 187500000 187680000 187000000 188180000 
2.14 chr2 191907655 191972789 191407655 192472789 
2.15 chr2 198244598 198954831 197744598 199454831 
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2.16 chr2 199489760 200152198 198989760 200652198 
2.17 chr2 204574890 204649276 204074890 205149276 
2.18 chr2 219066980 219191569 218566980 219691569 
2.19 chr2 228639557 228664568 228139557 229164568 
2.20 chr2 231083171 231171423 230583171 231671423 
2.21 chr2 234143048 234208258 233643048 234708258 
2.22 chr2 241563739 241608453 241063739 242108453 
2.23 chr2 242470000 242490000 241970000 242990000 
2.24 chr2 242724543 242740537 242224543 243199373 
3.01 chr3 18699977 18825669 18199977 19325669 
3.02 chr3 46150937 46486611 45650937 46986611 
3.03 chr3 48446237 51095279 47946237 51595279 
3.04 chr3 52978418 53142980 52478418 53642980 
3.05 chr3 53100000 53170000 52600000 53670000 
3.06 chr3 71160000 71190000 70660000 71690000 
3.07 chr3 100910000 101270000 100410000 101770000 
3.08 chr3 101560223 101576029 101060223 102076029 
3.09 chr3 141070000 141150000 140570000 141650000 
3.10 chr3 141072289 141154542 140572289 141654542 
3.11 chr3 188400000 188490000 187900000 188990000 
4.01 chr4 3398068 3450541 2898068 3950541 
4.02 chr4 26132361 26132361 25632361 26632361 
4.03 chr4 38324347 38373273 37824347 38873273 
4.04 chr4 38580000 38590000 38080000 39090000 
4.05 chr4 48344930 48430354 47844930 48930354 
4.06 chr4 74736180 74873602 74236180 75373602 
4.07 chr4 102702364 103001649 102202364 103501649 
4.08 chr4 103391275 103548216 102891275 104048216 
4.09 chr4 106063987 106217358 105563987 106717358 
4.10 chr4 123031494 123558828 122531494 124058828 
5.01 chr5 532632 685849 32632 1185849 
5.02 chr5 10670274 10759514 10170274 11259514 
5.03 chr5 38855122 38881538 38355122 39381538 
5.04 chr5 40219972 40623346 39719972 41123346 
5.05 chr5 55436851 55442249 54936851 55942249 
5.06 chr5 71683885 71747448 71183885 72247448 
5.07 chr5 72502029 72559339 72002029 73059339 
5.08 chr5 96200770 96373750 95700770 96873750 
5.09 chr5 129723552 131833599 129223552 132333599 
5.10 chr5 134422204 134453814 133922204 134953814 
5.11 chr5 141435466 141543989 140935466 142043989 
5.12 chr5 149590000 149630000 149090000 150130000 
5.13 chr5 150169843 150338714 149669843 150838714 
5.14 chr5 158764177 158856513 158264177 159356513 
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5.15 chr5 172313034 172329734 171813034 172829734 
5.16 chr5 173269956 173399325 172769956 173899325 
5.17 chr5 176782218 176806636 176282218 177306636 
6.01 chr6 382559 403799 0 903799 
6.02 chr6 3416922 3445536 2916922 3945536 
6.03 chr6 14711961 14734463 14211961 15234463 
6.04 chr6 19720000 19830000 19220000 20330000 
6.05 chr6 20640419 20891190 20140419 21391190 
6.06 chr6 21427143 21444899 20927143 21944899 
6.07 chr6 31236467 31313602 30736467 31813602 
6.08 chr6 32626272 32626952 32126272 33126952 
6.09 chr6 42000000 42010000 41500000 42510000 
6.10 chr6 90809560 91014029 90309560 91514029 
6.11 chr6 106435025 106442096 105935025 106942096 
6.12 chr6 111493953 111919424 110993953 112419424 
6.13 chr6 127413222 127532807 126913222 128032807 
6.14 chr6 128215237 128297611 127715237 128797611 
6.15 chr6 137959235 138006504 137459235 138506504 
6.16 chr6 143865221 143924048 143365221 144424048 
6.17 chr6 149558895 149610339 149058895 150110339 
6.18 chr6 159489791 159515309 158989791 160015309 
6.19 chr6 167360389 167485800 166860389 167985800 
7.01 chr7 2752152 2912928 2252152 3412928 
7.02 chr7 6500000 6550000 6000000 7050000 
7.03 chr7 17430004 17445706 16930004 17945706 
7.04 chr7 20580000 20589000 20080000 21089000 
7.05 chr7 26694926 26911904 26194926 27411904 
7.06 chr7 27231762 27248891 26731762 27748891 
7.07 chr7 28142088 28214300 27642088 28714300 
7.08 chr7 50096251 50323456 49596251 50823456 
7.09 chr7 98724730 98785080 98224730 99285080 
7.1 chr7 100401433 100433794 99901433 100933794 
7.11 chr7 107437613 107584780 106937613 108084780 
7.12 chr7 116889718 116917118 116389718 117417118 
7.13 chr7 128567032 128581835 128067032 129081835 
7.14 chr7 148211140 148251668 147711140 148751668 
7.15 chr7 148400000 148580000 147900000 149080000 
8.01 chr8 27189213 27303015 26689213 27803015 
8.02 chr8 49047317 49206630 48547317 49706630 
8.03 chr8 90854846 90877546 90354846 91377546 
8.04 chr8 126529074 126541090 126029074 127041090 
8.05 chr8 129501028 129571140 129001028 130071140 
8.06 chr8 130577267 130624661 130077267 131124661 
9.01 chr9 4980756 4984530 4480756 5484530 
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9.02 chr9 93904561 93952033 93404561 94452033 
9.03 chr9 117538334 117692882 117038334 118192882 
9.04 chr9 139257147 139405093 138757147 139905093 
10.01 chr10 6038478 6125322 5538478 6625322 
10.02 chr10 27160000 27180000 26660000 27680000 
10.03 chr10 30689316 30772703 30189316 31272703 
10.04 chr10 35256960 35552648 34756960 36052648 
10.05 chr10 59901559 60065351 59401559 60565351 
10.06 chr10 64348342 64566258 63848342 65066258 
10.07 chr10 75469091 75695724 74969091 76195724 
10.08 chr10 81032532 81048611 80532532 81548611 
10.09 chr10 82214586 82306330 81714586 82806330 
10.1 chr10 94248310 94485763 93748310 94985763 
10.11 chr10 101274058 101320120 100774058 101820120 
10.12 chr10 104217592 104401203 103717592 104901203 
10.13 chr10 126320000 126550000 125820000 127050000 
11.01 chr11 1873232 1880596 1373232 2380596 
11.02 chr11 58174653 58434545 57674653 58934545 
11.03 chr11 60776209 60789643 60276209 61289643 
11.04 chr11 61543499 61624181 61043499 62124181 
11.05 chr11 64133163 64164833 63633163 64664833 
11.06 chr11 65575263 65663547 65075263 66163547 
11.07 chr11 76281593 76302073 75781593 76802073 
11.08 chr11 87011889 87120819 86511889 87620819 
11.09 chr11 96018862 96045998 95518862 96545998 
11.1 chr11 114323972 114447782 113823972 114947782 
11.11 chr11 118758089 118766356 118258089 119266356 
11.12 chr11 128380000 128400000 127880000 128900000 
12.01 chr12 6490381 6493100 5990381 6993100 
12.02 chr12 12613534 12711368 12113534 13211368 
12.03 chr12 40214265 40828306 39714265 41328306 
12.04 chr12 48195939 48208368 47695939 48708368 
12.05 chr12 68476749 68508276 67976749 69008276 
12.06 chr12 103410209 113777547 102910209 114277547 
12.07 chr12 120146301 120146925 119646301 120646925 
13.01 chr13 27531267 27543781 27031267 28043781 
13.02 chr13 40678443 41032853 40178443 41532853 
13.03 chr13 42840000 42940000 42340000 43440000 
13.04 chr13 42951449 43055002 42451449 43555002 
13.05 chr13 44406102 44490181 43906102 44990181 
13.06 chr13 99778655 100064765 99278655 100564765 
14.01 chr14 69254294 69307621 68754294 69807621 
14.02 chr14 75702235 75747118 75202235 76247118 
14.03 chr14 88404343 88555206 87904343 89055206 
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15.01 chr15 38836777 38925195 38336777 39425195 
15.02 chr15 41367036 41687824 40867036 42187824 
15.03 chr15 67441750 67468285 66941750 67968285 
15.04 chr15 91142885 91221307 90642885 91721307 
16.01 chr16 11371759 11718433 10871759 12218433 
16.02 chr16 23826417 23867776 23326417 24367776 
16.03 chr16 28338043 28895130 27838043 29395130 
16.04 chr16 30469919 30514723 29969919 31014723 
16.05 chr16 49321282 50827809 48821282 51327809 
16.06 chr16 68554754 68680903 68054754 69180903 
16.07 chr16 81910000 81920000 81410000 82420000 
16.08 chr16 82870000 82920000 82370000 83420000 
16.09 chr16 85995436 86011337 85495436 86511337 
17.01 chr17 25819513 25869033 25319513 26369033 
17.02 chr17 32567679 32640025 32067679 33140025 
17.03 chr17 37903731 38089717 37403731 38589717 
17.04 chr17 40492540 40546652 39992540 41046652 
17.05 chr17 54858402 54949047 54358402 55449047 
17.06 chr17 57801597 58046076 57301597 58546076 
17.07 chr17 70636731 70642923 70136731 71142923 
17.08 chr17 76645300 76858539 76145300 77358539 
18.01 chr18 12774326 12818922 12274326 13318922 
18.02 chr18 46395022 46395022 45895022 46895022 
18.03 chr18 56876228 56893396 56376228 57393396 
18.04 chr18 67511645 67546090 67011645 68046090 
18.05 chr18 77183529 77237142 76683529 77737142 
19.01 chr19 1106477 1127981 606477 1627981 
19.02 chr19 10412409 10602180 9912409 11102180 
19.03 chr19 33731379 33735149 33231379 34235149 
19.04 chr19 46847901 47146676 46347901 47646676 
19.05 chr19 49168942 49248730 48668942 49748730 
19.06 chr19 55368865 55386920 54868865 55886920 
20.01 chr20 6080000 6100000 5580000 6600000 
20.02 chr20 30696392 31420757 30196392 31920757 
20.03 chr20 33799280 33882720 33299280 34382720 
20.04 chr20 43068996 43072706 42568996 43572706 
20.05 chr20 44680853 44749251 44180853 45249251 
20.06 chr20 48955424 48968438 48455424 49468438 
20.07 chr20 57809343 57829301 57309343 58329301 
20.08 chr20 62301795 62376939 61801795 62876939 
21.01 chr21 16817311 16838662 16317311 17338662 
21.02 chr21 34768097 34776695 34268097 35276695 
21.03 chr21 40458722 40468838 39958722 40968838 
21.04 chr21 45611686 45633388 45111686 46133388 
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22.01 chr22 21911220 21998833 21411220 22498833 
22.02 chr22 30269907 30592487 29769907 31092487 
22.03 chr22 35720000 35740000 35220000 36240000 
22.04 chr22 37260000 37269000 36760000 37769000 
22.05 chr22 39659773 39756650 39159773 40256650 
22.06 chr22 41648502 42336172 41148502 42836172 
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Appendix 5 – Differently expressed genes (q ≤ 0.05) 
A. CD versus control analysis 
Gene Name IBD 
locus 
Extended 
start (bp)  
Extended 
end (bp) 
LogFC Q-value Mean 
FPKM 
GLS 2.14 191407655 192472789 -0.42 3.5E-07 99.8 
PAPD5 16.05 48821282 51327809 -0.26 7.7E-05 12.8 
CORO1C 12.06 102910209 114277547 -0.32 3.7E-04 56.4 
PLEKHH3 17.04 39992540 41046652 0.59 3.7E-04 1.6 
MTMR2 11.09 95518862 96545998 -0.33 4.7E-04 20.8 
HSPE1 2.15 197744598 199454831 -0.29 1.8E-03 99.3 
MIER1 1.07 67098347 68243552 -0.26 1.8E-03 80.1 
FTL 19.05 48668942 49748730 -0.29 1.8E-03 819.2 
RAPGEF3 12.04 47695939 48708368 0.51 1.9E-03 3.6 
NOTCH4 6.08 32126272 33126952 0.56 2.1E-03 1.3 
SNX13 7.03 16930004 17945706 -0.26 2.4E-03 53.3 
ZC3H15 2.13 187000000 188180000 -0.20 2.8E-03 64.4 
CAST 5.08 95700770 96873750 -0.24 3.1E-03 313.5 
TCTN1 12.06 102910209 114277547 0.31 3.4E-03 7.4 
EGFL7 9.04 138757147 139905093 0.55 3.8E-03 3.4 
GLTP 12.06 102910209 114277547 -0.25 3.9E-03 39.9 
VANGL2 1.17 160337622 161419496 0.84 4.3E-03 1.6 
ANO7 2.23 241970000 242990000 0.51 4.4E-03 12.7 
ZRANB2 1.08 70491829 71540166 -0.18 4.7E-03 71.2 
MOB4 2.15 197744598 199454831 -0.19 4.9E-03 27.8 
GRB10 7.08 49596251 50823456 0.36 4.9E-03 5.2 
RAPGEF6 5.09 129223552 132333599 -0.22 5.2E-03 23.5 
RGS12 4.01 2898068 3950541 0.33 5.2E-03 6.3 
GCG 2.11 162610536 163624051 0.89 5.3E-03 51.3 
CAPN10 2.22 241063739 242108453 0.25 5.6E-03 11.3 
ARFGAP1 20.08 61801795 62876939 0.25 5.8E-03 17.4 
UBE2V2 8.02 48547317 49706630 -0.17 6.7E-03 39 
P4HTM 3.03 47946237 51595279 0.23 6.9E-03 14.1 
GGT7 20.03 33299280 34382720 0.32 7.0E-03 4.5 
TAGLN2 1.16 159300000 160390000 -0.26 7.3E-03 194 
DLL4 15.02 40867036 42187824 0.36 7.4E-03 5.7 
ELF1 13.02 40178443 41532853 -0.19 7.4E-03 48 
YIPF2 19.02 9912409 11102180 0.26 7.4E-03 17.5 
FCAMR 1.26 206439904 207468955 -0.51 7.6E-03 1.9 
ROR2 9.02 93404561 94452033 0.51 7.9E-03 1.7 
RNY1 7.15 147900000 149080000 0.69 8.1E-03 160.1 
UGT1A1 2.21 233643048 234708258 -0.50 9.1E-03 20.9 
UBA7 3.03 47946237 51595279 0.34 9.3E-03 37.1 
CHST12 7.01 2252152 3412928 0.50 1.1E-02 2.1 
PPTC7 12.06 102910209 114277547 -0.24 1.1E-02 12.3 
SNORA74B 5.15 171813034 172829734 0.44 1.1E-02 420.8 
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LogFC Q-value Mean 
FPKM 
RORC 1.14 151292984 152302356 0.35 1.1E-02 11.5 
MIB2 1.01 694804 1846703 0.39 1.2E-02 11.5 
DNAH17 17.08 76145300 77358539 0.38 1.2E-02 0.8 
FER1L4 20.03 33299280 34382720 0.71 1.2E-02 4.4 
ASCC2 22.02 29769907 31092487 -0.18 1.2E-02 34.9 
GIPC2 1.09 77950517 79123626 -0.21 1.2E-02 25.2 
ACAP3 1.01 694804 1846703 0.32 1.2E-02 8.2 
SDR42E1 16.07 81410000 82420000 -0.40 1.3E-02 12.8 
RP11-
81H14.2 
12.05 67976749 69008276 0.81 1.3E-02 4.1 
FLVCR2 14.02 75202235 76247118 -0.33 1.3E-02 17.1 
THBS3 1.15 155112197 156511444 0.33 1.4E-02 5.2 
VPS25 17.04 39992540 41046652 -0.19 1.4E-02 58.5 
PABPC1L 20.04 42568996 43572706 0.39 1.4E-02 5.3 
DENND1B 1.22 196842380 198313558 -0.19 1.4E-02 48.4 
ITSN1 21.02 34268097 35276695 -0.19 1.5E-02 18 
PITX1 5.1 133922204 134953814 0.56 1.5E-02 4.4 
RAC1 7.02 6000000 7050000 -0.20 1.5E-02 179.6 
MGAT3 22.05 39159773 40256650 0.53 1.6E-02 2.4 
VWA1 1.01 694804 1846703 0.45 1.6E-02 7.7 
CAPN10-AS1 2.22 241063739 242108453 0.31 1.6E-02 1.1 
RNF215 22.02 29769907 31092487 0.31 1.6E-02 2.4 
CCNL2 1.01 694804 1846703 0.19 1.6E-02 54.8 
TRAF3IP2 6.12 110993953 112419424 -0.23 1.6E-02 41.7 
ZNF282 7.15 147900000 149080000 0.21 1.6E-02 8 
TMEM138 11.03 60276209 61289643 -0.17 1.6E-02 28.9 
PPP1CB 2.03 28102911 29147084 -0.20 1.6E-02 138.7 
MACC1 7.04 20080000 21089000 -0.31 1.7E-02 12.7 
SNRNP70 19.05 48668942 49748730 0.25 1.7E-02 48.2 
FUBP1 1.09 77950517 79123626 -0.14 1.7E-02 88.4 
SEC14L2 22.02 29769907 31092487 0.30 1.7E-02 3.9 
GDPD3 16.04 29969919 31014723 -0.47 1.8E-02 40.2 
CCDC88B 11.05 63633163 64664833 0.56 1.8E-02 8.8 
MAGI3 1.12 113803808 114877568 -0.20 1.8E-02 42.6 
MUC1 1.15 155112197 156511444 0.63 1.8E-02 51.9 
LYRM7 5.09 129223552 132333599 -0.18 1.8E-02 12.4 
PRICKLE4 6.09 41500000 42510000 0.31 1.9E-02 3.5 
SLC12A9 7.1 99901433 100933794 0.23 1.9E-02 8.3 
RPL26L1 5.16 172769956 173899325 -0.25 1.9E-02 21.9 
HAS3 16.06 68054754 69180903 -0.71 2.0E-02 4.5 
HOTTIP 7.05 26194926 27411904 0.48 2.0E-02 8.5 
MAPRE1 20.02 30196392 31920757 -0.16 2.0E-02 44.8 
SAR1B 5.1 133922204 134953814 -0.15 2.1E-02 71.1 
SNORA42 7.02 6000000 7050000 0.63 2.1E-02 86.6 
CISD1 10.05 59401559 60565351 -0.21 2.1E-02 34.4 
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Gene Name IBD 
locus 
Extended 
start (bp)  
Extended 
end (bp) 
LogFC Q-value Mean 
FPKM 
TRIM25 17.05 54358402 55449047 -0.23 2.1E-02 30 
SLC25A28 10.11 100774058 101820120 0.22 2.1E-02 15.3 
SLC4A10 2.11 162610536 163624051 -0.65 2.1E-02 6 
UGT1A13P 2.21 233643048 234708258 -0.49 2.1E-02 6.9 
GLT8D1 3.04 52478418 53642980 0.16 2.1E-02 25.6 
HELZ2 20.08 61801795 62876939 0.48 2.1E-02 5.1 
KRTAP5-AS1 11.01 1373232 2380596 0.51 2.2E-02 1.7 
ACTR2 2.07 65104914 66192016 -0.19 2.2E-02 122.4 
DLD 7.11 106937613 108084780 -0.15 2.2E-02 103.4 
DUSP22 6.01 0 903799 0.22 2.2E-02 14.3 
ABCA7 19.01 606477 1627981 0.40 2.3E-02 5.3 
TP53INP2 20.03 33299280 34382720 -0.43 2.3E-02 33.2 
SBNO2 19.01 606477 1627981 0.34 2.4E-02 5.4 
CBX7 22.05 39159773 40256650 0.25 2.5E-02 6.4 
NGRN 15.04 90642885 91721307 0.21 2.5E-02 46.4 
AHCYL2 7.13 128067032 129081835 -0.26 2.6E-02 272.1 
LAMB2 3.03 47946237 51595279 0.28 2.6E-02 21.3 
FKRP 19.04 46347901 47646676 0.25 2.6E-02 1.8 
TNFRSF18 1.01 694804 1846703 0.78 2.7E-02 1.5 
CDC42EP5 19.06 54868865 55886920 0.30 2.7E-02 111.4 
SERBP1 1.07 67098347 68243552 -0.13 2.8E-02 112.3 
USP2 11.11 118258089 119266356 -0.52 2.9E-02 11.5 
AFF4 5.09 129223552 132333599 -0.19 2.9E-02 43.3 
IDE 10.1 93748310 94985763 -0.18 2.9E-02 34.8 
MASTL 10.02 26660000 27680000 -0.23 2.9E-02 7.4 
AS3MT 10.12 103717592 104901203 0.35 2.9E-02 1 
NISCH 3.04 52478418 53642980 0.21 2.9E-02 17.7 
C1orf86 1.02 1970681 3014575 0.27 2.9E-02 5.4 
GNG12 1.07 67098347 68243552 -0.24 2.9E-02 107.1 
PQLC1 18.05 76683529 77737142 0.25 2.9E-02 15.7 
NT5C2 10.12 103717592 104901203 -0.20 2.9E-02 87.7 
TMEM135 11.08 86511889 87620819 -0.21 2.9E-02 55.6 
PDGFRB 5.12 149090000 150130000 0.36 2.9E-02 7.7 
UGT1A10 2.21 233643048 234708258 -0.37 2.9E-02 60.1 
KRT8P46 4.08 102891275 104048216 0.36 3.0E-02 1.6 
AGRN 1.01 694804 1846703 0.41 3.0E-02 5.4 
ALDH1L2 12.06 102910209 114277547 0.42 3.0E-02 2.7 
SLC35C2 20.05 44180853 45249251 0.15 3.0E-02 20.9 
MAML2 11.09 95518862 96545998 -0.17 3.0E-02 14.3 
PSME3 17.04 39992540 41046652 -0.18 3.1E-02 28.2 
CGN 1.14 151292984 152302356 -0.26 3.1E-02 76.4 
APOM 6.07 30736467 31813602 -0.30 3.1E-02 3.6 
FCER1G 1.18 160963601 161979745 -0.34 3.1E-02 38.9 
FAM213A 10.09 81714586 82806330 -0.34 3.1E-02 51 
 Appendix 5 – Differently expressed genes (q ≤ 0.05) 
243 
 
Gene Name IBD 
locus 
Extended 
start (bp)  
Extended 
end (bp) 
LogFC Q-value Mean 
FPKM 
SOX9-AS1 17.07 70136731 71142923 0.58 3.1E-02 1.8 
INSL5 1.07 67098347 68243552 1.93 3.1E-02 22.1 
LENG8 19.06 54868865 55886920 0.23 3.1E-02 40.7 
BAD 11.05 63633163 64664833 0.35 3.1E-02 27.8 
AC074117.10 2.02 27098097 28252871 0.23 3.2E-02 5.2 
RBM6 3.03 47946237 51595279 0.18 3.3E-02 47 
AC011298.2 2.22 241063739 242108453 0.86 3.3E-02 0.6 
UGT1A6 2.21 233643048 234708258 -0.48 3.3E-02 10.4 
RP11-
474B16.1 
12.06 102910209 114277547 -0.56 3.3E-02 5.4 
SLC39A8 4.08 102891275 104048216 0.25 3.3E-02 45.5 
CDC42SE2 5.09 129223552 132333599 -0.14 3.4E-02 79.7 
NUAK1 12.06 102910209 114277547 0.36 3.4E-02 1.6 
RP11-
510J16.5 
16.07 81410000 82420000 -0.50 3.4E-02 1.9 
TNFRSF14 1.02 1970681 3014575 0.20 3.4E-02 48.5 
ATP5E 20.07 57309343 58329301 -0.17 3.5E-02 53 
NRCAM 7.11 106937613 108084780 0.63 3.6E-02 1 
ARID3A 19.01 606477 1627981 0.37 3.6E-02 1.3 
SEH1L 18.01 12274326 13318922 -0.17 3.6E-02 17.5 
UGT1A7 2.21 233643048 234708258 -0.47 3.6E-02 8.8 
MEI1 22.06 41148502 42836172 0.51 3.6E-02 9.8 
CD244 1.17 160337622 161419496 -0.44 3.7E-02 1.8 
DVL1 1.01 694804 1846703 0.25 3.7E-02 10.6 
GDPGP1 15.04 90642885 91721307 -0.24 3.8E-02 8.8 
KIFAP3 1.19 168590748 170019049 -0.23 3.9E-02 33.3 
RABEP2 16.03 27838043 29395130 0.24 4.0E-02 13.8 
FAM193B 5.17 176282218 177306636 0.21 4.0E-02 17.7 
SUV420H2 19.06 54868865 55886920 0.34 4.0E-02 3.4 
LAD1 1.25 200374229 201524059 -0.24 4.0E-02 75.6 
IPMK 10.05 59401559 60565351 -0.20 4.0E-02 11.7 
C12orf23 12.06 102910209 114277547 0.25 4.1E-02 16.7 
HCG27 6.07 30736467 31813602 0.41 4.1E-02 2.8 
FZD8 10.04 34756960 36052648 0.38 4.2E-02 1.6 
PPM1F 22.01 21411220 22498833 0.23 4.2E-02 3.7 
BRAT1 7.01 2252152 3412928 0.27 4.2E-02 7.2 
CFD 19.01 606477 1627981 0.41 4.2E-02 16 
EMILIN1 2.02 27098097 28252871 0.39 4.3E-02 6.8 
CHTF8 16.06 68054754 69180903 -0.16 4.3E-02 32.6 
ANKRD16 10.01 5538478 6625322 0.22 4.3E-02 3.2 
DYRK2 12.05 67976749 69008276 -0.22 4.4E-02 51.3 
IFT81 12.06 102910209 114277547 0.21 4.4E-02 4.8 
HSPA7 1.18 160963601 161979745 0.77 4.5E-02 1.8 
UGT1A4 2.21 233643048 234708258 -0.48 4.7E-02 2.5 
GPC1 2.22 241063739 242108453 0.32 4.7E-02 2.2 
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Gene Name IBD 
locus 
Extended 
start (bp)  
Extended 
end (bp) 
LogFC Q-value Mean 
FPKM 
DNAJB3 2.21 233643048 234708258 -0.53 4.7E-02 3.1 
SEMA3F 3.03 47946237 51595279 0.43 4.7E-02 2.6 
MLX 17.04 39992540 41046652 -0.17 4.8E-02 34.3 
C1QB 1.05 22181214 23211473 -0.32 4.8E-02 98.4 
CHP1 15.02 40867036 42187824 -0.22 4.9E-02 178.4 
PFKFB4 3.03 47946237 51595279 0.31 4.9E-02 4.9 
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LogFC q-value Mean 
FPKM 
GLS 2.14 191407655 192472789 -0.32 8.4E-05 99.8 
MTMR2 11.09 95518862 96545998 -0.31 8.9E-04 20.8 
HSPE1 2.15 197744598 199454831 -0.28 1.6E-03 99.3 
RAPGEF6 5.09 129223552 132333599 -0.23 1.7E-03 23.5 
PAPD5 16.05 48821282 51327809 -0.21 1.7E-03 12.8 
NOTCH4 6.08 32126272 33126952 0.48 2.0E-03 1.3 
MOB4 2.15 197744598 199454831 -0.19 2.2E-03 27.8 
ANO7 2.23 241970000 242990000 0.50 2.7E-03 12.7 
MIER1 1.07 67098347 68243552 -0.23 4.1E-03 80.1 
TRIM25 17.05 54358402 55449047 -0.25 6.1E-03 30 
RNY1 7.15 147900000 149080000 0.71 6.2E-03 160.1 
FTL 19.05 48668942 49748730 -0.23 6.6E-03 819.2 
ZRANB2 1.08 70491829 71540166 -0.17 6.8E-03 71.2 
CORO1C 12.06 102910209 114277547 -0.23 8.7E-03 56.4 
PPTC7 12.06 102910209 114277547 -0.22 1.0E-02 12.3 
SERBP1 1.07 67098347 68243552 -0.14 1.1E-02 112.3 
RGS12 4.01 2898068 3950541 0.27 1.1E-02 6.3 
DNAH17 17.08 76145300 77358539 0.36 1.1E-02 0.8 
FUBP1 1.09 77950517 79123626 -0.14 1.1E-02 88.4 
TAGLN2 1.16 159300000 160390000 -0.23 1.2E-02 194 
GRB10 7.08 49596251 50823456 0.30 1.2E-02 5.2 
IFT81 12.06 102910209 114277547 0.22 1.4E-02 4.8 
VANGL2 1.17 160337622 161419496 0.69 1.4E-02 1.6 
EGFL7 9.04 138757147 139905093 0.45 1.6E-02 3.4 
ZC3H15 2.13 187000000 188180000 -0.16 1.6E-02 64.4 
SOX9-AS1 17.07 70136731 71142923 0.60 1.6E-02 1.8 
AGPAT2 9.04 138757147 139905093 -0.33 1.7E-02 78.6 
FCER1G 1.18 160963601 161979745 -0.33 1.8E-02 38.9 
OSGIN2 8.03 90354846 91377546 -0.17 1.8E-02 6.5 
KRTAP5-AS1 11.01 1373232 2380596 0.47 1.8E-02 1.7 
UBE2V2 8.02 48547317 49706630 -0.15 1.9E-02 39 
C1QB 1.05 22181214 23211473 -0.35 1.9E-02 98.4 
HLA-DRB5 6.08 32126272 33126952 2.63 1.9E-02 22.4 
CDH13 16.08 82370000 83420000 0.51 1.9E-02 7.1 
NXPE1 11.10 113823972 114947782 0.29 2.1E-02 199.8 
KCNH8 3.01 18199977 19325669 0.40 2.2E-02 1 
TCTN1 12.06 102910209 114277547 0.25 2.3E-02 7.4 
FAM49B 8.06 130077267 131124661 -0.15 2.4E-02 41.8 
IQCH 15.03 66941750 67968285 0.29 2.6E-02 2.4 
GLTP 12.06 102910209 114277547 -0.20 2.6E-02 39.9 
EMC8 16.09 85495436 86511337 -0.20 2.7E-02 9.1 
PRICKLE4 6.09 41500000 42510000 0.28 2.7E-02 3.5 
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Extended 
start (bp)  
Extended 
end (bp) 
LogFC Q-value Mean 
FPKM 
RBM5 3.03 47946237 51595279 0.12 2.9E-02 127.5 
SNORA74B 5.15 171813034 172829734 0.38 2.9E-02 420.8 
RNF26 11.11 118258089 119266356 -0.25 2.9E-02 5.3 
RORC 1.14 151292984 152302356 0.33 2.9E-02 11.5 
CD244 1.17 160337622 161419496 -0.44 2.9E-02 1.8 
UBA7 3.03 47946237 51595279 0.28 2.9E-02 37.1 
PPP1CB 2.03 28102911 29147084 -0.18 2.9E-02 138.7 
ACTR2 2.07 65104914 66192016 -0.18 3.0E-02 122.4 
RBM6 3.03 47946237 51595279 0.17 3.0E-02 47 
MASTL 10.02 26660000 27680000 -0.22 3.0E-02 7.4 
ARHGEF28 5.07 72002029 73059339 0.25 3.4E-02 10 
VPS25 17.04 39992540 41046652 -0.17 3.4E-02 58.5 
HMBS 11.11 118258089 119266356 -0.25 3.4E-02 9.6 
CAST 5.08 95700770 96873750 -0.17 3.5E-02 313.5 
ELF1 13.02 40178443 41532853 -0.14 3.5E-02 48 
MAPRE1 20.02 30196392 31920757 -0.15 3.5E-02 44.8 
DLL4 15.02 40867036 42187824 0.27 3.6E-02 5.7 
ASCC2 22.02 29769907 31092487 -0.14 3.7E-02 34.9 
AS3MT 10.12 103717592 104901203 0.30 3.8E-02 1 
LAD1 1.25 200374229 201524059 -0.23 3.8E-02 75.6 
ITLN1 1.17 160337622 161419496 0.42 3.9E-02 389.8 
CTSZ 20.07 57309343 58329301 -0.18 4.0E-02 104.3 
SNORA42 7.02 6000000 7050000 0.54 4.0E-02 86.6 
SEC14L2 22.02 29769907 31092487 0.24 4.1E-02 3.9 
PFKFB4 3.03 47946237 51595279 0.28 4.2E-02 4.9 
RAPGEF3 12.04 47695939 48708368 0.35 4.2E-02 3.6 
CHTF8 16.06 68054754 69180903 -0.14 4.2E-02 32.6 
FAM65C 20.06 48455424 49468438 0.28 4.3E-02 3 
VIL1 2.18 218566980 219691569 -0.19 4.5E-02 185.4 
GDPD3 16.04 29969919 31014723 -0.39 4.6E-02 40.2 
FCAMR 1.26 206439904 207468955 -0.38 4.6E-02 1.9 
PCNP 3.07 100410000 101770000 -0.12 4.6E-02 39.5 
PSME3 17.04 39992540 41046652 -0.16 4.8E-02 28.2 
CACNA2D2 3.03 47946237 51595279 0.35 4.9E-02 1 
CFAP70 10.07 74969091 76195724 0.31 4.9E-02 1.7 
P4HTM 3.03 47946237 51595279 0.17 4.9E-02 14.1 
CSTB 21.04 45111686 46133388 -0.32 4.9E-02 37.4 
HCG27 6.07 30736467 31813602 0.37 5.0E-02 2.8 
 
  
 Appendix 5 – Differently expressed genes (q ≤ 0.05) 
247 
 
C. UC versus CD analysis 
Gene Name IBD 
locus 
Extended 
start (bp)  
Extended 
end (bp) 
LogFC Q-value Mean 
FPKM 
TMEM259 19.01 606477 1627981 -0.36 4.01E-05 21.8 
GAL3ST2 2.23 241970000 242990000 -0.96 2.39E-04 4.3 
GPC1 2.22 241063739 242108453 -0.56 4.72E-04 2.2 
FER1L4 20.03 33299280 34382720 -0.99 5.22E-04 4.4 
BAD 11.05 63633163 64664833 -0.52 5.22E-04 27.8 
MBD3 19.01 606477 1627981 -0.33 1.03E-03 11 
HMHA1 19.01 606477 1627981 -0.51 1.05E-03 7.7 
YIPF2 19.02 9912409 11102180 -0.31 1.53E-03 17.5 
CHST12 7.01 2252152 3412928 -0.58 1.72E-03 2.1 
PAPD5 16.05 48821282 51327809 0.23 1.75E-03 12.8 
LFNG 7.01 2252152 3412928 -0.40 2.04E-03 18.4 
AGRN 1.01 694804 1846703 -0.52 4.30E-03 5.4 
H2AFX 11.11 118258089 119266356 -0.52 4.56E-03 11.9 
LRP3 19.03 33231379 34235149 -0.49 5.03E-03 1.8 
ZBTB46 20.08 61801795 62876939 -0.42 5.33E-03 1.8 
SOCS6 18.04 67011645 68046090 0.27 5.35E-03 25.9 
LRCH4 7.1 99901433 100933794 -0.30 5.35E-03 15.4 
SLC2A4RG 20.08 61801795 62876939 -0.38 5.45E-03 13.1 
ZNF512B 20.08 61801795 62876939 -0.56 5.74E-03 0.8 
RAPGEF3 12.04 47695939 48708368 -0.51 6.02E-03 3.6 
NDUFS7 19.01 606477 1627981 -0.42 6.02E-03 61.5 
SMPD3 16.06 68054754 69180903 -0.34 6.31E-03 19.5 
FBXL15 10.12 103717592 104901203 -0.53 6.68E-03 3.5 
NUDT22 11.05 63633163 64664833 -0.35 6.68E-03 44.1 
LRPAP1 4.01 2898068 3950541 -0.20 6.68E-03 49.8 
MIB2 1.01 694804 1846703 -0.41 7.03E-03 11.5 
PLEKHA4 19.05 48668942 49748730 -0.49 8.25E-03 0.9 
SLC1A5 19.04 46347901 47646676 -0.32 8.73E-03 32.2 
RAC1 7.02 6000000 7050000 0.24 9.21E-03 179.6 
AC114730.3 2.24 242224543 243199373 -0.70 9.21E-03 3.1 
DVL1 1.01 694804 1846703 -0.32 9.21E-03 10.6 
CFD 19.01 606477 1627981 -0.59 9.21E-03 16 
STMN3 20.08 61801795 62876939 -0.52 9.21E-03 2.2 
UGT1A10 2.21 233643048 234708258 0.49 1.01E-02 60.1 
DENND1B 1.22 196842380 198313558 0.22 1.02E-02 48.4 
GLS 2.14 191407655 192472789 0.25 1.08E-02 99.8 
CBX7 22.05 39159773 40256650 -0.31 1.08E-02 6.4 
UGT1A13P 2.21 233643048 234708258 0.66 1.09E-02 6.9 
ACAP3 1.01 694804 1846703 -0.35 1.09E-02 8.2 
ABHD16B 20.08 61801795 62876939 -0.55 1.09E-02 1.2 
RGS14 5.17 176282218 177306636 -0.53 1.20E-02 6 
RPS6KB1 17.06 57301597 58546076 0.15 1.20E-02 12.6 
FBXW5 9.04 138757147 139905093 -0.27 1.25E-02 45.6 
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Gene Name IBD 
locus 
Extended 
start (bp)  
Extended 
end (bp) 
LogFC Q-value Mean 
FPKM 
PQLC1 18.05 76683529 77737142 -0.28 1.26E-02 15.7 
CCDC85B 11.06 65075263 66163547 -0.79 1.33E-02 1.6 
P4HTM 3.03 47946237 51595279 -0.24 1.33E-02 14.1 
ATP5D 19.01 606477 1627981 -0.36 1.35E-02 60.7 
ACER3 11.07 75781593 76802073 0.25 1.35E-02 31.2 
IQCD 12.06 102910209 114277547 0.58 1.35E-02 1.6 
RAB24 5.17 176282218 177306636 -0.45 1.35E-02 11.1 
SNRNP70 19.05 48668942 49748730 -0.26 1.36E-02 48.2 
GFI1 1.1 92054283 93054283 -0.30 1.36E-02 5.1 
CDC42EP5 19.06 54868865 55886920 -0.35 1.39E-02 111.4 
USP32 17.06 57301597 58546076 0.17 1.54E-02 11.3 
ARFGAP1 20.08 61801795 62876939 -0.24 1.58E-02 17.4 
RNASET2 6.19 166860389 167985800 -0.24 1.58E-02 72.2 
FLVCR2 14.02 75202235 76247118 0.37 1.69E-02 17.1 
RPL17P11 2.21 233643048 234708258 0.63 1.76E-02 3 
PLEKHH3 17.04 39992540 41046652 -0.43 1.76E-02 1.6 
MACC1 7.04 20080000 21089000 0.32 1.76E-02 12.7 
IRF5 7.13 128067032 129081835 -0.40 1.76E-02 4.1 
LENG9 19.06 54868865 55886920 -0.40 1.84E-02 4.7 
TMEM160 19.04 46347901 47646676 -0.64 1.97E-02 3.7 
PPM1F 22.01 21411220 22498833 -0.30 1.98E-02 3.7 
LEPREL2 12.01 5990381 6993100 -0.48 2.04E-02 1.8 
UGT1A1 2.21 233643048 234708258 0.52 2.06E-02 20.9 
CAST 5.08 95700770 96873750 0.21 2.16E-02 313.5 
LPP 3.11 187900000 188990000 0.19 2.20E-02 151.6 
C1QTNF6 22.04 36760000 37769000 -0.36 2.24E-02 3.6 
YOD1 1.26 206439904 207468955 0.24 2.29E-02 7.9 
INSL5 1.07 67098347 68243552 -2.11 2.32E-02 22.1 
AC009506.1 2.1 160191494 161378364 -0.35 2.39E-02 5.4 
GAL3ST1 22.02 29769907 31092487 -0.80 2.45E-02 2.3 
NT5C2 10.12 103717592 104901203 0.22 2.45E-02 87.7 
MEI1 22.06 41148502 42836172 -0.58 2.54E-02 9.8 
SPAG4 20.03 33299280 34382720 -0.61 2.54E-02 3.1 
C2orf82 2.21 233643048 234708258 -0.28 2.54E-02 7.7 
NEU4 2.23 241970000 242990000 -0.83 2.58E-02 10.7 
CD27 12.01 5990381 6993100 -0.63 2.68E-02 9.7 
PUSL1 1.01 694804 1846703 -0.36 2.68E-02 5.4 
SLC12A9 7.1 99901433 100933794 -0.23 2.70E-02 8.3 
ZRANB2 1.08 70491829 71540166 0.16 2.72E-02 71.2 
CKAP4 12.06 102910209 114277547 -0.34 2.77E-02 26.1 
GNG12 1.07 67098347 68243552 0.27 2.78E-02 107.1 
PIN1 19.02 9912409 11102180 -0.21 2.78E-02 23.5 
FAM193B 5.17 176282218 177306636 -0.24 2.86E-02 17.7 
PRKAA1 5.04 39719972 41123346 0.14 2.86E-02 75.3 
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end (bp) 
LogFC Q-value Mean 
FPKM 
C9orf91 9.03 117038334 118192882 -0.28 2.88E-02 4.4 
SLC41A2 12.06 102910209 114277547 0.24 2.93E-02 85 
PPP1R35 7.1 99901433 100933794 -0.33 3.01E-02 8.4 
C1orf86 1.02 1970681 3014575 -0.30 3.03E-02 5.4 
GCG 2.11 162610536 163624051 -0.79 3.15E-02 51.3 
PEX10 1.02 1970681 3014575 -0.18 3.15E-02 10.8 
GLTPD1 1.01 694804 1846703 -0.31 3.15E-02 13.9 
APOBEC3C 22.05 39159773 40256650 -0.49 3.23E-02 8.1 
AFF4 5.09 129223552 132333599 0.19 3.30E-02 43.3 
GHDC 17.04 39992540 41046652 -0.23 3.30E-02 6.6 
MAML2 11.09 95518862 96545998 0.18 3.44E-02 14.3 
TAS1R3 1.01 694804 1846703 -0.53 3.48E-02 0.8 
YDJC 22.01 21411220 22498833 -0.30 3.48E-02 7.1 
BRAT1 7.01 2252152 3412928 -0.29 3.51E-02 7.2 
CGREF1 2.02 27098097 28252871 -0.91 3.56E-02 1.9 
SNX8 7.01 2252152 3412928 -0.33 3.58E-02 11 
MXD3 5.17 176282218 177306636 -0.36 3.58E-02 18.5 
C9orf142 9.04 138757147 139905093 -0.30 3.62E-02 16.5 
SAR1B 5.1 133922204 134953814 0.15 3.64E-02 71.1 
CDX1 5.12 149090000 150130000 -0.21 3.73E-02 122.2 
CAMTA1 1.03 7469507 8686232 0.18 3.73E-02 45 
CARD9 9.04 138757147 139905093 -0.52 3.80E-02 1.3 
CAPN10 2.22 241063739 242108453 -0.21 3.83E-02 11.3 
WNK4 17.04 39992540 41046652 -0.43 3.88E-02 6.5 
BCL7C 16.04 29969919 31014723 -0.22 3.91E-02 16.1 
GGT7 20.03 33299280 34382720 -0.29 4.08E-02 4.5 
HLA-DRB6 6.08 32126272 33126952 -2.13 4.08E-02 0.9 
B3GALT5 21.03 39958722 40968838 -0.73 4.08E-02 35.1 
UGT1A7 2.21 233643048 234708258 0.53 4.26E-02 8.8 
UGT1A4 2.21 233643048 234708258 0.55 4.26E-02 2.5 
PTMS 12.01 5990381 6993100 -0.25 4.30E-02 25.9 
MRPL23 11.01 1373232 2380596 -0.21 4.30E-02 51.8 
DEXI 16.01 10871759 12218433 -0.33 4.42E-02 7.4 
FAM83E 19.05 48668942 49748730 -0.27 4.42E-02 16.5 
TMEM135 11.08 86511889 87620819 0.22 4.44E-02 55.6 
TNFRSF14 1.02 1970681 3014575 -0.19 4.45E-02 48.5 
RP1-
170O19.14 
7.06 26731762 27748891 -0.76 4.45E-02 2.6 
RP11-
119F19.2 
10.08 80532532 81548611 0.32 4.52E-02 3.3 
ADCY7 16.05 48821282 51327809 -0.30 4.55E-02 9.2 
RGS19 20.08 61801795 62876939 -0.41 4.55E-02 4.3 
HLA-DPB1 6.08 32126272 33126952 -0.44 4.59E-02 60.4 
UGT1A9 2.21 233643048 234708258 0.51 4.67E-02 6.4 
UGT1A8 2.21 233643048 234708258 0.59 4.69E-02 5.9 
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start (bp)  
Extended 
end (bp) 




12.06 102910209 114277547 0.28 4.69E-02 2.1 
TTC33 5.04 39719972 41123346 0.19 4.79E-02 15.2 
CORO1C 12.06 102910209 114277547 0.21 4.83E-02 56.4 
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CD45pos Leukocyte predictive genes 
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CD326pos Epithelial cell predictive gene 























CD4pos T helper cell predictive genes 






















CD8pos Cytotoxic T cell predictive genes 



















CD14pos Monocytes predictive genes 
Ensemble Gene ID Estimate value 
ENSG00000011009 4.57E-06 
ENSG00000011083 -5.9E-05 
ENSG00000011275 -3.6E-05 
ENSG00000012779 6.45E-05 
ENSG00000012822 -1.4E-05 
ENSG00000013275 -1.4E-05 
ENSG00000013364 2.05E-06 
ENSG00000013441 6.44E-06 
ENSG00000013503 -8.4E-05 
ENSG00000013563 -8.7E-05 
ENSG00000014216 -1.7E-05 
ENSG00000014257 5.12E-05 
ENSG00000015133 2.58E-05 
ENSG00000019505 -1E-05 
ENSG00000021355 2.84E-06 
ENSG00000023191 4.54E-06 
Intercept 0.215859 
 
